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Introduction 
The hepatitis B virus 
The hepatitis B virus (HBV) is one of the smallest human viruses known and belongs to 
the family of Hepadnaviridae; it was the first human hepatitis virus that could be 
characterized. Before the discovery of the virus two types of transmission of infectious 
hepatitis were distinguished on the basis of epidemiological observations: the classical 
hepatitis (type A) was transmitted by the faecal-oral route, while type B was transmitted 
parentally.' 
In 1963, B8 Blumberg discovered a previously unknown antigen in the blood of an 
Australian aboriginal (Australia antigen) and within a few years this was found to be 
related to the parentally transmitted type B hepatitis.' In the early seventies the virus was 
seen by electron microscopy3 and the genome was found to be a small, circular DNA that 
was partially double-stranded (figure I). The nucleotide sequence of the virus contains only 
3200 nucleotides (3.2 kb) and revealed 4 overlapping genes for the production of seven 
viral proteins. 
Pre·52 
1- Sill/ace antigen related peptides 
2- Core antigen related peptides 
3- HBxAg 
4- HBV-DNA polymerase 
Pre-core 2 
Figure 1. The genollle of the hepatitis B virus consisting of 3200 nue/eotides 
representing 4 open readingfi'ames drawn as arrows. (Smface, Core, X and 
Polymerase) 
The first open reading frame encodes a family of hepatitis B surface antigen (HBsAg)-
related polypeptides that make up the outer envelop of the virus. The major HBsAg 
polypeptide is encoded by the 8 gene. The pre-82 sequences are cotranslated with 8 
sequences to yield pre-821S or middle-sized polypeptides. Cotranslation of the upstream 
3 
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pre-Sl sequences, yield pre-SlIpre-S2/S or large sized polypeptides. The second HBV open 
reading frame, the C gene, encodes the major hepatitis B core antigen (HBcAg) 
polypeptide and hepatitis B e antigen (HBeAg), these are the major components of the 
virus inner nucleocapsid. These particles are important targets for the immune response 
against the virus. The soluble HBeAg is secreted into serum and associated with virus 
replication and high infectivity. The third HBV open reading frame encodes the hepatitis B 
x antigen (HBxAg), which function is not clear. It is probably one of the co-factors in the 
pathogenesis of hepatocellular carcinoma.' The fourth and largest HBV open reading frame 
encodes the HBV -DNA polymerase, which is responsible for the endogenous DNA-
polymerase activity in virus particles. HBV-DNA polymerase has been shown to be the 
reverse transcriptase (RT) polypeptide of the virus. In this context, any mutation that 
affects the polymerase activity will not only affect the amount of virus produced, but also 
the number of templates available to encode virus proteins, and elicit appropriate and 
timely immune responses. 
Chronic hepatitis B 
Inoculation with the hepatitis B virus causes hepatocellular necrosis and inflammation, 
which severity ranges from asymptomatic to acute liver failure. Acute infection wiH 
resolve spontaneously in 90% of the adults; the reason why in certain patients the acute 
infection will not resolve but progresses to chronic hepatitis B is not yet clear. Both viral 
factors and host factors can probably influence the outcome of the acute infection. 
Chronic infection with the hepatitis B virus is a serious liver disorder which can result in 
chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma. It is estimated that 
5% of the world population is chronic HBsAg carrier,' the majority of these will even not 
show any disease progression. In our population about half of the HBsAg carriers did not 
show any signs of liver inflammation (normal serum transaminases) or viral replication 
(HBV-DNA negativity by PCR). Currently patients with detectable HBV-DNA by PCR in 
combination with the lack of any signs of liver inflammation do rarely show progression of 
their liver disease. Longitudinal studies on the natural history of chronic liver disease due 
to HBV have shown that ongoing replication (HBeAg either HBV-DNA positivity by 
hybridization technique) 01' liver inflammation are features which predict unfavourable 
evolution of the disease.'·7 .• Permanent termination of HBV replication is found to be the 
major event that will influence outcome.9•IO.1I Spontaneous remission of disease activity 
may occur in approximately 10% of HBeAg positive carriers per year. 
Antiviral therapy 
The ultimate goal of antiviral therapy in chronic hepatitis B is to prevent progression of 
liver disease to cirrhosis, hepatocellular carcinoma or liver failure and subsequently 
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improve life expectancy and quality of life (table I). Ihis can be obtained by elimination 
of the virus from the body and the induction of protective antibodies against the virus. 
However, improvement of prognosis can be achieved by suppression of HBV replication or 
induction of HBeAg ser.oconversion despite the continued presence of HB~Ag. This 
situation of viral latency is associated with normalization of serum transaminase levels and 
decrease in necro-illflammatory activity on liver biopsies. Therefore, in most clinical 
studies, the therapeutic outcome (response) is defined as clearance of HBeAg and HBV-
DNA in serum, and subsequently improvement of liver disease. 
Table 1. Goals of antiviral therapy for chronic hepatitis B 
• Loss of markers of viral replication (HBV-DNA I HBeAg) 
II Nonnalization of serum transaminase levels (AL T) 
II Disappearance of liver cell inflammation 
• Improvement of symptoms (quality of life) 
• Decrease of progression of liver disease 
II Decrease in incidence of hepatocellular carcinoma 
.. Improvement of survival 
• Diminished infectivity 
• Loss of HBsAg and development of anti-HBs 
Until now the only agent known to have a lasting beneficial effect in chronic hepatitis B is 
alpha-interferon (a-IFN). It demonstrates both antiviral and immunomodulating effects of 
whom the last one is probably the most important in chronic hepatitis B. a-IFN will 
enhance the HLA class I antigen expression on the membranes of virus-infected 
hepatocytes, and thereby amplify viral antigen recognition and display. Ihe 
immunomodulatory effects of a-IFN include enhancement of antigen-processing cells, 
natural killer cells and cytotoxic I-lymphocytes, and increased release of cytokines. 
Standard a-IFN treatment takes three to six months with weekly doses around 30 MU and 
will induces long-tenn remission in 25-40 percent of patients. 12,1J 
However, polymerase chain reaction (peR) techniques are able to detect products of viral 
replication in patients classified as 'healthy carriers'. In spite of HBeAg seroconversion the 
disease will probably continue to progress in these patients. Recently Fattovich et al. 
observed that ALI normalization is a crucial sign for inactivation of the progression of the 
disease.14 Ihis can be clarified by the fact that in a proportion of patients viral mutations 
arise which are able to escape the immunological control. 
In conclusion a-IFN treatment can significantly improve outcome both after short-tenn and 
long-term follow-up analysis. However three major reasons forced us to develop new 
antiviral strategies: 
l. Several patients will not fulfil virological and serological criteria for a-IFN therapy. 
2. Since a-IFN has significant side effects there are contra-indications for interferon 
therapy, especially in patients with advanced liver disease,15,16 
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3. The majority (60-75%) of patients does not respond to a-IFN therapy. 
Therefore, the majority of patients with chronic hepatitis B will not benefit from standard 
a-IFN therapy and new antivirals are needed. 
Nucleoside analogues 
Over the last decade, advances in 
the understanding of the molecular 
virology of the hepatitis B virus 
have resulted in a renewed interest 
in nucleoside analogues for the 
treatment of chronic hepatitis B. 
Since the discovery that the 
replicative cycle of HBY involves 
an obligate RNA intermediate and 
a cytoplasmic reverse-transcriptase 
Table 2. Nomenclature of Nucleosides 
Purine 
Pyrimidine derivatives 
Adenine 
Guanine 
Cytosine 
Uracil (RNA) 
Thymidine (DNA) 
step, the HBY polymerase has become the major focus in the search for novel therapeutics 
that could block replication. Because the reverse transcriptase is not involved in human cell 
replication, nucleoside analogues may have little toxicity. However, most of the first 
generation nucleoside analogues as vidarabine, acyclovir, didanosine, zidovudine and 
ribavirin were either ineffective, associated with unacceptable toxicity or both. ,s,'7,'8,'9,2o The 
advent of an in vitro cell line (human hepatoblastoma, Hep G2) which propagates the 
Nucleoside analogue (NA) 
.j, 
NA mon'ThosPhate 
NA diphosphate 
.j, 
NA triphosphate 
,(\, 
viral polymerase 
viral DNA 
celllliar polymerase 
cellular DNA 
. chain tennination . possible toxicity 
. polymerases inhibited 
Figure 2. Metabolism and activity of 
nucleoside analogu~s. 
6 
virus21 , allowed the development of a 
screening system22 to test a promising 
new generation nucleoside analogues.23 
A nucleoside analogue must first be 
phosphorylated to its triphosphate (TP) 
fonn, for antiviral activity. Antiviral 
drug selectivity is established by 
primary phosphorylation with a viral 
encoded enzyme followed by the 
conversion to the TP form by cellular 
nucleotide kinases (figure 2). Therefore 
virus infected cells accumulate the 
active triphosphate form of the drug 
more properly than the uninfected cells. 
Recently some new nucleoside showed 
very promising results in vitro, but first 
I would like to summarize the clinical 
studies on nucleoside analogues in the 
past (table 3). 
Table 3, Nucleoside analogues for chronic hepatitis B 
Generic name (analogue) Abbreviation Proprietary name 
Acyclovir ACV Zovirax 
Vidarabine ARA-A Vira-A 
Didanosine ddl Videx 
Zalcitabine ddC Hivid 
Ribavirin RTCA Virazole 
Zidovudine AZT Retrovir 
Ganciclovir DHPG Cymevene 
Fialuridine FIAU 
new nucleoside analogues in clinical testing for chronic hepatitis B 
Lamivudine 3TC, SddC Epivir 
Famciclovir FCV Famvir 
Lobucavir BHCG Cygalovir 
Phosphonylmethoxyethyladenine PMEA Adefovir 
Deoxythiafluorocytosine FTC 
Carbodeoxyguanosine 2-CDG 
Introduction 
Results 
Little or no efficacy 
Inconvenient, toxic 
No efficacy 
Inconvenient, toxic 
No efficacy 
Little or no efficacy 
Limited efficacy 
Extremely toxic 
Effective, non-toxic 
Effective, non-toxic 
Promising 
Promising 
More data required 
More data required 
Acyclovir [9-(2-hydroxyethoxymethyl) guanine] is a non-cyclic guanosine analogue 
discovered in 1974 and is licensed for the treatment of herpes vims infections in many 
countries. In hepatitis B virus infections acyclovir inhibits viral DNA synthesis in an in 
vitro model. In human studies the observed poor antiviral effect and the possible renal and 
neurological toxicity of the dmg suggested that it was not justifiable in chronic hepatitis 
B.18 
Administration of vidarabine (adenine arabinoside, ARA-A) and its soluble monophosphate 
analogue ARA-AMP resulted in only a transient decrease in levels of HBV-DNA both 
after intravenous or intramuscular injection. 17,24 The inhibitory function is not virus specific 
and the triphosphate form has been recognized as a potent inhibitor of cellular polymerase-
(/.. A combined approach with (/.-IFN also failed to show advantage to interferon therapy." 
In addition after 4 weeks of therapy 47% of patients complained of myalgia, requiring 
withdrawal of treatment in 29% of cases; also neurotoxicity has been reported during 
therapy," 
2',3'-Dideoxyinosine (ddl) and 2',3'-dideoxycylidine (ddC) are nucleoside analogues that 
inhibit HIV reverse transcriptase and HBV -DNA polymerase in vitro.26 Translating these 
results in clinical studies in HBV infected patients was disappointing," The potential 
development of neuropathy as well as lactic acidosis make these dmgs unsuitable for 
antiviral therapy in chronic hepatitis B." 
Ribavirin is a purine analogue with a structure similar to guanine and inosine. Although 
ribavirin has been shown to have a broad spectmm of antiviral activity against both RNA 
7 
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and DNA viruses, it is not a direct inhibitor of viral polymerases but its main mode of 
action appears to be interference with viral mRNA synthesis. In a pilot study in 18 patients 
treated for 6 months with ribavirin at three different doses, HBV-DNA levels decreased by 
an average of 20 per cent. Also ALT levels decreased during therapy, however, all changes 
were transient and returned to pretreatment levels once ribavirin was discontinued.20 
ZidovlIdine (3'-azido-3'-deoxythymidine, AZT) has proven to be a potent antiviral in HIV-I 
infected patients.2S These inhibitor of the reverse transcriptase activity also demonstrated 
marked decrease in HBV replication both ill vitro and in vivo. 29 However a randomized 
placebo controlled trial in 24 patients could not find an additional effect when zidovudine 
was given in combination with a-IFN. In addition patients undergoing combination therapy 
exhibited more dose-limiting bone marrow toxicity than those on a-IFN monotherapy?O 
Ganciclovir is a guanine nucleoside analogue that has been shown to be effective for the 
treatment of CMV. In spite of weak in vitro inhibition of HBV replication)l some pilot 
studies showed a decrease in HBV-DNA levels after HBV recurrence after liver 
transplantation.32 The poor oral bioavailability and the substantial myelosuppression limits 
the clinical use of the dmg. 
In two preliminary dose-finding studies on jiailll'idine marked suppression of HBV-DNA 
was observed during two to four weeks of treatment.)) However prolongation of treatment 
in twelve patients resulted in the death of five and others survived after liver 
transplantation. )4 
CytidIne: Lamlvudlne: 
Figure 3. Structure of the natura/nucleotide cytidine and its analogue lamivudine. 
A number of new nucleoside analogues including famciclovir and lamivudille are in phase 
III clinical trials and others in phase I or " (lobucavir, adefovir). These agents all show 
promise by reducing the amount of complete viral particles in the serum and the 
expression of viral related proteins in the liver in the majority of patients. In vitro studies 
show that lamivudine is the most potent inhibitor of viral replication with cytotoxicity only 
at high dosages.)S Therefore we decided to start a clinical evaluation of this dmg which 
showed the largest therapeutic index (high efficacy with low toxicity). 
8 
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Lamivudine 
Lamivudine is the orally administered (-) enantiomer of the racemic mixture 2',3'-dideoxy-
3'-thiacytidine (SddC, 3'TC, figure 3) and was discovered to have potent anti-HlV 
activity.J6 The (+)-form of the antiviral stereoisomer is susceptible to deamination by 
deoxycytidine deaminase and was found to he more toxic than the (-) enantiomer.J7.38 Anti-
HBV activity takes place by direct inhibition ofHBV-DNA polymerase and by termination 
of the pro-viral DNA chain during elongation. Tllis in contrast to famciclovir that acts as 
inhibitor of initiation of the pro-viral DNA chain (figure 4). The potent and selective anti-
HBV activity of lamivudine results from an efficient drug uptake, resistance to cytidine 
deaminase, a high affinity for deoxycytidine kinase, and high selectivity toward the 
polymerase, the target of nucleoside analogue toxicities.J9 
~ ~ ~ a infectious HBV virion attachmen~~ ______ ----,V',,-,,-___ ~_~~ 
Goigi -~ ',ccel"e-ca-cs-ce---, 
~OO ~ ~ budding 
uncoating ER 
A nucleus ~~~~ tranSlatiO~ V ) surface 1 tranS;ri;tion, ~ reinfection .2:::~~~:'; (+) DNA 
~ }RL ~ H ~::.:::n:-Sf_at_io_n_'?\._. _ .. __ ~~encapS:dation \(-) DNA 
eee-DNA .......... '-{,jJ core +0 7(~O, 
Figure 4. 
• polymerase 11. 
LAMlVUDINE 
Proposed life-cycle of HBV in hepatocytes. Lamivudine will terminate the 
prolollgatioll of the proviral DNA chaill, marked X. 
9 
Lamivudine treatment for chronic hepatitis B 
Objectives of the study are: 
1. To assess the virological, biochemical and histological efficacy of tamivudine 
monotherapy in chronic hepatitis B patients. 
2. To evaluate the pharmacokinetics, safety and efficacy of lamivudine and a-IFN 
combination therapy. 
3. To evaluate the possible mitochondrial toxicity, as observed in fialuridine, during 
lamivudine therapy. 
4. To describe the 'lamivudine withdrawal hepatitis' and the role of lamivudine influencing 
the outcome of the flare. 
5. To evaluate the· incidence, molecular background and clinical impact of lamivudine 
resistance. 
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Summary 
Background/Aims: Information on the kinetics of the pretreatment steady-state of the 
hepatitis B virus (HBV) can be obtained from serial measurements of serum HBV -DNA 
concentrations following lamivudine ((-)enantiomer of 3'-thiacytidine)-induced perturbation 
of the balance between virus production and clearance. 
Methods: In a placebo-controlled, dose-ranging triallamivudine (5 to 600 mg per day) was 
administered for 4 weeks to 17 patients with chronic replicative hepatitis B. Serum HBV-
DNA levels were quantified by standard liquid hybridization techniques. The time-
dependent concentrations of serum HBV-DNA following lamivudine adtninistration were 
subjected to iterative least-squares regression in order to obtain kinetic data on HBV life-
time and viraemia. 
Results: In patients with stable HBeAg positive chronic hepatitis B responding to 
lamivudine, HBV -DNA declined exponentially with a half-life of approximately 2-3 days. 
The minimum virus production and clearance per day in patients with chronic hepatitis B 
was calculated to be 6.09xlOlI virions/day (range 0.26 to 21.06xlOII virions/day). 
Compared to the HBeAg levels before treatment, relative amounts of HBeAg were 1.00 ± 
0.16 and 0.96 ± 0.20 at days 22 and 28 of treatment, respectively. Four weeks after 
temlination of lamivudine treatment the relative amount of HBeAg was 1.04 ± 0.19. 
Conclusion: The half-life of HBV in chronically infected patients is longer and in vivo 
turnover rates are higher compared to recently published data on the human 
immunodeficiency virus type 1 and the hepatitis C virus. The constant expression of 
HBeAg as observed in the present study during a 28-day lamivudine treatment period does 
not allow calculation of a definite decay rate for virus-producing cells. Our data, however, 
imply that the minimum half-life of infected cells may exceed 100 days. 
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Introduction 
The hepatitis B virus (HBV) has a partially double stranded DNA genome and replicates 
via an RNA intermediate,l,2 Measurement of semm HBV -DNA is an effective non-invasive 
method of assessing the replicative activity of HBV, since serum HBV-DNA represents 
virion DNA, and its presence correlates with replicating and infectious HBV.J Kinetic 
information on viral turnover can be obtained after the balance between virus production 
and clearance is disturbed.4,s,6,7,8 Lamivudine, the (-)enantiomer of 3'-thiacytidine, is an oral 
2"3'-dideoxy-nucleoside that interferes with the reverse-transcriptase activity of the 
hepatitis B virus polymerase and inhibits DNA synthesis by terminating the nascent 
proviral DNA chain. At concentrations sufficient to completely block HBV replication, the 
drug does not affect transcription of HBV-specific RNA.9,IO,Il In the present study, we 
administered lamivudine to patients who were chronically infected with hepatitis B virus. 
From serial measurements of viraemia in patients responding to lamivudine, we obtained 
kinetic information on the dynamics of HBV replication in vivo. 
Patients and methods 
In a placebo-controlled, dose-ranging trial, lamivudine was administered for 4 weeks to 17 
patients with chronic replicative hepatitis B, in doses of 5 to 600 mg per day.12 The 
diagnosis of chronic hepatitis B was based on elevated serum aminotransferase levels for at 
least 6 months, presence of HBeAg and histological examination. For inclusion into the 
study semm HBV-DNA had to exceed 10 pglml. All patients were anti-HCV, anti-HDV 
and anti-HIV-1/2 negative. Blood samples were obtained 4 weeks before and directly prior 
to initiation of treatment, and subsequently on days 3, 7, 14, 21, and 28. Further serum 
samples were taken 1, 2, 4, 6, and 8 weeks after termination of antiviral treatment. Serum 
was prepared under a laminar flow bench and frozen at -80°C. All patients consented to 
participate in the study, which was approved by the Ethics Conl1l1ittee for Medical 
Research in Rotterdam in accordance with the 1975 Declaration of Helsinki. Lamivudine 
doses of less than 20 mg had no effect on HBV-DNA levels, while a substantial decline in 
the amount of HBV-DNA was observed in 11 patients receiving 20 to 600 mg. For studies 
on the dynamics of HBV turnover, only the data of these 11 responders were taken into 
account. The mean age of these 11 patients was 31.9 years (range 18-60 years). 
Histological examination revealed chronic persistent hepatitis in 3/11 and chronic active 
hepatitis in 8/11 patients. 
Semm HBV -DNA levels were quantified by standard liquid hybridization techniques 
(Genostics assay, Abbott Laboratories, North Chicago, Ill., USA). The lower detection limit 
of this assay is 2 pglml, Le. 5.8x 105 HBV genomes per ml serumy,14 Relative amounts of 
HBeAg were assessed by the micro particle ELISA IMx system (Abbott Laboratories, 
North Chicago, Ill., USA). 
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The time-dependent concentrations of serum HBY-DNA following lamivudine 
administration were subjected to iterative least-squares regression in order to obtain kinetic 
data on HBY life-time and viraemia. As rationalized below, the underlying three-
compartment kinetic models including HBY -releasing infected hepatocytes ([A)), serum 
HBV-DNA ([B)), as well as a fictitious degradation compartment ([C]) was reduced to a 
first-order problem. In the present case, it was found sufficient to determine the two 
parameters HBV-DNA concentration prior to lamivudine administration and the rate 
constant for HBY -DNA decline, Bo and k" respectively. The fit protocol included a 
repeatedly initialized downhill simplex optimization." Typically, less than 500 function 
evaluations were needed for convergence. The agreement between simulated and observed 
data was characterized in a least-squares sense by the nonnalized fit-error: 
s'=r.; [ (Bi'm-B,"'''!!.,]' 
where i runs over all n data points and 8i is the uncertainty of a sample set to either 5% or 
to a minimum of 2 pglml (5.8 x 10' HBY genomes!ml) in HBY -DNA determinations. To 
account for the intrinsic non-linear properties of the model function, confidence boundaries 
for the parameters Bo and ~ were derived from the fractional increase in the sum of 
squares of residuals l6,17 computed according to: 
(Sma<! Sm''')' = 1 + (p - 1) . (n - p)"' . F/P,'.n.p.a} 
where 11 and p are the number of HBV-DNA samples and fit parameters, respectively, and 
F is the Fisher variance ratio. For the varying numbers of degrees of freedom, critical F-
values for a two-tailed test of the F-distribution function were obtained from statistical 
tables.'s The rejection probability was set to a = (31.712)% associated with one standard 
deviation based on the assumption of a multi variate Gaussian distribution. The deviations 
in each of the optimum parameters required to increase the sum of squares of the residuals 
from sm!n2 to the threshold Smin2 were iteratively determined using a modified secant 
algorithm." The asynmlCtry of the i' isocontour on the error hyper-surface was tested with 
a bi-directional search using positive and negative deviations in each single parameter,16 
and for each value the larger deviation was given for the confidence interval. Fit 
significances were tested by analysis of variances (ANOY A). Other data are presented as 
mean ± S.D. 
Minimum virus production and clearance per day was calculated from the initial slope 
according to Bo x k, multiplied by the extracellular fluid volume, which was estimated 
from the individual patient's body weight, and assuming that serum and extracellular fluid 
compartments are in equilibrium. 
Results 
Within the framework of a three-compartment kinetic model,8 the hepatitis B virus is 
produced in infected hepatocytes (compartment [A)) and subsequently released into the 
blood (compartment [B)) at a rate constant k,. Clearance of free virus from the blood, as 
assessed by total serum HBV -DNA, will occur at rate constant k, into a fictitious 
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degradation compartment ([C]). A small percentage of free virions will bind to and enter 
hepatocytes at a rate constant k.,: 
k, k, 
[A];;::,=====' [B] ___ • [C] 
k., 
However, virus uptake by hepatocytes previously uninfected (de /laVa infection) or infected 
(superinfection) cannot be discriminated, and transformation of non-infected into virus-
producing hepatocytes cannot be measured ill vivo. 
Administration of lamivudine, which terminates the nascent proviral DNA chain, 
effectively inhibits hepatitis B virus replication (k,~O). Since nucleoside analogues, 
including lamivudine, have no recognized direct effect on the immune system or 
nonspecific degradation processes,20,21.22 degradation of HBV-DNA should not he affected, 
implying a non·vanishing rate for this process (k,>O). Decline rates of antibody·complexed 
and uncomplexed virions may be different. Thus, k2 must be interpreted as a compound 
rate of antigen·specific and non'specific processes. Rate constants k., and I<, are 
numerically indistinguishable if k,~O leading in the limit to identity with a first-order 
exponential decay as one of the rates k.1 or ~ approaches zero, Such a fit behavior was 
observed in most cases. Biologically, rate constant ~ can be anticipated to exceed k'l 
(1<,» k.,), and therefore kinetic data are derived from a simple first-order kinetic for 
HBV-DNA degradation (d[B]ldt ~ I<,[B]). 
During a 4-week pretreatment phase serum HBV -DNA levels ranged from 62 to 882 pglml 
(1.8x 10' to 2.6x 10' genome equivalents per ml) and varied little in the individual patients, 
indicating steady-state conditions. Following lamivudine treatment with at least 20 mg once 
daily, all patients showed a rapid decline in serum viraemia, which continued over the 
complete 28-day treatment period (figure lA). The decline in serum HBV-DNA was 
exponential, as demonstrated by a straight-line fit to the data on a log plot and pennitted 
the determination of a half-life of approximately 2-3 days. The calculated minimum daily 
production and clearance ofHBV ranged from 0.26 to 21.06xlO" virions per day (table I). 
The rate of HBV elimination from serum after initiation of antiviral therapy was 
determined by the first-order decay described above. Results for viral clearance from serum 
yielded half-lifes of tJn ~ In211<, ~ 3.02 ± 3.20 days. Vims half-lifes in patients treated with 
20 mg lanlivudine once daily were longer than in patients with doses of 100 to 600 mg 
once daily (4.99 ± 5.55 vs. 2.67 ± 2.48 days). TIns may reflect an incomplete inhibition of 
HBV replication in patients treated with only 20 mg lamivudine once daily. The individual 
results for all 11 investigated patients (including confidence intervals from F-statistics) are 
summarized in table 1. After termination of the 4-week Iamivudine treatment period, serum 
HBV-DNA concentrations increased rapidly. The mean HBV-DNA concentration before 
initiation of treatment was 340 ± 293 pglml and after tennination of treatment was 152 ± 
133 pglml at week 1, 228 ± 154 pglml at week 2, 277 ± 266 pglml at week 4, 275 ± 241 
pglml at week 6 and 298 ± 198 pg/ml at week 8 . 
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Figure 1. Serum HBV-DNA and aminotransferase determinations in patients with 
chronic hepatitis B responding to lamivudine, All patients (n = II) responding to 
lamivudine treatment are shown. Treatment with 20 to 600 mg lamivudine once daily was 
initiated at day 0 and subsequently continued jar 4 weeks, Upper panel: Dots (~ represent 
the experimental HBV-DNA values as determined by liquid hybridization techniques. Lines 
(----J are calculated from the fit parameters given in table 1, Lower panel: Dots represent 
the experimental ALT and AST values determined by enzymatic standard methods, The 
normal ranges jar ALT and AST are 5 - 30 and 5 - 30 lUll, respectively, The lower edge 
oj each panel indicates the analytical sensitivity, 
The core gene of HBY encodes for both core antigen (HBcAg) and a cleavage product, the 
e antigen (HBeAg), which is secreted by infected cells, HBeAg is generally a good marker 
of active HBY replication because the gene product is generated from the template that is 
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also lIsed for replication. In patients treated with at least 20 mg lamivudine once daily, the 
amount of HBeAg showed no decline. Compared to the HBeAg levels before treatment, 
the relative amounts of HBeAg were 1.00 ± 0.16 and 0.96 ± 0.20 at days 22 and 28 of 
treatment, respectively. Four weeks after termination of lamivudine treatment the relative 
amount of HBeAg was 1.04 ± 0.19. 
Hepatocyte damage and turnover can be estimated only by surrogate parameters sllch as 
aminotransferases, which are released due to direct virus-related cytopathic and/or immune-
mediated processes. Alanine aminotransferase (AL T) is a cytosolic enzyme mainly present 
in the liver. Aspartate aminotransferase (AST) is a mitochondrial enzyme present in many 
organs, which is considered to be a more pronounced surrogate parameter of cell 
destruction. In none of the patients chronically infected with HBV was a decline in 
aminotransferases observed during treatment with lamivudine for 28 days (figure IB). 
Table 1. Summaty dala of HBV turnover during the pretreatment steady state. a 
Patient Lamivudine HBV-DNA 
[mg I day] 
tin Production and Bo (ln21k,) clearance 
[pg/ml] b [10' I ml] b [days] [lOll virions Iday] 
01 20 95.2 ± 62.9 2.76 ± 1.82 2.58 ± 2.31 0.86 
02 20 98.0 ± 49.7 2.84 ± 1.44 11.34 ± 6.61 0.26 
03 20 77.4 ± 49.3 2.25 ± 1.43 1.05 ± 0.95 1.75 
04 100 50.3 ± 51.9 1.46 ± 1.51 4.49 ± 2.33 0.33 
05 100 1096.7 ± 546.9 31.80 ± 15.86 1.65 ± 0.48 18.17 
06 100 150.5 ± 63.2 4.37 ± 1.83 0.47 ± 0.09 8.68 
07 300 368.7 ± 320.8 10.69 ± 9.30 3.02 ± 1.32 3.48 
08 300 348.8 ± 211.0 10.12 ± 6.12 5.58 ± 2.15 2.15 
09 300 317.7 ± 174.3 9.21 ± 5.06 0.90 ± 0.39 8.49 
10 600 84.8 ± 58.8 2.46 ± 1.71 1.35 ± 0.58 1.73 
II 600 510.6 ± 188.2 14.81 ± 5.46 0.84 ± 0.20 21.06 
For definition of kinetic parameters see Methods. 
b I pg HBV-DNA Ri 2,9xlO~ genome equivalents,l2,1l 
Discussion 
The hepatitis B virus is a small DNA virus with a circular double-stranded, partly single-
stranded genome. Four mRNA transcripts of known function have been identified. The 
longest (3.5 kB) is the template for the expression of pre-core/core and polymerase 
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proteins. The hepatitis B e antigen (HBeAg) is a cleavage product of the core antigen 
(HBcAg) and is secreted from infected cells. Since the 3.5 kB genomic RNA also serves as 
a template for reverse transcription, semm HBeAg generally represents a good marker of 
active HBV replication because the pre-core!core gene product is generated from the 
template that is also used for replication. Minus strand DNA synthesis initiates at the 3'-
short direct repeats (DR)-I with the terminal protein of the polymerase as a primer and, as 
synthesis progresses, the RNA template is simultaneously degraded by RNase H. Plus 
strand DNA synthesis initiates at the 3' end of the short direct repeats (DR)-2 and synthesis 
continues until the terminal protein at the S end of the minus strand is passed, producing 
an open circular DNA molecule. I.2 Lamivudine inhibits DNA synthesis by tenninating the 
nascent proviral DNA chain and apparently does not interfere with transcription from the 
covalently closed circular HBV-DNA or with translation.'·Io.I1 
In a recent study the half-life of the hepatitis B vims in vivo has been estimated to be 
around 1.0 day." In the same study the daily HBV production was calculated to be 
2.2x 1 0" particles. This rate is similar to the minimum virus production and clearance per 
day in the patients of the present study (6.1 X 1011 particles). However, the HBV half-life ill 
vivo as determined in the present study is significantly longer (2-3 days) than in the study 
of Nowak et al." This discrepancy is not readily explained, but may be related to dose-
dependent differences in dmg efficiency. 
Despite a profound effect 011 virus replication, we observed no effect of lamivudine on 
HBeAg expression during the 4-week treatment period. The constant expression of HBeAg 
during the 4-week treatment period with lamivudine was confirmed in three independent 
assays (radioimmunoassay, Abbott IMx system, and Kodak Amerlite) (data not shown). In 
a previous study, 4 of 32 patients treated with 25-300 mg lamivudine for 12 weeks showed 
a sustained clearance of HBeAg." In these four patients the mean HBV-DNA levels were 
significantly lower at baseline. From a clinical point of view it can be speculated that 
prolonged treatment periods with complete suppression of HBV replication may be 
beneficial. Continuous e.g. immune-mediated elimination of HBV -infected hepatocytes and 
hepatocellular regeneration without subsequent viral infection should lead to increased rates 
of HBeAg clearance. 
Aminotransferases are surrogate parameters of hepatocyte damage and turnover. It has been 
suggested that the operating mechanism of hepatocellular damage in patients chronically 
infected with the hepatitis B virus is immune-mediated.2,24 Therefore, the continuous 
expression of viral proteins and the insignificant change of aminotransferase levels during 
a 4-week treatment with lamivudine are in agreement with the proposed model. Similarly, 
in the study by Dienstag et al. no effect of lamivudine on AL T levels was observed within 
the initial eight weeks of treatment." 
In the study of Nowak et aI., an initial decay of HBeAg in patients taking lamivudine was 
considered to reflect the decay of infected hepatocytes. The half-life of infected 
hepatocytes was calculated to range between 10 and 100 days with an average of fIn ~ 13 
days." The constant expression of HBeAg as observed in the present study during a 28-day 
lamivudine treatment period does not allow the calculation of a definite decay rate for 
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virus-producing cells. Our data, however, imply that the minimum half-life of infected cells 
may exceed 100 days. In patients with an infected cell half-life of more than 100 days, one 
year of treatment would not reduce the number of infected cells to less than 10% of its 
initial value. 
In the present study, kinetic analysis of hepatitis B virus turnover in vivo revealed a half-
life of approximately 2-3 days. In patients with chronic hepatitis B, the minimum virus 
production and clearance per day was calculated to be 6.09±7.33xI0" virions/day. A recent 
comparison of methods for detection of HBV-DNA using the Eurohep HBV-DNA 
standards revealed that the results obtained by the Abbott liquid hybridization assay were, 
on average, 19 times lower than calculated.25 Thus, the minimum HBV production and 
clearance per day may be at least one order of magnitude higher. 
Viral dynamics have recently also been investigated in patients infected with HIV _1 5,6,7 and 
in patients chronically infected with the HCV,s HIV-l production in vivo was estimated to 
yield around 10' copies per day with a mean virus half-life of 1.2 to 2 days."'" Similar 
data were reported for HCV with an in vivo half-life of 2 days and an estimated minimum 
daily vinls production of 6.7xlOIO virions per day.s Compared to these two RNA viruses, 
the hepatitis B virus replication in vivo is even more productive. Similar to HIV -1 and 
HCV, the initial viral load before initiation of treatment is independent of viral decay 
slopes (clearance rate constants), indicating that the serum HBV-DNA concentration is 
largely a function of viral production. 
HBV replicates by means of an RNA intermediate. The process is catalyzed by a 
translation product of the polymerase open-reading frame that has reverse transcriptase 
activity. The enzyme is found in association with the virion and achieves a high rate of 
nucleotide misincorporation during transcription because such enzymes lack proofreading 
activity.24.26 Due to the compact organization of the HBV genome only few of the 
mutations that occur during the normal replication cycle permit the entry of a new virus to 
the pool for natural selection. Nevertheless, patients with chronic nepatitis B have been 
shown to have viruses with different sequences cocirculating and some regions of the 
genome are poorly conserved between different isolates. The high HBV turnover rates in 
vivo evidently explain the rapid generation of viral diversity. Although the single~cycle 
mutation rate for HBV is not known, precedent set by other vimses27,28.29,3o suggests that it 
may possibly lie somewhere between 10-5 and 10-4 per base per cycle, with considerable 
variation from base to base depending on sequence context.31 ,32 Therefore as for HIV_1 4,6 it 
is conceivable that, on average, every mutation at every position in the HBV genome 
occurs numerous times each day in an infected patient. 
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Summary 
Backgrollnd & Aims: Lamivudine inhibits hepatitis B virus replication. 'Fhis study 
investigated 6 months of lamivudine treatment at three doses. 
Methods: Fifty-one patients (43% white, 49% Asian) with chronic hepatitis B were 
randomly assigned to receive 25, 100, or 300 mg of lamivudine orally once daily for 24 
weeks with 24 weeks' follow-up. 
Reslilts: Serum hepatitis B DNA by liquid hybridization decreased in all patients and was 
undetectable at the end of the treatment in 7 of 12 (58%, 25 mg), 13 of 14 (93%,100 mg), 
and 14 of 16 (88%, 300 mg) patients. Of the 36 patients with abnormal alanine 
aminotransferase (ALT) levels at baseline, 7 of 11 (64%,25 mg), 5 of 11 (45%, 100 mg), 
and 5 of 14 (36%, 300 mg) normalized ALT at treatment completion. Quantitative 
decreases hepatitis B e antigen and hepatitis B surface antigen concentrations were 
observed at all doses. In most patients, markers of replication returned after treatment. Two 
patients (4%) were anti-HBe positive at the end of follow-up. Lamivudine was well 
tolerated. The incidence of adverse events was similar across all dose groups. However, 2 
patients developed temporary hepatic decompensation after increase in transaminase levels 
after treatment. Conclusions: Lamivudine was well tolerated and induced sustained 
suppression of hepatitis B replication during treatment in all patients at all doses. These 
data support investigation of longer treatment durations of 100 mg once daily. 
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Introduction 
Hepatitis B virus (HBV) infection remains a considerable health problem worldwide and a 
significant cause of liver disease and liver cancer in humans,l The objective of treatment of 
chronic hepatitis B is to suppress HBV replication to prevent progression to cirrhosis, 
hepatic decompensation, and hepatocellular carcinoma.2 
Alpha-interferon (a-IFN) is currently the most effective and the only approved treatment 
for chronic hepatitis BY However, the relative rate of hepatitis B e antigen (HBeAg) 
disappearance induced by a-IFN in unselected patients ranges from 20% to 30%.' 
Lamivudine, the negative enantiomer of 2'3'-dideoxy-3'·thiacytidine, is an oral nucleoside 
analogue that inhibits viral DNA synthesis by terminating the nascent pro-viral DNA chain. 
Unlike some dideoxynucleosides, lamivudine does not inhibit mitochondrial DNA synthesis 
or the proliferation of cells at concentrations that block the synthesis of viral DNA' and 
does not include mitochondrial toxicity ill vitroY The compound has been well tolerated in 
long-term studies of patients with human immunodeficiency virus (HIV) infections at doses 
of 600 mglday for more than I year.' III vitro and ill vivo models of HBV infection 
showed that lamivudine potently inhibited HBV replication.'·1D In previous phase IIIl trials, 
lamivudine given for 1-3 months resulted in a marked but temporary reduction in serum 
HBV _DNA."·12 
The objectives of this study were to assess the safety and efficacy of long-term lamivudine 
therapy in patients with chronic hepatitis B and to establish the optimal dose. 
Patients and Methods 
Criteria for selection of patients 
Patients with biopsy-proven chronic hepatitis B who had previously participated in the 28-
day, dose-ranging study of lamivudine" were eligible for inclusion if they were serum 
HBV -DNA positive, had alanine aminotransferase (ALT) concentrations of <300 lUll, and 
were serum positive for both hepatitis B surface antigen (HBsAg) and HBeAg for 6 
months preceding screening and at the time of screening. 
Patients were ineligible for inclusion if they had evidence of the following: decompensated 
liver disease (bilirubin level more than two times upper limit of nonnal (ULN), prothrorn~ 
bin time prolonged by >2 seconds, albumin level <30 gil, or a history of ascites, variceal 
haemorrhage, or hepatic encephalopathy); abnormal renal function (serum creatinine> 130 
,"mol/l); haemoglobin concentration <6.3 mmoVI, white cell count <3 x 10'/1, or platelet 
count <50 x 109/1; coinfection with hepatitis C, hepatitis delta, or HIV; a serious, 
confounding medical illness; or treatment with antiviral, inununomodulatory, or 
corticosteroid therapy since completing the previous lamivudine study. Women who were 
pregnant, lactating, or of childbearing potential and not using an effective method of 
contraception were also excluded from this study. 
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Table 1. Characteristics of study participants in the three treatment groups at 
baseline 
Lamivudine 
Treatment group 25 mg 100 mg 300 mg 
(no. randomized) (n ~ 16) (n ~ 16) (n ~ 19) 
male/female 10/6 13/3 13/6 
mean age (yr ± SEM) 35 ± 4 36 ± 4 37 ± 3 
Race Asian 9 7 9 
Black 0 I I 
White 6 7 9 
Other 0 
AL T (IU/I, mean ± SEM)' 69 ± 9 75 ± 13 91 ± 20 
HBV -DNA Ipg/ml, mean ± SEM) 147 ± 41 123 ± 25 132 ± 20 
Previous interferon use 6 (37%) 5 (31%) 8 (42%) 
Cirrhosis" 5 4 
111e ULN at the four centres ranged from 30 to 55 lUll. 
" At time of randomization to preceding lamivudine study. 
Informed consent and ethics 
The study was conducted according to the Declaration of Helsinki and Good Clinical 
Practice. The protocol was approved by the local medical ethics committees of the four 
centres. All patients gave their written informed consent. 
Randomization 
The patients were randomly assigned to receive 25, 100, or 300 mg of lamivudine (Glaxo 
Wellcome Research and Development Ltd., Greenford, England) orally once daily for 24 
weeks, with a further 24-week follow-up after treatment. The 25- and 100-mg doses were 
double-blind, but as a result of the three capsule once daily regimen, the 300-mg dose was 
not double-blind. 
Treatment randomization was stratified according to whether the patient had previously 
received a-IFN. 
Clinical evaluation 
Safety was monitored by clinical and laboratory evaluations (including the detemlination of 
anion gap and lactate) at baseline, 2 weeks and 4 weeks after treatment start, and every 4 
weeks thereafter until the end of follow-up. Compliance was assessed by questioning the 
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patient and by comparing the number of tablets returned with the number of days on 
treatment. 
Viral parameters were assayed centrally by Covance (Harrogate, England) to Good 
Laboratory Practice standards. Serum HBV-DNA was assessed quantitatively by the Abbott 
Genostics liquid hybridization assay (Abbott Laboratories, Abbott Park, IL). A validation 
of the performance of this assay conducted by Covance determined the lower limit of 
quantification to be 3 pgfml. HBeAg and anti-HBe were assessed qualitatively by Kodak 
Amerlite, Kodak Clinical Diagnostics, Amersham (Buckinghamshire, England). HBeAg 
was also assessed semiquantitatively using a 12-point standard curve calibrated against the 
Paul Ehrlich Institute standard (Paul Ehrlich Institute, Federal Agency for Sera and 
Vaccines, Langen, Germany). HBsAg was assessed quantitatively by Kodak Amerlite, and 
anti-HBs was assessed quantitatively by Abbott IMX (Abbott Laboratories) using the 
standards provided with the kits. 
Statistical analysis 
Analyses were performed on a per protocol basis for the proportion of patients serum 
HBV-DNA negative at the end of treatment. Analyses were performed on an intention-to-
treat population, defined as all patients with confirmed chronic hepatitis B infection who 
received at least one dose of the study medication, for all other parameters. Two-tailed p 
values and 95% confidence intervals were used. 
Time until suppression of HBV-DNA was calculated as the first visit when the patient's 
serum HBV-DNA concentration decreased below the limit of quantification. Times to 
suppression were compared pairwise between treatment groups by the log rank test, and 
stratified by the investigator. 
For the purposes of the analysis, all HBsAg concentrations >90,000 IUlml were set to 
90,000 IU/ml, and all HBV-DNA values <3.0 pgfml were set to 1.5 pgfml. 
Results 
Enrollment and baseline characteristics of the patients 
Fifty-one patients were enrolled, and their baseline characteristics are shown in table 1. At 
baseline, the mean (± SEM) serum HBV-DNA of all patients randomized was 134 ± 16 
pgfml and the mean ALT was 79 ± 9 lUll. Nineteen patients (37%) received at least one 
previous course of a-IFN, 15 patients (29%) had normal transaminase levels, 25 patients 
(49%) were Asian, and 22 (43%) were white. Ten patients (20%) were previously reported 
as having cirrhosis. There were 110 clinically relevant differences in these parameters be-
tween the 25-, 100-, and 300-mg dose groups. However, the mean ALT and serum HBV-
DNA concentrations at baseline for Asian patients were 56 ± 9 lUll and 104 ± 19 pgfml, 
respectively, compared with 110 ± 16 lUll and 161 ± 30 pgfml for white patients. 
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Efficacy 
Lamivudine therapy induced rapid decreases in serum HBV -DNA concentration in all 
patients at all doses (figure I), irrespective of the baseline HBV-DNA concentration. 
Undetectable serum HBV-DNA was attained by week 2 in 6 of 16 (38%), II of16 (69%), 
and 11 of 19 (58%) of the patients in the 25-, 100-, and 300-mg groups, respectively. The 
time until undetectable serum HBV-DNA was significantly shorter in the 100- and 300-mg 
groups than in the 25-mg group (p ~ 0.016 and 0.027, respectively). 
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A comparisoll o/meall ser/lm HBV-DNA cOllcelllralioll by dose (pg/ml ± SEM) 
in all patients during and after treatment. 0 Treatment period. Lamivudine at 
25 mg (l», 100 mg (*), and 300 mg (0). 
Serum HBV-DNA was undetectable at the end of treatment in 34 of 42 (81%) patients, 
and 7 of 12 (58%), 13 of 14 (93%), and 14 of 16 (88%) patients in the 25-, 100-, and 300-
mg cohorts, respectively. Serum HBV -DNA decreased precipitously but failed to become 
negative in 7 patients, 5 receiving 25 mg and I in each of the 100-mg and 300-mg cohorts. 
A further patient in the 300-mg cohort was serum HBV-DNA positive at the week 24 
assessment only (8 pg/ml), despite being negative throughout treatment and for 12 
subsequent weeks of the posttreatment period. 
This per-protocol analysis includes 3 patients (1 from each treatment group) who were 
borderline negative for HBV-DNA (,;4 pg/ml). Four patients known to have completed 
their therapy before their end of treatment assessment (and who were HBV -DNA 
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negative), becoming strongly positive for HBV-DNA by the time of that visit, were 
excluded from the analysis (I in each of the 25-rug and 100-lllg cohorts, and 2 receiving 
300 rug). Also excluded from the analysis were the 5 patients who withdrew from the 
study during the treatment period, only 2 of whom were serum HBV-DNA positive at the 
time of withdrawal (I in each of the 25-mg and 300 mg cohorts). 
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Figure 2. A comparison of mean serum HBeAg concentration by dose (Paul Ehrlich 
units per Illl ± SEM) in all patients during and after treatment. 0 Treatment 
period Lamivudine at 25 mg (~), 100 mg (*), and 300 mg (0). 
Mean serum HBeAg concentration (± SEM) decreased across all treatment groups from 
1268 ± 166 Paul Ehrlich units per Illi at baseline to 256 ± 53 Paul Ehrlich units per ml at 
the end of treatment. The data for each treatment group are presented in figure 2. The 
response of HBeAg was not dose dependent with a median percent decrease at week 24 of 
78%, 82% and 79% in the 25-, 100-, and 300-mg cohorts, respectively. Similar trends were 
observed in HBsAg concentration, which decreased from a mean (± SEM) of 41,275 ± 
4497 lUlml at baseline to 19,491 ± 3427 lUlml at the end of treatment. No difference was 
seen in response between Asian and white patients. 
AL T concentration decreased across all dose groups from a mean (± SEM) of 79 ± 9 lUll 
at baseline to 39 ± 3 lUll at the end of treatment. Of the 36 patients with abnormal ALT at 
baseline, 17 (47%) had normalized ALT by the end of treatment: 7 of II (64%), 5 of 11 
(45%), and 5 of 14 (36%) in the 25-, 100-, and 300 mg cohorts, respectively. Eleven 
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A comparison a/mean ALT concentration (lUll ± SEM) in white (a) and Asian 
(*) patients during and after treatment. 0 Treatment period 
patients experienced at least a twofold increase of ALT during the treatment period: 2 of 
16 patients (13%) in the 25-mg, 4 of 16 (25%) in the 100-mg, and 5 of 19 (26%) in the 
300-mg group. For all patients, the mean time to onset of the ALT elevation was 8 weeks. 
The mean ALTs ± SEM for both white and Asian patients are given in figure 3. Seven of 
the II patients with at least a twofold increase of AL T during the treatment period were 
white, and the maximum mean ALT of 181 ± 31 lUll (median, 150 lUll; range, 16-534 
lUll) for this cohort occurred 12 weeks after treatment completion. In contrast, the 
maximum mean ALT for Asian patients of 130 ± 75 lUll (median, 39 lUll; range, 16-1460 
lUll) occurred 20 weeks after treatment completion. 
After the completion of treatment, serum HBV -DNA became rapidly positive. Within I 
month of completing treatment, the majority of the patients had returned to pretreatment 
concentrations of serum HBV -DNA with a more gradual return in AL T, HBeAg, and 
HBsAg concentrations. 
Four patients (8%) seroconverted to anti-HBe during the study, 2 during the treatment 
period, and 2 after treatment. No clear predisposing factors were observed in the patients 
who seroconverted: 3 patients had received prior interferon treatment; 2 patients were 
Asian and 2 were white; 2 patients were receiving the 100-mg dose, whereas the remaining 
2 patients were receiving 25 and 300 mg, respectively; mean baseline serum HBV -DNA 
was 73 ± 36 pg/ml, and mean baseline ALT was 70 ± 9 lUll. At the conclusion of the 
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follow-up, 2 patients remained anti-HBe positive and I patient had reverted to HBeAg and 
HBV-DNA positivity. The remaining patient had no HBV serology data available. 
Safety 
In total, II patients withdrew over the course of the study. Five patients withdrew during 
the treatment period: 2 patients because of adverse events (recurrent nausea and headache); 
2 patients stopped treatment for personal reasons; and I failed to return. 
Table 2. Adverse events during lamivudine treatment. 
Lamivudine 
25 mg 100 mg 300 mg Total 
Treatment group (no. randomized) (n ~ 16) (n ~ 16) (n~ 19) (n ~ 51) 
Patients experiencing an adverse event" 5 (31 %) 4 (25%) 5 (26%) 14 (27%) 
Symptoms 
Nausea and vomiting 2 0 2 4 (8%) 
Fatigue 0 2 3 (6%) 
Abdominal discomfort and pain 0 2 (4%) 
Skin rashes 0 2 (4%) 
Diarrhea 0 2 (4%) 
Dizziness 0 0 1(2%) 
Hypoglycemia 0 0 1(2%) 
Headache 0 0 1(2%) 
Dyspepsia 0 0 1(2%) 
Vertigo 0 0 1(2%) 
Constipation 0 0 1(2%) 
Acne and folliculitis 0 0 1(2%) 
Eczema 0 I 0 I (2%) 
Muscle pain 0 0 I (2%) 
Pigmentary skin disorders 0 0 I (2%) 
Laboratory abnormalities 
Amylase> 2x ULN 0 0 1(2%) 
CPK> 5x ULN 0 0 2 2 (4%) 
Considered by the investigator to be at least possibly related to lamivudine treatment. 
Adverse events occurring during the treatment period and considered by the investigators 
to be at least possibly related to lamivudine are listed in table 2. Two patients experienced 
serious adverse events considered by the investigator to be related to lamivudine 
(hypoglycaemia in a diabetic patient and elevation of transaminases to 2.5 times the 
baseline level), but both patients continued lamivudine treatment, and the events resolved. 
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All other events were mild and also resolved on continued treatment. For all patients, the 
most common adverse events considered to be related to therapy were gastrointestinal (i.e., 
nau~ea, diarrhea) or fatigue. The incidence of all adverse events was similar across all 
treatment groups. There were no significant changes in laboratory parameters related to 
potential mitochondrial toxicity (creatinine phosphokinase, amylase, lipase or lactate) 
during or after the treatment period in any of the three treatment groups. 
During the posttreatment period, 8 patients (16%) experienced elevated ALT of more than 
three times the baseline value. These elevations followed return of measurable semm 
HBV-DNA and were considered to represent a reactivation of hepatitis B after the period 
of suppression of replication. All of these cases remained asymptomatic and resolved 
spontaneously, with the exception of 2 patients whose increases in transaminase levels 
were temporarily associated with elevations in bilirubin and prolongation of prothrombin 
time. One patient received a short course of prednisone. 13 Additional monitoring after the 
conclusion of this study showed that both patients had seroconverted to anti-HEe positive 
status. During the 1 -year study period, no signs of disease progression were observed. 
Discussion 
TIllS study confirmed that lamivudine suppresses HBV replication in patients with chronic 
hepatitis B and is well tolerated. A reduction in semrn HBV-DNA concentration was seen 
in all patients at all doses, with the 100- and 300-mg doses superior to the 25-mg dose in 
reducing HBV-DNA. In the parameters of efficacy used in tins study, the 300-mg dose 
provided no advantage in antiviral effect (loss of HBV -DNA) over the 100-mg dose. 
Of patients receiving the 100- and 300-mg doses, 27 of35 patients (77%) were HBV-DNA 
negative at the week 24 assessment. This is in contrast to the 22 of 22 patients (100%) 
who were negative after 3 months for the same doses reported by Dienstag et a1. 12 and may 
be explained by the higher number of withdrawals in this study, variation near the cutoff 
of the HEV-DNA liquid hybridization assay, and completion of therapy before the week 
24 assessment. Taking these factors into account, only 3 of 35 (9%; I patient receiving 100 
mg and 2 receiving 300 mg) did not experience total suppression of serum HBV -DNA 
throughout the treatment period. 
Lamivudine also reduced the serum concentration of HBeAg and HBsAg by approximately 
80% in the study population, an effect that occurred independently of the development of 
anti-HBe or anti-HBs. A trend to normalization of ALT was also observed and is 
suggestive of a concurrent reduction in liver inflammation. This is further supported by 
data showing improved histology during treatmene4 and with previous reports of a 
correlation in humans between progressive liver disease and the presence of serum markers 
for ongoing HBV replication. IS 
Unlike a-IFN. the response to treatment of lamivudine was not dependent on pretreatment 
characteristics. This study included patients who would normally be considered poor 
responders to a-IFN; at baseline, 29% of the popUlation had normal ALT levels, 55% had 
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HBV-DNA concentrations above lOa pglml, 49% were of Asian origin, and 37% were 
nonresponders to a previous course of uMIFN. However, a sustained response to uMIFN is 
generally achieved through seroconversion from HBeAg to anti-HBe. For the majority of 
patients, serum HBV-DNA retumed rapidly after treatment, with only 2 patients (4%) 
confIrmed anti-HBe positive at the end of the follow-up period. It is unlikely that the large 
cohort of Asian patients reduced the overall rate of seroconversion observed; the small 
number of seroconversions in this study occurred in both Asian and white patients. 
Chronic HBV infection is sustained by multiple copies of covalently closed circular DNA 
(cccDNA) in the nucleus, which act as templates for replication. I' The pool of cccDNA is 
maintained by an intracellular conversion pathway to ensure that a stable number of copies 
of cccDNA exist in equilibrium. 17 Inhibition of HBV replication by lamivudine may result 
in a decline in the total HBV load through two mechanisms: a combination of diminished 
production of viable virus (permitting new cells to remain uninfected) with hepatocyte 
turnover, resulting in a decrease in the number of infected cells; and depletion of the 
number of copies of cccDNA within the infected hepatocyte through inhibition of 
production of replicative intermediates. However, without host immune response to HBV, 
the potential for infection remains as long as cccDNA persists. 
Despite the potent suppression of replication observed in this study, sustained response to 
therapy was rare. Considerably 10ngerMterm treatment regimens may be required to induce 
a sustained response. Further studies to assess lamivudine alone and in combination with 
interferon on the histological evolution of the disease are ongoing. 
Lamivudine was well tolerated during the study period. The overall incidence of adverse 
events was low, and both the type and severity of events reported did not increase with 
increasing dose. Some patients showed a marked increase in serum HBV -DNA after 
treatment with a subsequent elevation of ALT 8-20 weeks after treatment. In most patients, 
the acute hepatitis-like events were asymptomatic and can be related to the return of HBV 
replication after treatment cessation; the 2 patients with increases in AL T levels after 
treatment and associated temporary hepatic decompensation both subsequently 
seroconverted from HBeAg to anti-HBe after the conclusion of this study. However, 
careful monitoring remains indicated if lamivudine therapy is withdrawn in patients with 
marginally compensated Of decompensated liver disease, because severe reactivation of 
HBV replication may induce decompensation. I) 
In summary, lamivudine potently suppresses hepatitis B replication in chronic hepatitis B 
patients irrespectively of race and is very well tolerated. Data from tIus study suggest that 
a decline in inflammatory activity accompanies treatment and that long-term treatment dUM 
rations of 100 mg once daily and/or combination therapy are required. 
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Summary 
Lamivudine, a novel cytosine analogue exhibits potent antiviral activity against hepatitis B 
virus in vitro and in vivo. The standard HBV -DNA hybridization assay used in phase II 
clinical studies has a low sensitivity, the detection limit of HBV -DNA levels is 
approximately 10' genome equivalents per ml (gen.eq.lml). We used the a semi-
quantitative peR assay (detection limit _10' gen.eq.lml) to determine HBV-DNA levels 
during a 24 weeks lamivudine study in 51 stable chronic hepatitis B patients (HBsAg and 
HBeAg positive). Patients were randomly allocated to receive oral doses of 25, 100 or 300 
mg of lamivudine once daily. 
The median serum concentration of HBV-DNA fell from 10' to 10' gen.eq.lml, a four log 
median reduction. A trend towards more profound suppression of viral replication with 
increasing dose of lamivudine was observed. After 12 weeks of therapy 12% of patients 
had undetectable HBV -DNA in the peR assay; this increased to 26% after 24 weeks, while 
an additional 20% dropped to the level of detection of the assay. 
We conclude that a 24-week course of lamivudine decreases serum HBV-DNA to the level 
of peR detection in 46% of patients. Such additional viral suppressive activity with higher 
doses and more protracted lamivudine may be of clinical utility prior to liver 
transplantation. Further studies are needed to define the degree of virus suppression 
required in clinical practice, and methods to increase the efficacy of vims suppression. 
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Introduction 
Lamivudine, the (-)enantiomer of 2'3'-dideoxy-3'-thiacytidine, was found to be a non-toxic 
potent inhibitor of hepatitis B virus (HBV) replication. I.' In patients treated at doses of at 
least 100 mg, lamivudine induced reduction in HBV-DNA levels to below the detection 
limit of the liquid phase hybridization assay (Genostics; Abbott Laboratories, Chicago, Ill, 
USA) in the majority of patients""" 
The limit of detection of the Abbott liquid hybridization assay used for quantitative 
measurement of HBV -DNA levels in serum is approximately 107 genome equivalents per 
ml (gen.eq.lml), when the test is calibrated on the well defined Eurohep HBV-DNA 
standard.' The semiquantitative polymerase chain (PCR) method expands the scale of 
measurement to a detection limit of approximately 10'_10' gen.eq.lml.' In view of the 
scientific and clinical interest in information on HBV clearance from blood during 
lamivudine therapy, we measured HBV-DNA by the semiquantitative PCR assay during a 
24 weeks course of lamivudine in patients with chronic hepatitis B. 
Patients and methods 
Study design 
In a randomized single-blind (patient) study, 51 stable chronic hepatitis B patients (HBsAg 
(+) and HBeAg(+) for at least 6 months) received oral doses of 25, 100 or 300 mg 
lamivudine once daily for 24 weeks. Follow-up after treatment lasted 24 weeks. Patients 
selected for the study were to have serum HBV -DNA levels exceeding 10 pgfml 
(Genostics, Abbott) and ALT below 300 lUll. Results of this study have been reported 
elsewhere.s 
Analyzed sera 
At the start of the study and the visits at 12 and 24 weeks serum was aliquoted and frozen 
inmlediately at _20°C. Serum HBV-DNA was assessed quantitatively by liquid 
hybridization (Genostics, Abbott) with the lower limit of quantification, according to the 
manufacturer's standard, defined to be 3 pgfml. Per protocol analysis excluded one patient 
who was withdrawn from the study at baseline due to negative HBV -DNA result by 
hybridization assay, one patient was withdrawn at week 12 and 7 patients at week 24. Of 
these 5 attended the clinic at least three days behind the calculated week 24 visit, therefore 
their trial medication was scheduled to be completed at least three days before the week 24 
sample was taken. In 40 patients with HBV-DNA levels < 10 pgfml at week 24, PCR 
assays were performed in duplo on sera obtained at week 0, 12 and 24 of treatment (lOS 
samples). In the remaining II patients HBV-DNA levels were calculated from the results 
of the liquid hybridization assay (27 samples). According to Kuhns et aI' 103 pglml 
(Genostics, Abbott) is equal to 3 x 10' gen.eq.lml, subsequently we obtained evidence that 
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the Abbott assay may underestimate the actual number of HBV genomes.' In this study 
PCR results in 46 samples (tested in duplo) that were positive in the hybridization assay 
result, allowed the calculation of a conversion factor. We observed that I pg (Genostics, 
Abbott) is equal to 5 x 10' gen.eq.lml. In case the results of the liquid hybridization assay 
was negative and no serum was left for PCR analysis (6 samples), the HBV-DNA level 
result was taken as 10' gen.eq.lml. Negative PCR results were taken as 101 gen.eq.lml. All 
samples were assayed in duplicate, the two values of the semi-quantitative peR exhibited a 
maximum discrepancy of one log and were both used for analysis. 
Table 1. Characteristics of study participants according fa dose of lamivudine. 
Dose group 25 mg 100 mg 300 mg 
Total randomized (n) 16 16 19 
Male/female 10/6 13/3 13/6 
Mean age in years(range) 35 (18-65) 36 (17-66) 37 (18-62) 
Race Asian 9 7 9 
Caucasian/white 6 7 9 
Other I 2 I 
Median ALT lUll (range) 54 (15-130) 68 (20-184) 54 (23-352) 
Median AST lUll (range) 44 (23-89) 36 (20-135) 39 (18 -255) 
Median HBV-DNA pglml* (range) 99 (4 -498) 100 «3 -380) 117(21-391) 
*(Genostics, Abbott) 
Polymerase chain reaction and quantitation 
HBV-DNA was isolated from serum essentially as described by Boom.IO Briefly, 100 ~I 
serum was denatured in 800 ~I lysis buffer I (120 g guanidinium-iso-thiocyanate, 100 ml 
0.1 M Tris-HCI (PH 6.4), 22 ml 0.2 M EDT A (PH 8), 2.5 ml Triton X-IOO) and 40 ~I 
celite (0.2 g/ml) for 10 min at room temperature. After washing twice with lysis buffer 2 
(120 g guanidinium-iso-thiocyanate plus 100 ml 0.1 M Tris-HCI, pH 6.4), twice with 80% 
ethanol and once with acetone, respectively, the celite pellet was dried briefly in a vacuum 
exsiccator. DNA was released by incubating for 10 min in 100 ~I 10 mM Tris-HCI (PH 8) 
at 56 "C. 
Samples were diluted ten-fold in 10 mM Tris-HCI, pH 8, containing 10 ~glml poly A as a 
carrier. Dilutions up to I: 100,000 were made. Each sample was isolated twice on separate 
days. As reference, the Eurohep HBV -DNA standard containing 4.2 .10' gen.eq.lml for 
genotype adw and 3.8. 10' for genotype ayw was included in each dilution series. II Ten ~I 
'were used in a PCR assay with primers directed against the pre SI/S2 region of HBV 
i(primer I, nucleotide 3044-3067: 5'gtg.gag.ccc.tca.ggc.tca.gg, primer 2, nucleotide 169-188: 
I 
5'ggt.cct.agg.aat.cct.gat.gt). The PCR assay was performed in a Biomed 60 themlOcycler 
(Biomed, Theres, Germany) starting with preheating for 4 min at 94"C, followed by 40 
I cycles for I min at 94"C, I min at 52"C and I min at 74"C with I U Taq DNA 
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polymerase (Promega, Leiden, The Netherlands). The peR product of 328 bp was analyzed 
by standard 2% agarose gelelectrophoresis and confirmed after electroblotting (BioRad 
SemiDry transfer cell, Hercules, eA, USA) with a 12P-labelled oligonucleotide probe 
(probe: nucleotide 58-87: 5'cct.gct.ggt.ggc.tcc.agttcc.gga.aca.tga). The detection limit of 
our peR assay is around 500-1000 genome eq per ml, using the Eurohep standard, and has 
been validated in a quality assurance programme.1 Positive and negative control samples 
were included both during sample preparation and during the peR procedure. 
Statistical analysis 
The geometric means of HBV-DNA levels were calculated from the different dose groups 
at week 0, 12 and 24 of treatment. \Vilcoxon signed rank test was used to show 
statistically significant differences (p<0.05) between HBV-DNA levels comparing dose 
groups (ulUnatched pairs) and duration of treatment (matched pairs). 
Table 2. Pel' protocol analysis of patients with negative HBV-DNA according to dose 
of lamivudine. The lower limit of deleelion of Ihe HBV-DNA peR assay is 10' gen.eq./ml. 
25 mg 100 mg 300 mg 
Number of randomized patients 16 16 19 
Genostics negative 0(0%) 1(6%) 0(0%) 
Week 12 analysis (n) 16 15 18 
Genostics negative (patients) 7/16 (44%) 14/15 (93%) 15/18 (83%) 
peR negative (samples) 1132 (3%) 4/30 (13%) 7/36 (19%) 
Week 24 analysis (n) 13 14 15 
Genostics negative (patients) 6/13 (46%) 12/14 (86%) 13/15 (87%) 
peR negative (samples) 3/26 (12%) 8/28 (29%) 11130 (37%) 
Results 
The baseline characteristics of all patients randomized to this study are shown in table 1. 
The geometric means of HBV -DNA levels were calculated from the different dose groups 
at week 0, 12 and 24 of treatment. HBV-DNA levels were not significantly different at 
baseline for the three dose groups. All dose groups showed a statistical significant decrease 
of HBV-DNA levels between week 0 and 12 (p<0.001); between week 12 and 24 HBV-
DNA levels decreased significantly only for the 300 mg dose group (p<0.01). We observed 
no significant difference in HBV -DNA levels between the 100 and 300 mg dose groups 
(figure 1). 
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Figure 1. Serum HBV-DNA levels in the limiting dilution PCR in patients receiving 
lamivudine once daily according to dose [25 mg ( • ), J 00 mg ( , ) and 300 mg ( • ), 
geometric mean]. Patients with negative PCR taken as 101. Error bars represent SEM 
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Figure 2, Percentage of patients who became HBV-DNA negative by limiting dilution 
peR at baseline, aj/er J 2 and 24 weeks of lamivudine therapy according to dose [25 mg 
(.), JOOmg( ')and300mg(.)}. 
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When baseline values were compared to peR values at week 24, 67% of patients had over 
2 log reduction in the amount of HBV-DNA with a median 4 log reduction. 
At the week 12 assessment, I (3%), 4 (13%) and 7 (19%) of samples (2 per patient) were 
negative by peR in the 25, 100 and 300 mg cohorts respectively, while a further 5 (16%), 
3 (10%) and 6 (17%) were at the level of detectability of the peR assay (10' gen.eq.lml). 
At week 12 totally 27% of 49 patients (per protocol analysis) had HBV-DNA levels below 
or at the level of detection of the peR assay (figure 2). 
At the week 24 assessment, 3 (12%), 8 (29%) and II (37%) samples tested by peR were 
negative in the 25, 100 and 300 mg cohorts respectively, while a further I (4%), 4 (14%) 
and 12 (40%) samples were at the level of detectability of the peR assay (figure 2). 
Overall 26% of 42 patients (per protocol analysis) were negative for serum HBV-DNA by 
peR at the week 24 assessment, in addition 20% of patients had serum HBV-DNA 
concentrations at the level of detectability of the peR assay (figure 2). 
ALT normalization occurred in 17 (47%) of patients with abnonnal ALT at baseline 
(n~36). No significant correlation was found between ALT levels and HBV-DNA levels 
measured by peR. 
Discussion 
This study shows that suppression of serum HBV -DNA during a 24-week course of 
lamivudine is continuing below the level of detection of the liquid hybridization assay. Per 
protocol analysis showed that 46% of patients had HBV -DNA levels below or at the level 
of detection of the peR assay (,;10' gen.eq.lml); in comparison to 74% by the less 
sensitive liquid hybridization assay «10' gen.eq.lml). Higher daily doses (100 mg and 300 
mg) are more effective in suppressing HBV-DNA compared to the 25 mg (table 2, figure 
I, p<0.05). These results are in accordance with the findings after a three-month course of 
lamivudine. In that study a negative HBV-DNA test was observed in 70% of patients of 
the 25 mg group at 3 months, compared to 100 % in the 100 and 300 mg groups using the 
same liquid hybridization assay.4 
Our study showed a more profound suppression of HBV -DNA after 24 weeks compared to 
12 weeks of treatment (12% peR negativity at week 12 and 26% at week 24, table 2, 
p<O.Ol). The incidence of peR negativity increases with increasing duration of treatment. 
Prolongation of treatment is attractive firstly because lamivudine is well tolerated in 
clinical studiess.12 and secondly, but probably more important, since a correlation between 
persistent suppression of viral replication and subsequent improvement in liver histology 
has been found. 13 The results of the larger phase III study with liver histology as primary 
outcome variable are eagedy awaited. 
However, prolongation of lamivudine monotherapy beyond 6 months may result in the 
development of a lamivudine resistant mutant viruS. 14•1S In order to prevent the 
development of lamivudine resistant mutants it is an attractive thought to aim for rapid and 
profound inhibition of HBV replication. 
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Based on early kinetic studies the standard dose of lamivudine for the treatment of chronic 
hepatitis B was suggested to be 100 mg daily. Our data suggest a possibly more profound 
suppression induced by the 300 mg dosage than by the 100 mg dose. The highest daily 
dose of 300 mg showed the highest percentage of peR negative patients at week 24 and a 
statistically significant reduction of HBV-DNA levels between week 12 and 24 (figure I 
and 2). Therefore future studies should be monitored by a sensitive quantitative peR to 
confirm the relationship between the degree of virus suppression and outcome measures 
like the rate of developing mutants. In addition, further standardization of HBV-DNA 
measurement can be applied since recent publications suggest that our measurement still 
underestimates the number of HBV genomes.6 
A much smaller but very important group to whom such a powerful and easily 
administered antiviral drug could be of immediate value is HBV-DNA-positive patients 
who face liver transplantation. Antiviral therapy to reduce the level of circulating HBV-
DNA before liver transplantation is one of the logical approaches to improvement of the 
results of liver transplantation for HBY -related liver disease. Transplantation for patients 
with cirrhosis and hepatic decompensation has been hampered by the lack of treatments 
with a favourable efficacy and toxicity profile. 16. 18 Lamivudine can decrease HBV -viraemia 
to below the level of detectability by peR in 27% of all patients randomized to doses of 
100 mg or more for 24 weeks, and has been well tolerated in clinical studies to date.4,5.19 
In conclusion, our results for chronic hepatitis B patients indicate that lamivudine continues 
to potently suppress viral replication below the limit of detectability of traditional assays. 
Suppression in viral replication is more profound after 24 weeks of treatment in 
comparison to 12 weeks, resulting in the loss of detectable HBV-DNA by peR in 33% of 
patients after 24 weeks of therapy with 100 or 300 mg lamivudine daily. 
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Summary 
Lamivudine is an oral nucleoside analogue with strong antiviral activity against hepatitis B 
virus (HBV). In previous clinical studies, a course of lamivudine for 4-12 weeks induced a 
profound decrease in HBV viraemia with excellent tolerance, but data on histology have 
not yet been reported. We studied the liver histology of 13 patients with stable chronic 
HBV infection treated with 25 mg, 100 mg or 300 mg lamivudine daily for 6 months. All 
patients became HBV-DNA negative during treatment. The paired biopsies taken at entry 
and during treatment were scored by two independent observers, using the components of 
the histology activity index (HAl) and fibrosis (modified Knodell). The items scored were 
piecemeal necrosis, focal necrosis, confluent necrosis, portal inflammation and fibrosis. 
Before treatment, the biopsies yielded a mean HAl of 4.4 (±0.8), which decreased to HAl 
2.8 (±0.5) during treatment. An analysis of the individual components of the classification 
system showed a significant decrease in piecemeal necrosis from a pre-treatment 1.4 (±O.3) 
to 0.8 (±O.I) during treatment (p ~ 0.02). Although a trend was found for the other 
components, it was not statistically significant, probably due to the number of pairs 
examined. In conclusion these results suggest that prolonged suppression of viral 
replication by lamivudine can improve liver histology. In contrast to previously published 
reports on a-interferon therapy, tltis study indicates that the improvement in liver histology 
with lamivudine is independent of HBeAg seroconversion. 
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Introduction 
Lamivudine, the (-) enantiomer of 2'-deoxy-3'-thiacytidine, is an oral nucleoside analogue 
that strongly inhibits hepatitis B virus (HBV) replication both in vitrol and in vivo',', The 
aim of antiviral therapy for chronic hepatitis B is HBeAg seroconversion, since that event 
is usually followed by biochemical and histological remission of the liver disease.' 
Lamivudine for 6 months does not appear to induce HBeAg seroconversion, but 
biochemical remission ensues in the majority of patients. We tried to establish whether 
lamivudine therapy leads to histological improvement. 
Table 1. Demographic and baseline characteristics of the patients. 
Patient (n) 15 
Gender (mli) 12/3 
Age (mean, range) 
HBV-DNA (mean, range) 
HBeAg (mean, range) 
ALT (mean, range) 
a-Interferon non-responder (II) 
CaucasianlAsianIBlack (II) 
'" pg HBV-DNA (Genostics, Abbott) 
Patients and methods 
Study population 
32.4 (18-61) years 
169 (4-520) pg/ml* 
36579 (168-158716) U/I 
66 (32-188) lUll 
8 
11!3/1 
Fifteen patients with stable chronic (HBeAg positive) hepatitis B viral infection, who had 
previously participated in a 28-day lamivudine study, entered the study,' All had HBV-
DNA >3 pglml (Genostics, liquid hybridization assay, Abbott Laboratories, IL, USA) and 
HBeAg > I U/I (lMx, Micro particle Enzyme Immunoassay, Abbott Laboratories, IL, USA) 
detectable in serum and elevated alanilre aminotransferase (ALT) levels (>30 lUll), None 
of the patients had decompensated liver disease, severe hepatitis (ALT >300 lUll), co-
infection with hepatitis C, hepatitis D or HIV or other serious medical illnesses. Eight 
patients had previously received alpha-interferon (a-IFN) without response, 
These patients, part of a multicentre phase-2 study, had been randomly assigned to receive 
either 25, 100 or 300 mg lamivudine orally once daily for 24 weeks, The clinical, 
biochemical and virological results of tlus muiticentre study have been reported elsewhere.6 
A liver biopsy was obtained from thirteen of fifteen patients of our unit before and during 
treatment. Initially to exclude the occurrence of fialuridine (FIAU) like toxicity, the second 
biopsy was taken after 8 weeks (1I~4), 12 weeks (11~3), 16 weeks (1I~4) or 24 weeks (n~2) 
of therapy, 
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Liver biopsies 
Liver tissue was fixed in 4% phosphate-buffered formaldehyde, routinely processed and 
embedded in paraffin blocks; 5 Ilm sections were then cut. Liver sections were stained 
with haematoxylin and eosin (H&E), periodic acid-Schiff (PAS), PAS after diastase 
digestion and elastica Von Giesson stain. HBcAg was detected on paraffin-fixed slides 
with polyclonal rabbit anti-HBc (Dako Corp., Santa Barbara, CA, USA) as first antibody 
and peroxidase-labelled swine anti-rabbit IgG (Dako Corp., Santa Barbara, CA, USA) as 
second antibody after ill1ll1ersion in 3,3'-diamino benzidine (DAB) solution for 7 min. All 
liver. biopsies (n=26) were scored blindly by two observers using the Desmet modification 
of the Knodell scoring system.7.' The histology activity index (HAl) combines the scores 
for piecemeal necrosis, fresh confluent necrosis, intralobular degeneration/focal necrosis 
and portal inflammation. The percentage of hepatocytes found to be positive for HBcAg . 
ranged from none, <1%, 1-5%,5-30%,30%-70% to >70%. 
Statistical analysis 
We tested the hypothesis that within the study group no difference existed between the 
values before treatment and during treatment. For continuous variables (HAl, ALT, 
HBcAg), we used the Wilcoxon signed rank test for paired samples. P-values for 
components of the HAl and fibrosis were calculated using the chi-squared test. Results are 
given as mean ± standard error of the mean, (±SEM). 
Ethics 
This study was approved by the institutional review board, and all patients gave written 
informed consent. 
Results 
Baseline characteristics of the patients are shown in table 1. All 15 patients who entered 
the study completed treatment ami became HBV-DNA negative according to the standard 
hybridization technique (Genostics, Abbott) during treatment. In 13 patients, HBV -DNA 
became detectable within 4 weeks of termination of lamivudine treatment. However, two 
patients became HBeAg-negative during the same 6 months, one is still HBeAg and HBV-
DNA-negative. All patients had elevated serum ALT at entry, mean (±SEM) was 66 (±II) 
lUll. Serum-ALT dropped in five patients (33%) to the normal range (ALT ,;30 lUll). 
Mean post-treatment ALT was 44 (±6) lUll, this difference is statistically significant 
(p~0.02). 
Of 13 patients who underwent liver histological studies, histology improved in seven cases 
(figure I). Piecemeal necrosis decreased from a mean (±SEM) of 1.4 (±0.3) for pre-
treatment biopsies to 0.8 (±O.l) during treatment (p~0.02). An improvement was also found 
for portal inflammation. The total HAl improved from a mean (±SEM) of 4.4 (±0.8) before 
treatment to 2.8 (±0.5) during treatment; tillS difference was not statistically significant 
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(table 2). The improvement in HAl was most obvious for patients who received a 
cumulative dose of lamivudine of more than 5 gram (figure 2). No difference in fibrosis 
was observed. For six patients (46%), the HAl was nonnal (scoreS2) for the second liver 
biopsy (figure 1). The expression of HBcAg in hepatocytes disappeared in two cases. In 
one of these patients, a HBeAg seroconversion occurred. In the other patient very low 
levels of HBeAg remained detectable during treatment and HBeAg relapsed after the end 
of treatment. For all patients, the decrease in HBcAg expression during treatment was not 
statistically significant. 
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Discussion 
......................................•..•....... .1 ....... .1 .... , 
before treatment during treatment 
Individual histology activity index before and during treatment with 
lamivudille. 
The results of this study suggest that prolonged viral suppression without HBeAg 
seroconversion can induce histological improvement. The suppression of viral replication 
inactivates the disease process as reflected by significant improvement in serum-AL T and 
piecemeal necrosis. Moreover, the total HAl score improved during therapy. 
The liver biopsies were taken at different time-points during lamivudine therapy to 
determine whether duration of therapy is an important factor, but this issue could not be 
clarified in this study. In contrast, the cumulative dose of lamivudine seems to be more 
important, the critical limit being 5 grams (100 mg for 50 days) (figure 2). From previous 
studies, we know that 25 mg is a suboptimal dose;6 however, in the present study the four 
patients who received 25 mg daily became HBV -DNA negative, but in two of them the 
HAl score worsened during treatment. Overall no differences were detected between the 
three doses because of the small numbers. In addition, we tested HBV-DNA negative 
patients by polymerase chain reaction (HBV -DNA peR), out of the three patients who 
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became HBV-DNA negative by peR during treatment two had a marked improvement in 
HAl (5 points). 
This study covered a small group of patients treated with lamivudine for 6 months: 
histological improvement was already evident in the majority of patients. At present, no 
reports on patients treated for more than 6 months are available, so we still do not know 
the outcome of long-term viral suppression by lamivudine. From other studies we know 
that piecemeal necrosis in particular is the histological finding that predicts the 
development of cirrhosis.' This suggests that long-term viral suppression may eventually 
prevent the development of cirrhosis. 
Especially interesting is the fact that patients with a high HAl score before therapy 
exhibited the most pronounced improvement. This suggests that patients with severe 
hepatitis, who were actually excluded from this phase 2 study, would benefit the most from 
prolonged viral suppression. 
Table 2. Components 0/ HAl and fibrosis be/ore and dllring treatment 
in J 3 patients treated with lamivudine. 
2 
3 
4 
5 
(1-4) 
(1-5) 
Results are given as mean. 
* p = 0.02, chi squared test. 
Piecemeal necrosis 
Confluent necrosis 
Focal necrosis 
Portal inflammation 
Fibrosis 
Total HAl 
Knodell score 
Before 
treatment 
1.4 
0 
1.2 
1.8 
1.4 
4.4 
5.8 
During 
treatment 
0.8' 
0 
1.2 
1 
1.4 
2.8 
4.2 
The primary goals of therapy for chronic HBV infection are to diminish infectivity, 
improve the quality of life and inactivate the liver disease. These objectives are usually 
achieved when HBV is completely abolished, defined as elimination of all viral markers, or 
active viral replication is tennillated, characterized as sustained elimination of HBeAg and 
HBV-DNA and nomlalization of ALT levels.4,lo,1I When achieved, these factors, after a-
IFN therapy, lead to sustained histological improvement." Lamivudine has been shown to 
be a potent inhibitor of viral replication. Six months of lamivudine therapy is not sufficient 
to induce a pennanent response through HBeAg seroconversion and raises the issue of 
treatment outcome with this class of compounds. This outcome can be cessation of 
histological progression of the disease after persistent viral suppression. 
On the basis of our findings for this small group of patients, we suggest that our primary 
treatment goal should be redefined as improvement of the histological standard, in contrast 
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to the treatment goals defined for u-IFN therapy. 
In conclusion, lamivudine is a very effective inhibitor of lIBV replication. This results in 
improvement of serum transaminase levels and histological activity, especially piecemeal 
necrosis, also in the absence of HBeAg seroconversion. 
12 
10 
iil 
'0 .~ 8 
:f I=~:"'<~~' 1:) 6 ............................... -....... -.. -----... - .. -.. ro 
Figure 2. 
o " 
0.1 
............................................. 
1 10 
cumulative dose (gram) 
Individual histology activity index be/ore and during h·eatment. HAl is 
plotted against cumulative dose (duration x dose) o/lamil'udine at the time 
of the secolld liver biopsy. 
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Summary 
Alpha-interferon (a-IFN) achieves seroconversion in about one third of naive patients; 
attempts to achieve seroconversion in patients who have previously failed a-IFN have 
proven disappointing. Combination chemotherapy (a-IFN with a nucleoside analogue) 
might provide a treatment alternative for these patients. \Ve have undertaken a phase 2 
study in 20 patients who had previously failed at least one course of a-IFN. All patients 
were treated for 16 weeks with a-IFN in combination with 12 or 16 weeks of lamivudine 
(3'TC). This study was designed to assess the safety, tolerability and efficacy of the 
combination. In addition, pharmacokinetic studies were perfonned to identify/exclude 
significant phannacokinetic drug interaction. 
The combination was well tolerated, and side-effects of the combination were 
indistinguishable from the recognized side-effects of a-IFN. Phannacoklnetic studies 
performed on days 1 and 29 did not show any significant interaction. All patients achieved 
HBV-DNA clearance during treatment, but 19 relapsed aner the end of treatment. 
HBeAgianti-HBe seroconversion was observed for 4 patients, hut was sustained for a 
single patient (who also had sustained HBV-DNA clearance). 
In conclusion, combination therapy with a-IFN and lamivudine given for 16 weeks appears 
safe and is well tolerated. However, for this group of patients who had previously failed 
interferon monotherapy, the efficacy of combination interferonllamivudine therapy appears 
disappointing; other treatment strategies should he investigated. 
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Introduction 
Lamivudine, the negative enantiomer of 2'3'-dideoxy-3'-thiacytidine, is an oral nucleoside 
analogue that inhibits viral DNA synthesis by terminating the nascent proviral DNA chain. 
Unlike some dideoxynucleosides, lamivudine does not inhibit mitochondrial DNA 
synthesis 1 and does not suppress haemopoiesis at concentrations that inhibit the synthesis 
of viral DNA. 
Lamivudine has been used to treat more than 30,000 mv -infected patients, and has been 
well tolerated in long-tern) HIV studies at 600 mglday.' 
Suppression of hepatitis B virus (HBV) replication was observed when HIV!HBV co-
infected patients were treated with larnivudine.3 In dose-ranging studies of HBV-infccted 
patients, lamivudine was prescribed for 28 days to 6 months at doses from 5 mg to 600 
mg.'·s Marked reduction of serum HBV-DNA was observed for all doses greater than 20 
rng/day, though levels returned to pre-treatment values at conclusion of treatment for most 
patients. 
Currently, a-IFN is the only agent licensed for the treatment of chronic HBeAg-positive 
infection, but only one third of treated patients achieve HBeAg seroconversion.6 Further 
atternpts to suppress viral replication in patients who previously failed interferon have 
proven disappointing.7,8,9,JO,11 
Recently, Dienstag et al reported the results of lamivudine therapy (at 3 different doses) for 
patients with chronic hepatitis B infection. 12 Thirty two patients were treated, and the 
cohort included 17 patients who had previously failed interferon monotherapy. HBeAg 
seroconversion was achieved for 3/17. Therapy of chronic HBV infection might combine 
the antiviral properties of lamivudine with the immunomodulatory properties of a-IFN. 
Interferon-induced HBeAg/anti-HBe seroconversion may be favoured by lamivudine-
induced reduction of serum HBV -DNA. 
TIns multicentre study was designed to assess the safety, tolerability and efficacy of 
combination lamivudine/interferon therapy for the treatment of patients with chronic 
HBeAg and DNA-positive HBV infection who have previously failed to seroconvert with 
a-IFN monotherapy. 
Patients and methods 
Eligible patients were aged 18-70 and had compensated liver disease due to chronic HBV 
infection. All were HBsAg, HBeAg and HBV -DNA positive (> 10 pglml according to the 
Abbott Genostics assay). Patients had failed to seroconvert (from HBeAg to anti-HBe) 
with at least one prior course of a-IFN at a minimum dose of 13.5 MU per week for at 
least 16 weeks. At the time of screening, at least 6 rnonths had elapsed since most recent 
interferon treatment. Exclusion criteria included the presence of ()\o-illfection with HDV, 
HCV orHIV. . 
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Eligible patients were randomized to one of two treatment regimens. All patients received 
alpha 2b interferon (lntron A, Schering-Plough Inc, USA) 10 MU tbree times weekly for 
16 weeks. In addition, patients randomized to group A received placebo (orally) for 4 
weeks, followed by lamivudine 100 mg/day for 12 weeks. 
Patients in group B received lamivudine 100 mg/day for 16 weeks. Randomization was in 
the ratio 1 :2, treatments A:B. Randomization was double-blind and all patients were 
followed for 16 weeks post-treatment (figure I). 
r 
randomization 
-4 0 4 8 
t t 
pharmacokinetics 
Figllre 1. Design of the study 
12 
weeks 
Included: 
A n= 6 
B n=14 
follow-up 
16 20 24 28 32 
This design enabled the study to assess the tolerability of the combination therapy. ct-IFN 
monotherapy is associated with significant and predictable side~effects. These side~effects 
are most pronounced during the initial weeks of therapy. The inclusion of a (double-blind) 
placebo group enabled the study to distinguish morbidity associated with the 
interferonllamivudine combination therapy from the morbidity associated with a-IFN alone. 
All patients were followed after treatment for 16 weeks. 
Safety and tolerability were measured by clinical and laboratory evaluations at each clinic 
visit (baseline, weeks 1, 2, 3, 4, 6, 8, 12 & 16 of treatment, then every 4 weeks until the 
end of follow-up). An ALT "flare" was defined as a 3-fold rise in serum ALT to a value 
in excess of ten times the upper limit of normal. 
HBV markers were assayed centrally from stored serum by Coming Hazleton, Harrogate, 
UK. Serum HBV -DNA was measured quantitatively by the Abbott Genostics assay 
(Abbott, Chicago, Illinois, USA). HBeAglanti-HBe was assessed in a semi-quantitative 
assay (Kodak Amerlite, Kodak Clinical Diagnostics, Amersham, UK). HBsAg and anti-
HBs were measured by ELISA (Abbott, Chicago, Illinois, USA). 
Pharmacokinetics 
Lamivudine and ct-IFN pharmacokinetics were assessed on days I and 29. Blood samples 
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for a-IFN phannacokinetic analysis were taken before the first dose and at 0.5, 1, 1.5, 2, 3, 
4, 5, 6, 7, 8, 10, 12, 18 and 24 hours after dosing. Additional blood samples were taken 
pre-dose and 1, 2, 4, 8, 12 and 24 hours post-dose for lamivudine assay. Urine samples for 
the assay of lamivudine concentration were pooled in the following fashion: post-dose 0-6 
hours, 6-12 hours and 12-24 hours. 
Plasma samples were analyzed for a-IFN concentration by ELISA or IRMA at the 
Schering-Plough Research Institute, Kenilworth NJ, U~A. Serum and urine samples were 
analyzed for lamivudine concentration by a validated high pressure liquid chromatography 
method with UV detection." 
The non-compartmental pharmacokinetic analysis was performed using TOPFIT version 
2.0 software. I' The following parameters were determined for both a-IFN and lamivudine: 
Cm~\(' tma.,,' AVC, AVCIa.st- In addition, oral clearance (ClIF), Aet (amount excreted in urine 
Over time I), Cl, (renal clearance) and AUC~ were estimated for lamivudine. 
The study was approved by the local research ethics committees of the three participating 
centres, and all patients gave written informed consent. 
Table 1. Basic demography and pre-treatment characteristics of 20 patients. 
Group A Group B Total 
(n~6) (n~14) (n~20) 
Patient characteristics 
Age (yrs) 39(7) 39(13) 39(11) 
Sex (mil) 5/1 14/0 19/1 
Ethnic origin (asianicaucasian) 313 4/10 7/13 
Baseline variables 
Weight (kg) 76(9) 78(11 ) 77(10) 
Pre-treatment AL T (lUll) 66(46) 81(63) 77(58) 
Pre-treatment HBV -DNA (pg/ml)* 92(75) 187(156) 158(142) 
Pre-treatment histology** 
cirrhotic 0 2 2 
non-cirrhotic 5 12 17 
minimal/mild inflammatory activity 4 8 12 
moderate/severe inflammatory activity 6 7 
Data are presented as mean (standard deviation). 
• HBV-DNA (Genostics, Abbott) 
** 1 patient did not underwent a liver biopsy. 
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Results 
Efficacy 
Six patients were randomized to group A, and 14 patients were randomized to group B. 
Baseline characteristics with regard to age, sex, weight, ethnic origin, pre-treatment ALT 
and HBV-DNA are given in table l. 
In all patients serum I-!BV-DNA dropped to below the level of detection of the Abbott 
assay during treatment (table 2). For patients in group A, this was achieved on median day 
57 (end of week 8, 4 weeks after introduction of lamivudine; figure 2). For patients in 
group B, serum HBV -DNA clearance was achieved on median day 15 (figure 2). For 19 
patients, semm HBV-DNA relapsed when treatment was stopped. Sustained HBV-DNA 
clearance was observed for a single patient. This patient was randomized to group B, 
HBV-DNA clearance was achieved by the end of treatment week 2, and HBeAg/anti-HBe 
seroconversion was achieved during therapy. DNA clearance and seroconversion were 
associated with a transaminase flare at the end of treatment week 8. At the end of follow-
up, anti-BBe was sustained and serum ALT was normal. 
. Table 2. Cumulative numher oj patients with RBV-DNA, RBeAg negativity and ALT 
normalization during therapy. 
wk 0 wk4 wk 8 wk 12 wk 16 
HBV-DNA A (n~6) 0 0 4 5 6 
B (n~14) 0 13 14 14 14 
HBeAg A (n~6) 0 0 0 0 0 
B (n~14) 0 2 2 4 
ALT A (n~6) 0 2 3 4 5 
B (n~14) 3 4 6 9 II 
BBeAgianti-HBe seroconversion was achieved by 4 patients (all in group B; table 2 and 
figure 3). For 3 patients, seroconversion was not sustained, and all were HBeAg and 
HBV-DNA positive at end of follow-up. Serum ALT rose during therapy for 2 of these 
patients (though not fulfilling the definition of a "flare" for either patient). 
Serum AL T declined during therapy to reach lowest values 4 weeks after completion of 
therapy for both treatment groups (p<0.05, Wilcoxon test). In ten patients normalization of 
AL T was achieved during treatment (table 2). After stopping treatment values rose to 
achieve pre-treatment levels by the end of follow-up (figure 4). 
ALT flares were observed for 3 patients. A flare at 8 weeks was associated with sustained 
seroconversion for one patient. For 2 other patients, the ALT flare was observed during the 
second post-treatment month. This flare followed the post-treatment rise in serum HBY-
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HBV-DNA, pgfml (Genostics, Abbott) 
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weeks after starting therapy 
Response of serum HBV-DNA to combination therapy, shoWing response for 
6 patients in group A, and for 14 patients in group B. The delayed decline 
observed for group A suggests that inhibition was principally due to lamivudine 
treatment. HBV-DNA was measllred by the Abbott Genoslics assay which has 
a minimum sensitivity of 3 pglml. Values are expressed as mean. 
HBeAg, IUfl (Amerlite) 
Treatment period 
o 4 8 12 16 20 24 28 32 
weeks after starting therapy 
Response of serum HBeAg to combination therapy. HBeAg was measured by 
AmerNte assay. Values are expressed as mean. 
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DNA, and was associated with a decline in serum HBV -DNA. For these 2 patients, the 
flare was not associated with HBeAg/anti-HBe seroconversion. 
Safety 
The combination therapy was well tolerated. 
Seventeen patients completed 16 weeks of a-IFN therapy at full dose, and three required 
dose reduction. For the patient who achieved sustained HBeAg seroconversion, a-IFN dose 
was reduced at week 6 then stopped at week 12 in response to the ALT rise. Tins ALT 
rise was associated with seroconversion. 
For one patient, interferon dose reduction was required for malaise and fatigue, and 
symptoms responded to dose reduction. 
For another patient, interferon (and lamivudine) was stopped after 15 weeks of treatment. 
This patient developed myopathy during treatment. CPK was elevated before treatment 
(323 U/I, normal <110) rose further during therapy, and peaked (967 U/I) just after 
treatment withdrawal. At that time, a diagnosis of hepatocellular carcinoma was 
established. Muscle biopsy did not show ragged red fibers, the typical sign of 
mitochondrial dysfunction. All other patients completed placebollamivudine therapy 
without interruption or dose reduction. 
Serum CPK was measured at each outpatient attendance. For 12/20 patients CPK was 
elevated prior to antiviral treatment. For 14120 patients, at least 1 CPK elevation was 
documented during therapy (table 3). 
For 4 patients, CPK exceeded 3 times the upper limit of the normal reference range, for 
one patient at baseline and for one patient at the end of one week's therapy (patient was 
receiving interferon and placebo) and for one patient, CPK was normal throughout the 
treatment period, but rose during follow-up, the other patient developed hepatocellular 
carcinoma as mentioned before. 
Table 3. Abnormallaboratmy values be/ore, during and after treatment. 
group A + B group A group B group A + B group A + B 
n=20 n=6 n=14 n=20 n=20 
week -4-0 week 1-4 week 1-4 week 6-16 week 20-32 
CPK elevation 12 (60%) 5 (83%) 4 (29%) 8 (40%) 12 (60%) 
CPK> 3 ULN 1 (5%) I (17%) 0 0 2 (10%) 
Amylase elevation 3 (15%) 2 (33%) 3 (21%) 5 (25%) 6 (30%) 
ALT> 10 ULN I (5%) 0 0 1(5%) 2 (10%) 
Fourteen patients had normal serum amylase during the whole study period. Serum 
amylase was elevated (but never more than three times the ULN) for 6 patients on at least 
one occasion. For 3 patients, serum amylase was elevated at baseline, and remained 
elevated during therapy. No significant increase was observed during therapy for these 3 
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patients. For 2 patients, amylase was normal at baseline, and fluctuated about the upper 
limit of the normal range for the duration of treatment and follow-up. One patient had an 
elevated amylase level at one occasion during follow-up. No patient experienced abdominal 
pain suggestive of pancreatitis. Seniln lipase was not measured. 
Blood anion gap was calculated at each outpatient attendance. A widened anion gap, as 
found in cases of lactic acidosis, was not recorded for any patient. 
Adverse events were reported for all patients. Adverse events occurred with similar 
incidence in both treatment groups, and the incidence was comparable with reported 
adverse events for patients receiving a-IFN monotherapy. Adverse events reported during 
the first 4 weeks of therapy (the placebo-controlled phase of the study) did not distinguish 
group A from group B. 
Figllre 4. 
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Serum ALT levels during combination therapy. In group B an early ALT rise 
was observed: in group A the ALT rise occurred after switching placebo to 
lamivudine at week 4. III both groups ALT normality was observed 4 weeks 
after stoppillg therapy. 
Pharmacokinetics 
(a) a-IFN pharmacokinetics: after inspection of the log-linear plot of a-IFN against 
time for each patient, a terminal mono-exponential phase could not be identified, thus the 
parameters AZ ) tw , AVC", and %AUC extrapolated were not determined. Data from 8 
patients who received a-IFN concomitantly with lamivudine were available for 
pharmacokinetic analysis on day 1 and day 29. Maximum plasma concentrations (Cm~',) of 
a-IFN were attained, on average at 10 hours post-dose on day I, and at 6-7 hours post-
dose on day 29 (table 4a and figure 5). 
(b) lamil'udine pharmacokinetics: the pharmacokinetic parameters of lamivudine in 
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patients administered lamivudine concomitantly with u-IFN on day 1 and day 29 are 
shown in table 4b and figure 6. 
Comparison of a-IFN pharmacokinetics in tlus study to those obtained in other studies 
with 10 MU interferon s.c. indicates that co-administration of lamivudine does not alter the 
pharmacokinetics of a-IFN. Lamivudine phannacokinetics were unaltered by co-
administration of u-IFN. 
Table 4a. a-IFN pharmacokinetics on day 1 and day 29 of combination lamivudine/a-
IFN Iherapy. 
Day 1 Day 29 
Number 8 7 
A UC,~, (IU.hlm/) mean 275 715 
median 252 647 
range 117-491 401-1035 
C,= (IUlm/) mean 33.8 54.3 
median 29.6 54.7 
range 15.5-75.2 36.8-68.0. 
I,m (h) median 10 7 
range 5-12 4-10 
lU = international units, h = hour, ml = millilitre. 
Table 4b. Lamivudine pharmacokinetics in patients receiving combination therapy. 
Number 
A UC (ng.hlml) 
C,= (1/glml) 
1,= (h)' 
1/1} (h) 
CIIF (llh) 
CI, (llh) 
* values are median (range). 
Discussion 
Day 1 
7 
4503(3998-5073) 
1042(894-1215) 
1(1-2) 
4.1(2.7-6.1) 
22.2(19.7-25) 
14.8(10.6-20.5) 
Day 29 
8 
NC 
1008(759-1338) 
1(1-4) 
5.0(3.3-7.6) 
19.5(14.2-27) 
15.8(12.0-20.8) 
For treatment-naive patients with chronic replicative HBV infection, a-IFN is the treatment 
of choice. u-IFN achieves serum HBV-DNA clearance in 37% of treated patients, and 33% 
achieve HBeAg clearance.6 In addition, successful interferon-induced HBeAg clearance is 
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associated with a diminished risk for the subsequent development of liver failure.15 
Characteristics predicting interferon responsiveness have been identified. 16,17 Further 
attempts to suppress viral replication in patients who previously failed interferon therapy 
have proven disappointing, and favourable pre-treatment characteristics are poor predictors 
of response to retreatment in this patient group.7 
We have treated 20 patients who had previously failed to seroconvert in response to at 
least one course of a-IFN therapy. Treatment achieved prompt reduction in levels of serum 
HEV-DNA. For 20/20 patients, HBV-DNA became undetectable during treatment. The 
delayed clearance of viral DNA observed for treatment group A suggests that lamivudine, 
and not interferon, was responsible for reduction of semm viral DNA. Consistent with the 
observations of Dienstag et al,12 serum ALT rose during antiviral therapy for group B, and 
peaked during the second month of treatment. In contrast, senUll ALT did not rise during 
interferonllamivudine therapy for group A. Instead, ALT rose during the interferon/placebo 
phase, then declined during combination treatment. 
An AL T flare was observed for 3 patients. For one patient, AL T flared during treatment, 
and this was associated with HBeAgianti-HBe seroconversion and with sllbsequent 
sustained normalization of ALT. For this patient, the pre-treatment HEV-DNA was 98 
pg/ml. 
For 2 patients, ALT flared after treatment. Treatment withdrawal was followed by a rise in 
serom HEV-DNA, which in fact provoked an ALT flare. TillS flare may represent an 
enhanced immune response to renewed viral replication. TillS pattern of response has been 
observed following corticosteroid withdrawal, and the associated decline in serom HEV-
DNA may enhance subsequent response to interferon therapyY Unfortunately, the 
enhanced immune response observed for these 2 patients after combination therapy 
withdrawal was not associated with HBeAgianti-HBe seroconversion. 
Sustained HBeAgianti-HBe seroconversion was observed for a single patient. This result 
compares unfavourably with the success of Dienstag et alY In that study, 32 patients 
(including 17 who had previously failed interferon monotherapy) were treated with 
1amivudine. Of 17 interferon failures, 5 achieved sustained HBV-DNA clearance, and 3 
achieved HBeAgianti-HBe seroconversion. Our result suggests that combination 
lamivudine/interferon therapy is not superior to lamivudine monotherapy for the treatment 
of patients who have previously failed to respond to interferon monotherapy. Indeed, 
combination therapy may be associated with an inferior response rate, with more side-
effects, and with greater expense than lami vudine monotherapy. 
The results of combination lamivudine/interferon therapy appear similar to those achieved 
by interferon monotherapy retreatment of patients who have failed a previous course of u-
IFN.7 Janssen et a1. retreated 18 non-responders to interferon therapy. Despite favourable 
pre~treatment characteristics (for interferon response in treatment-naive patients), only 2 
patients achieved HBeAg/anti~HBe seroconversion. 
Interferon has been used in combination with other nucleoside analogues for the treatment 
of replicative HBV infection.8,9,1O,18 The combinations of interferonfara-AMpl8 and 
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Figure 5. 
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Pharmacokinetics of (J.-IFN at day 1 and day 29. Levels of (J.-IFN tend to be 
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receiving a-IFN. 
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hours after dosing 
Pharmacokinetics of lamivudine at day 1 and day 29 in group B. No 
difference was observed between group A and B in comparison to other 
studies. 10 
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interferon! zidovudine lO have proven toxic, and were associated with more side-effects than 
was treatment with interferon alone. Kakumu et at. studied the combination of 
interferonlribavirin.9 Ribavirin monotherapy inhibits HBV replication,9,11 but significantly 
greater inhibition is observed for interferon monotherapy than is observed for the 
interferonlribavirin combination.9 Janssen et al. found that the addition of zidovudine to 
interferon did not enhance the inhibition of viral replication observed for interferon 
monotherapy.IO 
These observations are consistent with the results of our study which suggest that 
combination interferonllamivudine therapy is not superior to the results of interferon and 
lamivudine monotherapy. Phannacokinetic studies performed as part of this study suggest 
that disappointing efficacy is not the result of unexpected pharmacokinetic interaction. The 
rate and extent of systemic exposure to a.-IFN (characterized by Cma.x, tmaX' and AVe) in the 
presence of lamivudine was similar to published values after administration of a.-IFN 
alone,I9 although the mean serum levels of interferon given in combination with 
lamivlldine seems to be lower than during monotherapy. However, all values fell in the 
broad range of interferon after subcutaneous administration of 10 MU in individuals not 
taking lamivudine. 
Pharmacokinetic data after administration of lamivudinc (on days 1 and 29) in the present 
study were similar to previous data.20 This indicates that concomitant administration of a.-
IFN has no appreciable effect on lamivudine pharmacokinetics. 
The combination of a.-IFN and lamivudine therapy appeared safe. Interferon treatment is 
associated with significant morbidity.21 In particular, flu-like symptoms and lethargy are 
experienced by most treated patients. Incorporation of an initial placebo treatment period 
for group A enabled this study to differentiate the side-effects of the lamivudine/interferon 
combination from the side-effects of interferon alone. Adverse events reported during the 
first 4 weeks of therapy did not distinguish treatment group A from treatment group B. 
Adverse events were reported for all patients at some time during the study, but these 
occurred with similar incidence in both treatment groups. The incidence appears 
comparable with reported adverse events for patients receiving interferon monotherapy.21 A 
relatively high dose of a-IFN was prescribed. Despite the high dose, 17/20 patients 
completed 16 weeks of therapy at full dose. Two patients required interferon dose 
reduction but one of them completed 16 weeks of therapy. For one patient, interferon (and 
lamivudine) was stopped after 15 weeks of therapy. TillS patient developed myopathy with 
elevated senun CPK. It is quite possible that CPK elevation and myopathy were associated 
with an underlying hepatocellular carcinoma, and were not secondary to lamivudine (or 
interferon) treatment. Semm amylase was slightly elevated on at least one occasion for 6 
patients. Semm amylase elevation was not associated with abdominal pain, and was not 
clearly related to antiviral therapy. Arterial blood lactate was not measured during this 
Shldy, but blood anion gap was calculated at each outpatient attendance. \Videning of the 
anion gap, reflecting a lactic acidosis, was not observed for any patient. The multisystem 
toxicity observed in fialuridine-treated patients as a probable consequence of mitochondrial 
DNA polymerase inhibition and incorporation of FIAU into mitochondrial DNA,22 was not 
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observed in lamivudine-treated patients.23 
Thus, the lamivudine/interferon combination therapy appears safe and well tolerated. 
Unfortunately, combination therapy given to patients who previously failed interferon 
treatment achieved seroconversion in only 1 of 20 patients. However, all four patients who 
became HBeAg negative during treatment received combination therapy from start. In two 
patients the first HBeAg negative result was at the end of therapy. Therefore, prolongation 
of therapy after 16 weeks would probably induce sustained response. Future studies with 
combination therapy should continue a-IFN treatment after 16 weeks in case of significant 
HBeAg response. Another strategy is to start lamivudine therapy a rew weeks before 
initiating interferon. Following this scheme HBV-DNA levels are low at the time of the 
first dose of interferon, which is found to be a good predictor of response to interferon 
treatment. 16 
The best treatment option for treatment-naive patients has yet to be determined. For this 
patient group, ongoing randomized studies are comparing lamivudine to interferon and to 
the combination of the two. 
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Summary 
Fialuridine is an antiviral agent with potent activity against hepatitis B virus replication ill 
vitro and in vivo. In a phase II study 7 of 15 patients experienced severe toxicity due to 
the drug after 9-13 weeks of treatment. Adverse effects included nausea, vomiting and 
painful paraesthesia; subsequently hepatic failure, pancreatitis, neuropathy, myopathy and 
lactic acidosis developed, probably due to multi-systemic mitochondrial toxicity. Possible 
mechanisms of fialuridine toxicity include mitochondrial injury and pyruvate oxidation 
inhibition. \Vhile other nucleoside analogues have shown evidence of inducing 
mitochondrial injury (zidovudine, didanosine, zalcitabine), others to date have not 
(lamivudine, famciclovir). Specific reconmlendations for future study of existing and new 
nucleoside analogues include testing for toxicity after prolonged incubation, specific 
investigations to measure mitochondrial function, toxicological tests and well designed 
clinical trials with appropriate testing to monitor for any adverse effects on mitochondrial 
integrity and function. 
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Introduction 
Over the past decade, advances in our understanding of the molecular virology of hepatitis 
B virus (HBV) have resulted in renewed interest in nucleoside analogues for the treatment 
of chronic hepatitis B. Most of the first generation nucleoside analogues, such as 
vidarabinc, aciclovir, didanosillc, zidovudine and ribavirin, were either ineffective, 
associated with unacceptable toxicity or both when used to treat chronic hepatitis B. The 
advent of an in vitro cell line (human hepatoblastoma, Hep G2) which propagates the 
virus led to the development of promising new generation nucleoside analogues.' One of 
these drugs was fialuridine, [1-(2'-deoxy-2'-fluoro-I-p-D-arabinofuranosyl-5-iodo )-uracil], 
an orally administered pyrimidine nucleoside analogue.2 Preliminary dose-finding studies 
showed marked suppression of viral replication during treatment for 2 or 4 weeks.3 
However, prolongation of the treatment period beyond 4 weeks resulted in severe multi-
organ toxicity characterized by delayed onset and refractory lactic acidosis, pancreatitis, 
hepatic failure and death.4 Available evidence suggested that the mitochondria were 
damaged by the drug. These untoward findings led to both scientific and procedural 
investigations. The aim of tlus discussion, in an attempt to prevent future clinical 
occurrences as experienced in the fialuridine trial, is to summarize the scientific data and 
mechanisms of mitochondrial damage and provide reconunendations for procedures of 
future clinical trials and monitoring parameters. 
Studies on fialuridine 
The clinical trial 
The phase II fialuridine trial was designed to evaluate the safety and efficacy of a 6-month 
treatment course in patients with chronic hepatitis B without decompensation or other 
serious medical illnesses.4 Fifteen patients received oral fialuridine 0.10 or 0.25 mglkg of 
body weight per day in 2 or 3 divided doses; II out of 15 patients had already participated 
in a study of a 4-week treatment course of fialuridine. Virological response was evident, 
with HBV -DNA levels dropping more than 90% within 4 weeks. During the first 2 months 
of treatment, only a few adverse effects were reported; subsequently, increasing fatigue, 
nausea, numbness and tingling of the feet or hands and abdominal cramps developed in the 
majority of patients. After 13 weeks, I patient experienced sudden-onset hepatic failure, 
shock and lactic acidosis, and the study was then immediately tenninated. During the first 
few weeks of follow-up, 7 patients exhibited varying degrees of hepatic failure, jaundice, 
lactic acidosis and biochemical signs of pancreatitis: 5 patients died and the other 2 
survived after emergency liver transplantation. None of the patients who had received 
fialuridine for less than 4 weeks (cumulative dose 200 mg) developed obvious clinical or 
biochemical signs of toxicity.4 
Histological analysis of liver explants from the patients who underwent liver 
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transplantation revealed micro vesicular and macro vesicular steatosis and cholestasis. 
Steatosis appeared to be an early sign of toxicity because 3 out of 6 patients with mild or 
no evidence of hepatotoxicity exhibited an increase in steatosis in their liver during 
treatment. 5 Electron microscopic evaluation of explanted livers showed swollen, misshapen 
mitochondria with fewer cristae and fat droplets of various sizes. The clinical symptoms of 
the toxicosis suggested multisystem mitochondrial injury. No data were available on either 
the levels of mitochondrial-DNA (mt-DNA) or the activity of the mitochondrial enzymes. 
Other flall/ridille studies 
In vitro studies of fialuridine in human hepatoblastoma cell lines showed that the 50% 
inhibitory dose (ID,,) for viral replication was 0.90 ~mollL. The 50% cytotoxic dose 
(CD,,) after 5 days of incubation was 344 ~mollL. These data yield a relatively 
satisfactory therapeutic index (CD" I ID" ) for fialuridine of 382.6.' 
Preclinical studies with laboratory animals did not predict the toxicity. Dogs and monkeys 
administered fialuridine 3 mglkglday for 90 days and 25 mglkglday for 30 days, 
respectively, did not exhibit any significant histological or biochemical abnonnalities.7 
Pilot studies of fialuridine administered for 2 to 4 weeks to patients with chronic hepatitis 
B infection or HIV infection did not show hepatotoxicity on initial analysis. Among the 67 
patients who participated in these pilot studies, 3 died of liver disease and I of pancreatitis 
within 6 months of completing therapy. Re-evaluation of these cases suggests that these 
events may have been caused by delayed toxicity of fialuridine.' 
After the emergence of toxicity, additional studies were perfonned to elucidate the 
mechanism of the fialuridine-induced hepatotoxicity. Studies performed by the 
manufacturer of fialuridine were conducted in rats; the animals were given fialuridine up to 
510 mglkglday, a dosage 1000 times greater than that administered to humans, for a period 
of 10 weeks. The animals tolerated the high dose better than expected; however, in the last 
weeks of the study a significant difference in body weight gain was observed. Liver 
samples showed significantly lower cytochrome c oxidase activity while citrate synthetase 
activity was increased. Plasma lactate levels were increased as were y-glutamyl transferase 
(y-GT) levels, but ALT and AST levels remained normal.' 
Lessons of the fialuridine studies 
Mechanism of mitochondrial toxicity 
The mechanism of toxicity of fialuridine is not yet fully understood, but most evidence 
points to mitochondrial injury. Various in vitro experiments have been performed to 
evaluate and understand more fully the mitochondrial toxicity of fialuridine. 
The triphosphate forms of some antiviral nucleoside analogues are substrates for, and can 
inhibit the activity of, nuclear-DNA (N-DNA) polymerase-a, -Il, -0 and -E as well as 
DNA polymerase-y (pol-y) the replication of mt-DNA. Neither clinical nor laboratory 
evidence supports inhibition ofN-DNA polymerases by antiviral nucleoside analogues such 
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as zidovudine, didanosine and zalcitabine. The relatively selective inhibition of DNA 
polymerase-y by iialuridine may explain in part its mitochondrial toxicity.'·, In addition to 
the inhibition of DNA polymerase-y activity, some nucleoside analogues (e.g. iialuridine) 
can be incorporated into the mt-DNA chain by the action of DNA polymerase-y.'·IO·I1 
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Hypothesized mechanism by which ./ialuridine causes mitochondrial 
dysfunction and related clinical problems. Abbreviations: Complex 1= 
NADH-CoQ reductase; Complex II= succinate-CoQ reductase; Complex III= 
ubiquinol cytochrome c reductase; Complex IV= cytochrome c oxidase; 
Complex V= ATPase; mt-DNA = mitochondrial DNA; N-DNA = nuclear DNA. 
Fialuridine replaces thymidine in both N-DNA and mt-DNA. The higher afftnity of DNA 
polymerase-y for fialuridine, compared with the nuclear polymerases, suggests that 
fialuridine is incorporated into mt-DNA at a higher rate. IO,12 In contrast to other nucleoside 
analogues such as zidovudine, iialuridine possesses a 3'-hydroxyl group; therefore, the 
nascent mt-DNA chain can extend beyond the inserted iialuridine (iigure I). This is 
probably an essential difference between iialuridine and other nucleoside analogues as far 
as the induction of severe mitochondrial injury is concerned. This may also explain why 
the cellular content of mt-DNA remained normal after incorporation of iialuridine, while 
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the mitochondrial function deteriorated in HepG2 cells. 13,14 Since no tnt-DNA editing 
system is known, tnt-DNA damage is considered permanent.",15 
It is likely that in the event of prolonged treatment, incorporation of fialuridine into mt-
DNA leads to both alterations in the transcription of mt-DNA and defective mitochondrial 
polypeptide synthesis (figure I). Most of the subunits in the respiratory chain (complex I, 
III, IV and V), all located in the mitochondrial inner membrane, are partly encoded by mt-
DNA. 16,17 Impaired oxidative phosphorylation by mitochondria leads to stimulation of 
anaerobic glycolysis to maintain cellular A TP levels. In vitro experiments with HepG2 
cells showed increased lactate levels after exposure to fialuridine, the increase being dose-
dependent. 13,14 The consequence of the defective synthesis of several key mitochondrial 
enzymes is the development of certain disorders, some of which are similar to those 
encountered in inherited diseases attributable to mt-DNA mutations (such as myopathy, 
neuropathy, lactic acidosis and liver failure). IS The brain remains unaffected in the 
fialuridine toxicity syndrome while pancreatitis is uncommon in the group of inherited 
diseases, 
Characteristic for mitochondrial mutations is the threshold effect. ls During accumulation of 
mutant mt-DNA, the phenotype will be unaffected until the threshold for expression is 
reached. At that point, major changes in phenotype occur even in the event of small 
changes in the amount of mutant mt-DNA. Apparently, a low percentage of wild type mt-
DNA is enough to maintain adequate synthesis of mitochondrial gene products. It is likely 
that this threshold effect also plays a role in fialuridine toxicity." 
Although current data suggest that this toxicity may be due to DNA polymerase-y 
inhibition and nucleoside analogue incorporation, as summarized in figure 1, several 
studies have provided evidence that other scenarios might also be possible. For example, 
studies of HepG2 cells have confirmed the effect of fialuridine on mitochondrial function 
(lactate levels exceeded by 500% those found for normal controls) but this was not caused 
by a decreased mt-DNA level and complex IV activity." This implies that in these 
relatively short cell studies the oxidation of pyruvate was inhibited by a mechanism other 
than depletion of mt-DNA or complex IV deficiency. Likely candidates are N-DNA 
encoded gene products, such as pyruvate dehydrogenase, or the N-DNA encoded subunits 
of the respiratory chain. In order to distinguish between these two possibilities, pymvate 
should also be assayed because in the former case, the lactate / pyruvate ratio will be much 
lower.2o.21 
Toxicity of other nucleoside analogues in clinical studies of hepatitis B virus 
Investigation of other nucleoside analogues (table I) revealed examples of mitochondrial 
toxicity. Long term treatment with zidovudine (AZT, 3t-azido-3 t-deoxythymidine) induced 
myopathy, with a prevalence of up to 20%, which generally improved when treatment was 
discontinued. Muscle biopsies from these patients showed the hallmark of mitochondrial 
dysfunction, ragged red fibers. Histochemical staining of complex IV showed a decrease in 
activity,22 and the amount of mt-DNA was decreased.2J Zidovudine also affected 
mitochondria in the liver, resulting in morphological changes such as steatosis and swollen 
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mitochondria as demonstrated by electron microscopy.24 Other nucleoside analogues, such 
as didanosine (ddl, 2',3'-dideoxyinosine) and zalcitabine (ddC, 2',3'-dideoxycytidine), also 
affect the mitochondrial system since both caused peripheral neuropathy and occasionally 
fulminant hepatic failure with steatosis, pancreatitis and lactic acidosis.25.26 
New nucleoside analogues, such as lamivudine and famciclovir, are now being investigated 
in clinical studies, investigating the treatment of chronic hepatitis B infection. Famciclovir 
is the well-absorbed oral fonn of penciclovir, an acyclic guanine derivative, and is widely 
used to treat varicella zoster and herpes simplex virus infections. Recently, activity against 
hepatitis B virus (HBV) replication was observed,"'28,29 Phase III studies of the efficacy in 
chronic hepatitis B, as well as the prevention of reinfection after liver transplantation, are 
ongoing. To date, no signs of mitochondrial toxicity during famciclovir treatment have 
been observed.30 
Lamivudine, the (-) enantiomer of 2'-deoxy-3'-thiacytidine, is another new nucleoside 
analogue that strongly inhibits HBV replication both in vitro31 and in vivo.32,33 Again, thus 
far neither clinical nor sub-clinical mitochondrial toxicity has been observed during long 
term treatment. 34 
Table 1. Nucleoside analogues for treatment of chronic hepatitis B. 
Generic name Abbreviation Proprietary name Toxicity 
Vidarabine ARA-A Vira-A myalgia, neuropathy 
Acyclovir ACV Zovirax neuropathy 
Ganciclovir DHPG Cymevene neutropenia 
Zidovudine AZT Retrovir mY9pathy, steatosis 
Ribavirin RTCA Virazole hemolytic anaemia 
Didanosine ddl Videx neuropathy, lactic acidosis 
Zalcitabine ddC Hivid neuropathy 
Fialuridine FIAU multi organ failure 
New nucleoside analogues in clinical testing for chronic hepatitis B 
Lamivudine 3TC/SddC Epivir not reported 
Famciclovir FCV Famvir nephrotoxicity 
Phosphonylmethoxyethyladenine PMEA Adefovir not thoroughly studied 
Deoxythiafluorocytosine FTC not thoroughly studied 
Carbodeoxyguanosine 2-CDG not thoroughly studied 
Organizational aspects and clinical implications for the future 
Several nucleoside analogues with potent activity against HBV are in the phase of 
experimental administration to patients with chronic hepatitis B. After a review of the 
fialuridine trial, the Institute of Medicine in the US has made reconunendations7 which 
allow clinical research to proceed but also minimize the risks inherent in new drug 
therapies.7 
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One of the recommendations of the US Institute of Medicine was to continue research into 
the mechanism of fialuridine toxicity. Based on these new findings, some additional 
recommendations for the preclinical testing of related dmgs can be proposed. 
General recommendations 
The efficacy and toxicity of antiviral agents should be assessed in cell culture systems.' In 
most studies, cytotoxicity is measured after relatively short incubation periods. A recently 
published study on antiviral agents in HBV-transfected cell lines showed considerable 
changes for some agents in the CD" between 4 and 12 days of incubation." Cytotoxicity 
evaluated at day 4 may give an underestimation of the toxic effect on cellular metabolism 
and thus, an overestimation of the therapeutic index. Therefore, prior to clinical testing, 
candidate antiviral agents should also be tested for toxicity after prolonged incubation. A 
therapeutic index of more than 1000 has been suggested as a Isafel index.J5 
Drugs with possible mitochondrial toxicity 
Based on the research that has been done into the mechanism of fialuridine toxicity, in the 
case of nucleoside analogues which might possibly induce mitochondrial toxicity, cell 
culture studies should be performed to evaluate the effect of the nucleoside analogue on 
inhibition of DNA polymerase-y, incorporation into N-DNA and/or mt-DNA and the total 
amount of mt_DNA. 1O,1J,14,19 Probably more important are assays of mt-DNA-encoded 
enzymes in relation to N-DNA-encoded enzymes and functional mitochondrial tests, such 
as assays of lactate and pymvate production from glucose or ATP synthesis from 
mitochondrial substrates.36,37 
Prolonged testing in animals remains important; 2 different species should be used.7 
Toxicological studies, using the route of administration intended for patients and a duration 
of treatment at least as long as that intended for clinical trials, and extended follow-up of 
at least a subsample of animals, should be key aspects of preclinical testing. All 
information from in vitro and animal studies must always be accessible.7 
Trial design and peliol'mance 
When the dmg is considered to be safe, on the basis of in vitro and in vivo tests, clinical 
studies can be performed in a few experienced centres.7 Preferably, the study should 
include patient controls to help differentiate drug effects from changes caused by the 
underlying disease.' Follow-up should last at least 6 months, especially for drugs which 
can modify nucleic acids and thus, possibly induce late toxicity.' During the study period, 
the trial sponsor should inform the investigators about all known adverse events on a 
continuing real-time basis, Similarly, the investigators should report all adverse events to 
the sponsor cumulatively, including all unexpected adverse events as well as all serious 
adverse events. A careful analysis of all available information (rather than a worst-case 
assumption) should then determine further actions.' It is important that patients included in 
the study are also made aware of possible and predictable adverse effects that may occur 
after discontinuation of the drug under study. 
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Additional testing recommendations 
We recommend that during initial studies of new nucleoside analogues, regular assays of 
plasma lactate levels be performed and that, in case of abnormal results or other signs of 
mitochondrial dysfunction, a liver biopsy be taken. Histological studies should focus on 
staining of fat droplets and electron microscopic evaluation of mitochondrial ultrastructure, 
since the accumulation of fat droplets and abnormal mitochondrial ultrastructure, as well as 
a decreased number of cristae, were found to be relative early signs of mitochondrial 
toxicity in the fialuridine trial."s If possible, complex I and IV and a mitochondrial N-
DNA-encoded marker enzyme in liver homogenate should be assayed. Serological markers 
for mitochondrial myopathy (creatine kinase, lactate, pymvate, acetoacetate and 3-hydroxy 
butyrate) and pancreatitis (amylase and lipase) must be assessed in the event of symptoms 
because they are usually involved in a later stage of the disease. 
Conclusion 
Laboratory and clinical studies to discover new approaches to the treatment of viral 
diseases should be continued. At the same time everyone involved in such investigations 
should be aware of the potential toxicity of these new drugs despite preclinical evidence of 
safety. By following tlus approach, important preclinical findings with nucleoside 
analogues can be transformed into safe clinical studies for the benefit of patients with 
chronic viral infections. 
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Summary 
Nucleoside analogues can induce mitochondrial dysfunction leading to severe clinical 
syndromes. Lamivudine, a new nucleoside analogue, is an active inhibitor of hepatitis B 
viral replication without apparent clinical toxicity. To assess subclinical mitochondrial 
toxicity, we studied the morphology and ftmction of the mitochondrial system in 15 
patients treated with lamivudine. Morphology was investigated by routine histological 
evaluation and electron-microscopic studies of mitochondria in liver biopsies. 
Mitochondrial function was assessed by 2-keto[I-14CJ isocaproic acid decarboxylation 
(KICA breath test) and by measuring the activity in liver biopsy specimens of the 
mitochondrial enzymes encoded by nuclear and mitochondrial DNA (mt-DNA) (Complex I 
and IV) as well as a mitochondrial and a cytosolic enzyme both encoded by nuclear DNA 
only (Complex II and lactic dehydrogenase [LDH]). 
All IS patients underwent a liver biopsy before treatment and a KICA breath test before 
and during treatment; 13 agreed to undergo a repeat liver biopsy during lamivudine 
treatment. Liver tissue with no or minimal fibrotic changes from 7 patients treated for 6 
months with lamivudine was suitable for assessment of the mitochondrial enzyme activity. 
We observed no signs of toxicity by routine histological or electron-microscopic 
evaluation. KICA breath tests revealed no differences in either peak exhalation or the area 
under the curve from 0 to 60 minutes between healthy controls (3.0% and 19.3%), 
untreated patients with chronic hepatitis B (3.4% and 19.3%), and patients treated with 
lamivudine (3.1% and 20.6%). The activities of the mt-DNA-encoded enzymes remained 
normal after lamivudine therapy. Unexpectedly a significant decrease in the activity of 
nuclear-DNA-encoded enzymes in patients with chronic hepatitis B in comparison with 
normal controls was found. The mean activity of Complex II dropped from 45.3 to 20.0 
,umo1.min'l, that of lactic dehydrogenase from 106 to 44 pmo1.min,1 (Wilcoxon rank sum 
p<0.05). 
In conclusion: No subclinical signs of mitochondrial toxicity resulting from lamivudine 
therapy for 6 months were observed. 
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Introduction 
Nucleoside analogues can induce mitochondrial toxicity,l The clinical manifestations of 
mitochondrial toxicity include myopathy, neuropathy, lactic acidosis, pancreatitis, and 
hepatic failure? Recently ill vitro and in vivo models of hepatitis B viral (HBV) infection 
led to the identification of new nucleoside analogues with marked inhibitory activity 
against HBV: fialuridine, lamivudine and famciclovir.3 A phase 2 trial with fialuridine for 
patients with chronic HBV infection was tenninated because of severe clinical 
multisystemic toxicity attributed to mitochondrial damage.'" In vitro studies indicated that 
fialuridine had only a minimal effect on the amount of mitochondrial-DNA (mt-DNA).'·' 
Incorporation of fialuridine in mt-DNA led to abnormalities of enzymes encoded by mt-
DNA. 
Lamivudine, the negative enantiomer of 2'-deoxy-3'-thiacytidine, markedly inhibits HBV 
replication both in vitro8 and in viVO. 9,1O At present clinical toxicity has not been observed 
during treatment for periods up to 1 year, but its effects on mitochondrial morphology and 
function have not yet been reported. 
The early clinical symptoms of mitochondrial toxicity are nonspecific complaints, such as 
fatigue, nausea, or muscle weakness. Biochemical markers of mitochondrial dysfunction, 
such as serum amylase, lipase, creatine phosphokinase (CPK), and lactate levels, only 
become abnormal when severe organ damage already exists. Histological analysis of 
patients with nucleoside analogue-induced toxicity (zidovudine, fialuridine) reveals 
moderate to marked steatosis and cholestasis. During experimental treatment with new 
nucleoside analogues, it is important to be able to detect mitochondrial dysfunction at an 
early stage. For this purpose we elected to test the mitochondrial integrity on two levels: 
mitochondrial function was assessed by the activity of functional mitochondrial enzymes, 
and morphology by the presence of steatosis and electron-microscopic evaluation of the 
mitochondria during a 6-month course of lamivudine. 
Patients and methods 
Study population 
Fifteen patients with chronic (hepatitis B e antigen [H8eAg] positive) HBV infection with 
detectable HBV-DNA (>3 pg/ml, Genostics, Abbott Laboratories, Chicago, IL) and 
elevated alanine aminotransferase (ALT) levels (>30 lUll) were treated with lamivudine. 
They all had mild disease and participated in a 24-week dose ranging (25, 100, or 300 
mg/day) study of lamivudine; two patients were treated for only 12 weeks because of 
unforeseen pregnancy and abdominal discomfort, respectively. All patients underwent a 
liver biopsy before treatment; for safety purposes another liver biopsy was obtained after 8 
weeks (n=4), 12 weeks (n=3), 16 weeks (n=4) or 24 weeks (n=2) of therapy. Two patients 
refused to undergo repeat liver biopsy during treatment. 
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Table 1: Demographic and baseline characteristics of the patients. 
Controls 
Patients (n) 
Gender (M/F) 
Age (mean, range) 
Interferon non-responder (n) 
CaucasianiAsianIBlack (n) 
ALT (mean, range)' 
HBV-DNA (mean, range)" 
HBeAg (mean, range)'" 
Uper limit of normal 30 IUII 
15 
1213 
32.4 (18-61) years 
8 
111311 
66 (32-188) lUll 
169 (4-520) pglml 
36579 (168-158,716) UII 
Standard hybridization technique (Genostics, Abbott) 
Microparticle Enzyme Immunoassay (IMx, Abbott) 
Pretreatment liver biopsy specimens were used as disease controls when possible; 
otherwise patients with chronic hepatitis B who fulfilled the inclusion criteria but did not 
enter the lamivudine study for other reasons served as disease controls. Macroscopic and 
microscopic nonnal liver tissue from four patients who undenvent herni-hepatectomy for 
small metastases served as the nonnal controls. 
MOIphology 
Liver tissue was taken by standard tru-cut needle and fixed in 4% phosphate-buffered 
fonnaldehyde, routinely processed and embedded in paraffin blocks; 5 JIm sections were 
then cut. Liver sections were stained with hematoxylin and eosin (H&E), periodic acid-
Schiff (PAS), with or without previous diastase digestion, and Van Oleson's stain. All liver 
biopsy specimens were scored blindly by two observers who used the Desmet modification 
of the Knodell scoring system,ll,12 Steatosis was scored semiquantitatively as none, mild, 
moderate, or severe. 
Electron-microscopic evaluation of the mitochondria in liver biopsy specimens from nine 
patients was perfonned during treatment. Four patients with chronic (HBeAg positive) 
HBV infection were used as controls. Liver tissue was fixed first in glutaraldehyde-
formaldehyde and then in 1% (wtlvol) osmium tetroxide at 4°C. After acetone 
dehydration, the specimens were embedded in LX 112 (Epon, LADD [Zeiss], Weesp, The 
Netherlands). Semi-thin plastic sections for light lnicroscopy were stained with a freshly 
prepared 1% toluidine blue solution in distilled water. Ultrathin sections (ultratome IV, 
UB, LKB, BrOlllilla, Sweden) were mounted on copper grids (300 mesh) and contrast 
stained with uranyl acetate (l0 minutes at 45°C) and lead citrate. The preparations were 
examined with a Zeiss 902 electron microscope (Zeiss, Weesp, The Netherlands). 
Magnifications of 3,000, 7,000, 12,000 and 20,000 were used to visualize the 
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mitochondrial morphology. Pictures were evaluated blindly for abnom13lities in 
mitochondrial density, cristae, smooth and rough endoplasmic reticulum (SER, RER), 
lysosomes and the lateral membranes, as described previouslyY 
Figure 1. Eleclron micrograph o[ a hepalic parenchymal cell from a patienl with 
chronic HBV in[eclion; al Ihe lime o[ Ihe liver biopsy Ihe palienl had received with a 
cumulalive dose o[ 33.6 g lamivudine (300 mg/day [or 16 weeks). Nucleus, mitochondria, 
smooth endoplasmic reticulum, and rough endoplasmic reticulum show no ultrash'uclural 
abnormalities. Bar: 1 pm. 
Inset: detail of a mitochondrion of the same patient showing intact cristae. Bar: O.58pm. 
Function 
K1CA-brealh lesl. For early detection of impaired metabolic capacity of the mitochondrial 
system we used the 2-keto[I-14C] isocaproic acid (KICA) breath test, as described by 
Lauterburg et al. 14 TillS breath test has been used as a noninvasive test of mitochondrial 
function for patients with alcoholic liver disease. After an ovemight fast the subjects, who 
rested for 30 minutes before as well as during the test, received lpCi KlCA together with 
20 mg/kg L-leucine dissolved in 200 tnl orange juice. Breath samples were obtained before 
and at 10-minute intervals during the test for 120 minutes. The exhaled I'CO, was 
quantified by liquid scintillation spectroscopy. All patients were tested before treatment, at 
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the time a liver biopsy was taken during treatment, and at the end of lamivudine therapy. 
To confirm its diagnostic value the test was also administered to seven alcoholic patients 
as positive controls and eight healthy persons as negative controls. The reproducibility for 
healthy controls was measured by repeating the test I week later. We analyzed the peak 
exhalation, of 14C02, the time to reach peak exhalation and the area under the 14C02 
exhalation curve (AUC) after 60 and 120 minutes (expressed as percent dose exhaled). 
Mitochondrial enzyme activities in liver lissue. Seven patients with no or minimal 
morphological changes (fibrosis stage 0 or 1)" at entry were eligible for the study of 
mitochondrial enzyme activity during lamivudine treatment. All timepoints of biopsy were 
presented and the cumulative dose of lamivudine at the time of biopsy ranged from 1.4 to 
50.4 g (median 11.2 g). Liver tissue was snap-frozen and stored in aluminium tins at -
80°C. Liver specimens of 5 to 20 mg were weighed, thawed, and homogenized with 0.5 ml 
0.25 moUl sucrose, to mmollL HEPES-KOH and I mmolll ethylenediaminetetraacetic acid 
(EDTA) (PH 7.4) in a tight-fitting, motor-driven (800 tpm) Potter-Elvehjem Teflon-glass 
homogenizer by 10 strokes at O°C. The homogenates were divided into small batches, 
frozen, stored at -84°C and thawed immediately before the assays, which were performed 
at 37"C. 
Complex I was measured after two extra freeze-thaw cycles as the rotenone-sensitive 
reduced form of nicotinamide adenine dinucleotide (NADH) decylubiquinone 
oxidoreductase. 15 Succinate dehydrogenase (Complex II) was assessed as succinate-
ferricenium oxidoreductase in 50 mmolll potassium phosphate (PH 7.5), 0.2 mmollL 
ferricenium (10 ,III of 10 mmol/l ferricenium hexafluorophosphate in to mmolll HCl in a 
volume of 0.5 ml) and to mmolll sodium succinate.I' The blank contained 10 mmolll 
sodium malonate and no succinate. The reaction was started with 5 to 10 pI liver 
homogenate and absorbancy was measured at 300 nm. Complex IV was measured as horse 
heart ferrocytochrome c oxidase. I7 Lactate dehydrogenase (LDH) was assayed according to 
Kornberg,I8 but with I ,umolll rotenone and total carnitine,I9 after alkaline hydrolysis for I 
hour at 56°C. LDH is a cytosolic enzyme that oxidizes lactate to pyruvate, a reaction 
enhanced by a low NADHlNAD+ in the liver. Carnitine, a small zwitter-ion, is an amino-
acid essential for transport of activated fatty acids from the cytosol into the mitochondria 
where oxidation occurs.20 \Ve also measured the total amount of protein in the homogenate. 
All enzyme activities are expressed as pmol substrate converted per minute per gram liver 
tissue. Complex IV is expressed as the first-order rate constant k per minute per gram. 
Statistical analysis 
We tested the hypothesis that within the study group no differences existed between the 
values for healthy controls and patients with chronic hepatitis B before and during 
treatment with lamivudine. For continuous variables we used the Wilcoxon signed rank 
test. Results are given as mean ± standard error of the mean (SEM). For patients who 
underwent a K1CA breath test or a liver biopsy before and during treatment, a subgroup 
analysis was performed with the Student's I-test for paired samples. 
88 
Lamivudine therapy and mitochondrial toxicity 
Ethics 
TIlls study was approved by the institutional review board, and all patients gave written 
informed consent. 
Results 
Baseline characteristics of the patients are shown in table I. All 15 patients became HBV-
DNA (Genostics, Abbott) negative during treatment and two patients became HBeAg-
negative (Genostics, Abbott). All patients had elevated semm alanine aminotransferase 
(ALT) levels at entry (mean ± SEM: 66 (±II) lUll); semm ALT decreased during therapy 
in five patients (33%) to the nomlal range (,;30 lUll). 
MOIphology. 
Standard histological evaluation of pretreatment liver biopsy specimens showed minimal 
macro vesicular steatosis in three patients that did not change during treatment. The 
remaining 12 patients did not have appreciable steatosis by liver biopsy either before or 
during treatment. The mean (± SEM) histology activity index (HAl) was 4.4 ± 0.8 before 
treatment and decreased to 2.8 ± 0.5 during treatment (table 2); piecemeal necrosis in 
particular improved significantly during treatment.21 
Table 2. Histological gradil/g, stagil/g al/d 1II00phoiogy ill 13 patiel/ts be/ore alld 
during treatment with lamivudine. 
Histology Activity Index (mean score) 
Fibrosis (mean score) 
Steatosis (number of patients)' 
Electron-microscopic abnormalities 
Before treatment 
4.4 ± 0.8 
1.4±0.4 
none 
none 
During treatment 
2.8 ± 0.5 
1.4 ± 0.4 
none 
none 
Minimal macro vesicular steatosis was observed in three patients but was not enough to score as mild 
steatosis (score I) and did not change during treatment 
Electron~microscopic evaluation of mitochondria (including density, cristae, smooth 
endoplasmic reticulum, rough endoplasmic reticulum, lysosomes and lateral membranes) 
revealed no differences between untreated patients and those treated with lamivudine. 
Moreover no individual patient showed significant morphological changes after treatment 
with lamivudine (figure I). Vims particles were not detected by electron microscopy in any 
patient. 
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Function. 
The KICA brealh lesl was validated in healthy controls and patients with alcoholic liver 
disease. For healthy controls peak exhalation and area under the curve at 60 minutes (mean 
± SEM) were 3.0 ± 0.16% and 19.3 ± 1.4%, respectively. Reproducibility within the group 
of healthy controls showed a variation of 5.1 % for peak exhalation and 0.8% for area 
under the curve at 60 minutes. The ability of the KICA breath test to detect abnormal 
mitochondrial function was tested in seven patients with alcoholic liver disease. In 
alcoholic patients KlCA decarboxylation in the liver was impaired, resulting in a lower 
peak exhalation and a lower fraction of the dose exhaled after 60 minutes (2.5 ± 0.3% and 
13.4 ± 1.8%, respectively). The KICA breath test revealed no differences between the 
healthy controls and the patients on lamivudine (table 3). There were no significant 
differences in either the pretreatment, during treatment or posttreatment breath analysis 
separated according to dose of lamivudine. When the initial KICA was taken as the 
individual reference value, no patient had an abnormal KICA breath test at the end of 
treatment. 
Table 3. Resulls of KICA brealh lesl for heallhy conlrols and palienls with chronic 
hepatitis B before and during treatment with lamivudine. 
Healthy Patients: Patients: 
controls pre-treatment 
(n~8) (n~15) 
Peak exhalation (%) 3.0 ± 0.16 3.4 ± 0.26 
Time of peak (min) 38.7 ± 3.0 42.7 ± 4.6 
AVC 60 (%) 19.3 ± 1.4 21.5 ± 2.5 
AVC 120 (%) 24.1 ± 1.4 26.9 ± 2.6 
Note: Results expressed as % of dosage Heo2 exhaled in J 0 minutes. 
Ave 60 means area under the Heo2 exhalation curve 0 to 60 minutes after intake. 
end of treatment 
(n~15) 
3.1 ± 0.16 
35.3 ± 3.4 
20.6 ± 1.5 
25.4 ± 1.6 
The activities of mitochondrial enzymes are shown in table 4 and figure 2. In patients 
treated with lamivudine the activities of mt-DNA-encoded enzymes were not different from 
those of patients with chronic hepatitis B before treatment. Among untreated chronic 
hepatitis B patients the activities of the enzymes encoded by nuclear-DNA (N-DNA) was 
lower than those in controls; the activity of Complex II in patients with chronic hepatitis B 
being 45% of that of normal controls and LDH activity 42% of that of normal controls. 
Carnitine levels in patients with chronic hepatitis B were 65% of that of normal controls. 
The activity of Complex I and the total amount of protein were also lower in patients with 
chronic hepatitis B but the values were not significantly different from those found for 
normal controls. 
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Discussion 
This study was initiated to evaluate the potential of mitochondrial toxicity as a result of 
lamivudine treatment. In several phase I and II studies of lamivudine, there were no 
instances of clinical symptoms which might be related to mitochondrial toxicity (lactic 
acidosis, pancreatitis or liver failure). To detect mitochondrial toxicity at a subclinical level 
in patients who were exposed to longwtenn lamivudine therapy we studied the morphology 
and function of the mitochondrial system prospectively in a closely followed cohort of 15 
patients. 
Histological evaluation of liver biopsy specimens showed no signs of mitochondrial 
dysfunctioning, such as steatosis by light microscopy or abnormalities in the morphology 
of the mitochondria by electron microscopy. Indeed, liver histology improved during 
lamivudine therapy. In patients with hepatic failure because of fialuridine, histological 
analyses revealed moderate to marked steatosis and cholestasis and electron microscopy 
showed mitochondrial abnormalities and accumulation of small fat droplets.4 In our group 
of patients who received up to 6 months of lamivudine these signs of mitochondrial 
damage were not detected. 
The KICA breath test has been used for assessment of mitochondrial dysfunction in 
patients with chronic alcoholic liver disease. KICA decarboxylation occurs mainly in 
mitochondria and is catalyzed by mitochondrial branched-chain 2-ketoacid dehydrogenase 
and thus reflects more than decreased liver cell mass as is assessed by the aminopyrine 
breath test and the galactose elimination test." In the rat more than 75% of the exhaled 
"CO, after KICA administration originates in the liver," suggesting that the KICA breath 
test reflects hepatic mitochondrial function. The decreased KICA decarboxylation found for 
patients with chronic alcoholic liver disease is believed to reflect functional impairment of 
the mitochondrial system as a result of ethanol toxicity. The KICA breath test is one of the 
few noninvasive tools available to quantify mitochondrial function and was therefore used 
to exclude impaired capacity of metabolism by the mitochondrial system because of 
lamivudine therapy. The KICA breath test revealed no differences between healthy controls 
and patients with chronic hepatitis B either before or during treatment. Using the initial 
KICA breath test result as an individual control, none of the patients developed 
abnormalities in KICA breath test at the end of treatment. KICA decarboxylation by the 
mitochondria was not suppressed during lamivudine treatment. 
To further evaluate the possibility of subclinical mitochondrial toxicity, we studied the 
activity of mitochondrial enzymes involved in oxidative phosphorylation. We chose to do a 
functional analysis instead of measuring the amount of mt-DNA which can be nonual 
despite of severe toxicity.6.7.23 The respiratory chain is divided into five functional units or 
complexes, embedded in the inner mitochondrial membrane. Four of them (Complex I, III, 
IV and V) are partially encoded by mt_DNA.24.25 
This biochemical study covered a small group of patients with mild compensated liver 
disease who received lamivudine for 6 months; all patients with significant fibrosis or 
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Table 4. Mitochondrial enzyme activity in patients with chronic hepatitis B with or without 'treatment with lamivudine in 
comparison to healthy controls. 
Enzyme, Compound Location Number of Nonnal controls Patients: Patients: 
subunits (n=4) pretreatment during treatment 
encoded by (n=7) (n=7) 
mt-DNA 
Complex I (amoLmin·' ) Mitochondrial inner 7 S.7± 0.8 4.3 ± 0.6 6.4± 0.9 
membrane 
Complex IV (k.min·' ) Mitochondrial inner 3 16.3 ± 2.6 36.4 ± U.S 29.3 ±3.8 
membrane 
Complex II (amoLmin·') Mitochondrial inner 0 45.3 ±3.6 20.2± 3.0 26.9 ± 2.0· 
membrane 
LDH (amoLmin·') Cytosol 0 106± 16 44±4.5 48 ± 3.9· 
Camitine (amol) Mainly cytosol 0.72± 0.08 0.47 ± 0.07 0.57 ± 0.07 
Protein (mg) 159±5 121 ± 16 143 ±9 
Note: Results are expressed per gram liver tissue. 
'Different from normal controls withp<0.05 (W"dcoxon ranksum). 
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cirrhosis were excluded to prevent variations in activity because of fibrotic tissue. The 
biochemical analysis showed no evidence that lamivudine treatment affected the 
mitochondrial system, as indicated by the normal activity of the mt-DNA-encoded enzymes 
(Complex I and IV). Patients with chronic hepatitis B and active viral replication showed 
subnormal activity of the mitochondrial enzymes, especially enzymes encoded by N-DNA. 
Protein levels were also decreased in these patients. One explanation for these findings is 
that active HBV replication, with the production of large amounts of hepatitis B surface 
antigen (HBsAg) and HBeAg proteins in hepatocytes, competitively inhibited the 
transcription of other proteins.26 It was of interest to note that the activity of some 
mitochondrial enzymes appeared to be restored during lamivudine treatment, especially in 
the five patients who underwent paired liver biopsies before and during treatment (figure 
2), although the differences were not statistically significant, possibly due to the small 
number of patients (n~5, p~O.08 for Complex I). 
Mitochondrial enzyme activity (% of normal) 
200,---------T ,---------,100 
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40 
50 
20 
OL-------------~ L-_______ -i0 
Before During Before During 
Complex I Complex II 
Figure 2. Improvement ill mitochondrial enzyme activity foundfor the five patients who 
underwent paired liver biopsies before and during treatment. Shown are the activities of 
Complex I (encoded by N- and mt-DNA) and Complex II (encoded by N-DNA). Results are 
expressed as percentage of normal. 
Lamivudine is known to block HBV replications that might result in partial normalization 
of the mitochondrial function. Additional possibilities are that the activity of the 
mitochondrial enzymes is decreased as a result of liver cell necrosis following 
inflammation because of the HBV infection. As a 6-month course of lamivudine resulted in 
normalization of serum transaminases in 47% to 87% of patients in a multicentre study?? 
In conclusion, nonnal mitochondrial morphology, normal KICA breath test results and 
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normal levels of mt-DNA-encoded enzymes indicate that it is unlikely that lamivudine 
treatment induces mitochondrial toxicity. In patients with chronic HBV infection and active 
viral replication, the activities of N-DNA-encoded enzymes were suppressed. Lamivudine 
treatment appeared to restore mitochondrial enzyme activity, possibly because of a 
decrease in the viral replication or general hepatocellular injury. 
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6.1 
HBV REACTIVATION WITH HEPATIC DECOMPENSATION 
AFTER LAMIVUDINE THERAPY FOR 
CHRONIC HBV INFECTION 
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Introduction 
Lamivudine is an effective reverse transcriptase inhibitor and also a potent inhibitor of 
hepatitis B virus replication in viVO,1.2,3,4 In view of its efficacy and remarkable safety 
profile, large scale phase III trials are ongoing. \Ve report a serious adverse event in a 
patient 5 months after a 6 months course of lamivudine, which may be associated with 
drug therapy. 
Case 
A 29-year-old Chinese man with chronic HBV infection (biopsy stage chronic hepatitis 
with minimal fibrosis, HBcAg in 30% of hepatocytes, HBeAg positive, HBV-DNA 
positive, AL T 7x ULN), who had received I standard course of alpha-interferon therapy 
and 2 previous courses of experimental antiviral therapy between 1990-93, started on 
lamivudine 1O0 mg/day in January 1994. He completed 6 months of therapy without any 
signs of side effects; HBV fell below levels of detection (Genostics, Abbott) at 2 weeks 
after initiation of therapy, HBeAg fell to a level just above detection-limit (IMx, Abbott) 
and serum aminotransferase levels became normal after 16 weeks of therapy. A liver-
biopsy at 16 weeks showed chronic hepatitis with some lobular activity; HBcAg was not 
detected. Four weeks after discontinuation of lamivudine therapy ALT levels increased and 
rose exponentially to 100x ULN 4 months later, associated with jaundice and a fall in 
clotting factors below 50% (incipient liver failure). Laparoscopy with liver-biopsy showed 
hepatic collapse; no evidence of cirrhosis was found. Coinfection with hepatitis A or 
superinfection with hepatitis D or hepatitis C was excluded. HBV serology showed a 
resurgence of active viral replication (HBV-DNA and HBeAg positive) from week 28-32 
onwards (figure I). 
Assuming a severe immunological reaction to hepatocytes infected with HBV, prednisone 
treatment was started with an initial dose of 30 mg/day. A marked drop in bilirubin and 
AL T followed, clotting factors returned to pre-treatment levels. Prednisone was decreased 
to 1O mg/day and stopped when HBV-DNA levels rose again. After stopping prednisone, 
hepatitis activity increased somewhat followed by HBV-DNA and HBeAg clearance; anti-
HBe antibodies have appeared. Currently, the patient is well and has completely nom,.l 
liver-tests. 
The temporal relation of increasing viral replication from week 28 and rising serum ALT 
also from week 28 strongly suggests that the severe hepatitis flare is a consequence of re-
infection of hepatocytes with immune reaction, following suppression of HBV replication 
by lamivudine. To date, 83 chronic hepatitis B patients have been treated with lamivudine 
for periods of 3 to 6 months. Post-treatment elevation of ALT (an elevation of <: 3 times 
baseline) occurred in 16% of patients within 8 to 24 weeks (median 12 weeks) of treatment 
cessation. Only 3 cases of ALT elevations were associated with hyperbilirubinaemia or 
jaundice and, with the exception of the case described above, resolved spontaneously. 
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Challges ill ALT, HBV·DNA, HBeAg alld bilirubill after withdrawal of 
lamivudine therapy. 
However, spontaneous hepatitis flare has been described in cluonic hepatitis B in particular 
in patients from East Asia' and the relation lamivudine therapy· hepatitis flare camlot be 
proved. On the other hand, liver·biopsy at the end of therapy showed absence of HBcAg in 
hepatocytes, and we assume massive reinfection of hepatocytes in the months after 
stopping lamivudine and an immune reaction similar to that of acute hepatitis subsequently. 
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In this patient the severe hepatitis flare was not fatal and subsequently led to HBeAg 
seroconversion, but such an event in a patient with cirrhosis could have grave 
consequences. Patients participating in lamivudine studies should be monitored carefully 
after discontinuation of therapy. When clinical signs of hepatitis occur, rapid and thorough 
investigation in a hepatological unit is advised and immunosuppressive therapy may be 
indicated. Frequent monitoring should continue until the flare resolves and the replication 
of HBV is controlled. 
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Summary 
Acute exacerbations of chronic hepatitis B virus infection occur after withdrawal of 
lamivudine therapy in about 16% of patients and are considered of little clinical 
significance. We observed 'lamivudine withdrawal hepatitis' accompanied by jaundice and 
incipient liver failure, but also followed by viral clearance. 
In order to investigate the incidence, severity and virological outcome of 'lamivudine 
withdrawal hepatitis' we monitored 41 patients for at least 6 months after discontinuation 
of experimental nucleoside analogue therapy. 
The incidence of hepatitis flares, defined as an abrupt elevation of ALT at least three times 
baseline level and ten times the upper limit of normal, was estimated to be 20%; in 5% of 
cases, hepatitis flares were associated with jaundice and incipient liver failure. A noticeable 
feature of 'Iamivudine withdrawal hepatitis' flares were the high HBV-DNA levels at the 
time of the AL T peak. 
To minimize risk of liver failure and to enhance elimination of HBV following flares 
reinstitution of lamivudine therapy was evaluated. In three patients with a severe hepatitis 
flare with jaundice, Iamivudine therapy was resumed, followed by HBV-DNA and HBeAg 
seroconversion. Such an event did not occur in six other patients with a non-icteric 
'lamivudine withdrawal hepatitis" who were not retreated with lamivudine. 
Active management of severe hepatitis flares is proposed, assuming that a rapid and 
effective suppression of viral replication in combination with the activated immune system 
can induce HBeAg seroconversioll accompanied by remission of disease activity. 
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Introduction 
Patients with chronic hepatitis B virus (HBV) infection can suffer acute exacerbations 
under various conditions. Studies in Taiwan showed an arulUal incidence of spontaneous 
acute exacerbation of 27% for HBeAg positive patients and 10% for anti-RBe positive 
patients. 1 In these studies acute exacerbation was defined as an abrupt elevation of alanine 
amino transferase (AL T) to more than 300 lUll in patients with chronic hepatitis B, 
minimal symptoms, normal bilirubin levels and baseline AL T levels below 150 lUll (upper 
limit of nonnal (ULN) 30 lUll). Some of these episodes were caused by hepatitis A, 
hepatitis D or hepatitis C infections,2.3 but the large majority were apparently due to 
increased host inmlUnity against HBV-infected hepatocytes.' In patients with HBeAg 
positive chronic hepatitis an acute exacerbation frequently precedes HBeAg ciearance.4.S.6 
However, a spontaneous acute exacerbation in HBeAg negative patients is often associated 
with reactivation of HBeAg.7,8.9 
Acute exacerbations have also been described after withdrawal of corticosteroid therapylO 
and cancer chemotherapy,lI,12 The mechanism of this syndrome is in all likelihood 
increased HBV replication and antigen expression on hepatocytes;I3,14 and after withdrawal 
of therapy rebound immune reactivity and innnune-mediated cytolysis of HBV-infected 
hepatocytes,I2 Finally, acute exacerbation or hepatitis flares are seen regularly during alpha-
inteferon (u-IFN) therapy. During the first four weeks of treatment they are regarded as 
drug-related toxicity; later these flares may be beneficial since flares are the hallmark of 
impending HBeAg seroconversion.13,14 Hepatitis flares usually occur without symptoms but 
are associated with clinical jaundice in 11-16% of cases. After withdrawal of cancer 
chemotherapy severe acute exacerbation leading to death has been described;II.17 mortality 
has also been described after prednisone withdrawal 18 or during u-IFN therapy among 
patients with cirrhosis and a diminished hepatic reserve,I9 
We previously reported on severe icteric hepatitis associated with reactivation of hepatitis 
B virus replication five months after withdrawal of lamivudine therapy,20 In view of the 
potentially serious consequences of acute exacerbation after nucleoside analogue therapy 
for patients with cirrhosis and diminished hepatic reserve, we carefully monitored all 
patients monthly after discontinuation of nucleoside analogue therapy for at least six 
months. In this paper we report on the incidence, severity, characteristics and virological 
outcome of posttherapy hepatitis flares and propose a management approach. 
Patients and methods 
We monitored 41 patients who had received nucleoside analogue treatment for more than 
six months for at least six months after discontinuation of therapy. We present three 
patients with an icteric hepatitis flare, with incipient liver failure in two. 
RBV-DNA levels were measured with a liquid hybridization assay (Digene, Murex, UK), 
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quantified with an EUROHEP standard as reference and expressed in genome equivalents 
(gen eq). Detection limit of the Digene assay is 1.6 x 10' gen.eq.lml. HBeAg levels were 
measured by micro particle enzyme immunoassay technology (IMx, Abbott, Chicago, Ill), 
quantified with a Paul Ehrlich standard as reference and expressed in Paul Ehrlich units 
(pEIU). The detection limit of the IMx assay was 0.6 PElU/ml). For all liver biopsies, the 
histology activity index (HAl) was calculated using the Desmet modification of the 
Knodell scoring system."·22 The upper limit of normal (ULN) for the level of serum 
alanine amino transferase (AL T) was 30 lUll. 
Sequence analysis to determine mutations in the highly conserved tyrosine-methionine-
aspartate-aspartate (YMDD) motif was performed amplifying a selected genomic region of 
the polymerase gene of HBV (nucleotide 56-806), using the primers ACPR (sense) and S3 
(antisense). Specifically, the region 459-806 was sequenced on a Vistra labstation 
(Amersham, UK) using dye terminator chemistry. Analysis was performed on an Applied 
373 automated sequencer (perkin Elmer, USA). The sequences were analyzed and aligned 
using Geneworks software (Intelligenetics,UK). 
Patients 
Case A. 
A 29-year-old man with chronic HBV infection and active viral replication who did not 
respond to u-IFN therapy received lamivudine for a period of 6 months. Before treatment 
the ALT level was 191 lUll and he was positive for both HBV-DNA (371 x 10' gen 
eq/ml) and HBeAg (7322 PEIUlml). A liver biopsy showed chronic hepatitis (HAl score 3) 
with minimal fibrosis; HBcAg expression was detected in 30% of hepatocytes and HBsAg 
in 5%. During treatment, ALT levels came within the normal range; HBV-DNA fell below 
the levels of detection and HBeAg dropped to a level just above the detection limit. A 
liver biopsy taken during treatment showed chronic hepatitis with some lobular activity 
(HAl score 3); HBcAg was not detected and HBsAg in 50% of hepatocytes. After 
discontinuation of lamivudine therapy ALT levels increased exponentially to 3000 lUll 
(IOOx ULN) 4 months later, jaundice developed and clotting factors dropped below 50% 
(incipient liver failure). HBV serology showed a resurgence of active viral replication 
(HBV -DNA 1893 x 10' gen.eq.lml, HBeAg 10545 PEIUlml). Liver biopsy showed severe 
activity (HAl score 10), immunohistochemistry showed HBcAg expression only in the 
cytoplasm and HBsAg was detected in 50% of hepatocytes. Assuming a severe 
immunological reaction to hepatocytes infected with HBV, prednisone therapy was started 
at an initial dose of 30 mg/day. A marked drop in bilirubin and ALT followed; clotting 
factors returned to pre-treatment levels. Prednisone was decreased to 10 mg/day and 
discontinued when the HBV-DNA levels rose again. After prednisone withdrawal, hepatitis 
activity increased somewhat, followed by loss of HBV -DNA and HBeAg; HBe-antibodies 
appeared.20 
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10 
ALT, Bilirubin, RBV-DNA and RBeAg levels af/er reaclivation and during 
retrealmenl with lamivudine, in a patient previously treated with lamivudine 
(case A). 
Six months later a reactivation of hepatitis activity was observed (HBV -DNA 260 x 10' 
gen eq/ml; HBeAg 1230 PEIUlml) and ALT rose to levels between 100 and 200 lUll. 
Recently (14 months after reactivation) a hepatitis flare was observed (ALT 7I I lUll, 
bilirubin 26 ~mol/I) in combination with high levels of viral replication (figure 1). We 
resumed lamivudine therapy (150 mg/day); HBV -DNA became undetectable and HBeAg 
seroconversion occurred within two months after reinstitution of lamivudine therapy. 
According to the polymerase chain reaction (peR, detection limit 500 gen.eq.lml) HBV-
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DNA is not detectable. The patient is still on lamivudine therapy (4 months after HBeAg 
seroconversion), since in another patient reactivation occurred when lamivudine was 
stopped after confirmation of HBeAg seroconversion (case B). 
Case B. 
A 40-year-old man with chronic hepatitis B, active viral replication (HBV-DNA 617 x 106 
gen.eq.lml; HBeAg 1975 PEIVlml) and elevated serum transaminase levels (ALT 113 lUll) 
was treated with lamivudine (100 mg/day) for I year. Before treatment liver histology 
showed chronic hepatitis with mild activity (HAl score 2) and cirrhosis; 15% of the 
hepatocytes exhibited positivity for HBcAg. Prothrombin time and albumin were in the 
normal range. During therapy, serum transaminase values came within the normal range. 
Despite good compliance, serum HBV-DNA did not become undetectable during treatment 
and started to rise again after 24 weeks of therapy. This secondary rise was found to be 
related to the development of a mutant virus which was resistant to lamivudine. Sequence 
analysis showed a replacement of Methionine by Isoleucine (Metm ----+ Iles52) in the YMDD 
motif of the reverse transcriptase gene. The virus population was cloned and the YMDD 
motif was sequenced at week 16, 36, 52 of therapy and 8 weeks after discontinuation. The 
percentages viral populations were calculated and we found 0% mutant virus (YIDD) at 
week 16, 8% at week 36 and 100% at 52 weeks. Eight weeks after discontinuation of 
therapy 100% of the viral population was found to be wild type HBV (YMDD). 
After 12 months of treatment, the liver biopsy showed cirrhosis with minimal histological 
activity (HAl score I) but about 20% of hepatocytes stiU exhibited nuclear core-expression 
with additional cytoplasmic expression, HBsAg was shown in 5% of hepatocytes. After 
discontinuation of treatment serum transaminases initially rose to just above pre-treatment 
levels (figure 2), but three months later they had increased exponentiaUy to 1270 lUll. 
Jaundice and a three-second prolongation of prothrombin time developed. Serum HBV-
DNA was 1971 x 106 gen.eq.lml, indicating a high level of viral replication; sequence 
analysis showed resurgence of the wild type hepatitis B virus. Other causes of hepatitis 
were excluded. In view of the incipient liver failure, intervention was indicated and 
treatment with lamivudine (100 mg/day) was resumed. This therapy was associated with an 
inunediate drop in serum transaminase values and disappearance of jaundice. Within two 
weeks, HBV-DNA became undetectable, HBeAg seroconversion was observed, and ALT 
normalized. Two weeks later seroconversion was confirmed and lamivudine treatment was 
withdrawn. Unfortunately, reactivation of wild type virus replication was observed four 
months later, this time without a hepatitis flare. 
Case C. 
A 49-year-old man with chronic hepatitis B, who previously had refused a-IFN therapy, 
was included in a placebo-controlled study of nucleoside analogues. Serum amino 
transferase levels were mildly elevated (ALT 74 lUll), HBV-DNA was in the low range 
(32 x 106 gen.eq.lml). Liver histology showed chronic hepatitis with mild to moderate 
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activity (HAl score 3) and no fibrosis. Immunohistochemistry revealed sporadic expression 
of HBcAg in the liver biopsy, HBsAg expression was shown in about 30% of hepatocytes. 
Fourteen weeks after discontinuation of the study medication a spontaneous hepatitis flare 
occurred (AL T 1560 lUll). Concomitant infections with hepatitis A virus (RA V), hepatitis 
D virus (HDV), hepatitis C virus (HCV), human illllllunodeficiency virus (HIV), Epstein-
Barr virus (EBV) and cytomegalovirus (CMV) were excluded. The patient was monitored 
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carefully and when jaundice developed (bilirubin 73 ,"molll, prothrombin time I sec 
prolonged) lamivudine therapy (150 mg/day) was started. 
A liver biopsy at that time showed chronic hepatitis with severe inflammatory activity 
(HAl score 11) and minimal fibrosis. Immunohistochemistry revealed sporadic nuclear 
expression of HBcAg and only cytoplasmic expression in some hepatocytes, HBsAg 
expression was still observed in 30% of hepatocytes. The randomization code was broken 
and it appeared that the patient had received the placebo. After initiation of antiviral 
therapy, serum transaminase levels returned to normal, jaundice disappeared and viral 
replication dropped to zero in combination with HBeAg seroconversion within 6 weeks. 
HBV-DNA is undetectable by peR. We have not yet discontinued lamivudine therapy. 
Discussion 
Incidence aJlll severity of IlamivlIdille withdrawal hepatitis' 
After withdrawal of lamivudine therapy, hepatitis flares -defined as an increase in ALT 
ranging from at least three times baseline levels to more than ten times the upper limit of 
normal (300 IU/I)- occur regularly. Based on the results in 83 patients from two 
multicentre studies, 'lamivudine withdrawal hepatitis' occurs in about 16% of patients.2),24 
For our cohort of patients who had been treated with lamivudine we also calculated the 
risk of the development of a post-treatment hepatitis flare. We observed eight hepatitis 
flares in 41 patients (20%) who had received treatment for more than one month and had 
been followed for at least six months after discontinuation of treatment. Mean peak ALT 
level of those flares was 997 lUll in comparison to 940 lUll in the study of Liaw et al. I 
Mortality has occasionally been described due to severe exacerbations of HBV infection, 
spontaneously,7 after cytotoxic therapy,II,12,17 after prednisone withdrawal '8 and after 
lamivudine withdrawal" Two of our patients (5%) developed incipient liver failure 
(jaundice and clotting factors below 50%). To minimize the risk of liver failure lamivudine 
retreatment was initiated; both patients recovered. 
Virological alld histological featllres dllrillg hepatitis flares 
Characleristics of hepalilis flares 
During the spontaneous hepatitis flares associated with chronic hepatitis B, low levels of 
HBV -DNA and HBeAg are usually observed at the time of the ALT peak, especially in 
jaundiced patients."·27.28 Hepatocyte damage is preceded by. a rise in HBV -DNA levels, the 
same pattern is observed during acute hepatitis B.2'} It is suggested that increased viral 
replication can trigger an immune reaction against HBV-infected hepatocytes.27 
This cellular compound of the immune reactivity -was studied in detail by Marinos et aI.; in 
patients after withdrawal of lamivudine an increased T helper-cell response was observed 
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ALT, Bilirubin, HBV-DNA and HBeAg levels before and after a spontaneous 
hepatitis flare treated with lamivudille (case C), 
after 1-3 months, in response to rebound viral replication,30 In our jaundiced patients the 
HBV -DNA levels were still high (clearly above the cut-off of insensitive hybridization 
assays) at the time of the ALT peak, therefore spontaneous reduction of hepatitis activity 
was uncertain, \Ve wondered whether blocking of viral replication with a subsequent 
decrease of viral antigen display on hepatocytes might reduce the hepatitis activity. 
Therefore we started lamivudine therapy, The vims-suppressing therapy in combination 
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with the ongoing immune response resulted in nonnalization of serum transaminase levels; 
HBV -DNA levels became undetectable by peR, and HBeAg seroconversion followed in all 
three cases within two months. 
This course was rewarding but also unexpected since HBeAg seroconversion is unusual 
during flares with high HBV -DNA levels and also unusual during lamivudine studies in 
stable chronic hepatitis B patients.2J•24 Virus suppression by lamivudine and the immune 
reaction associated with icteric flares might thus be synergistic in effective clearance of 
virus infected cells. In our group of 6 patients with an anicteric hepatitis flare after 
lamivlldine withdrawal, all patients had high HBV-DNA levels at the time of ALT peak. 
Retreatment was not initiated and all flares subsided spontaneously but no seroconversion 
was observed (figure 4). 
Lamivudine resistance and hepalilis flares 
In case B measurement of HBV -DNA and HBeAg indicated that HBV replication was not 
completely blocked during lamivudine therapy; it increased after 24 weeks of treatment 
due to the appearance of a lamivudine-resistant mutant virus. Sequence analysis of the 
HBV genome showed a mutation in the highly conserved tyrosine-methionine-aspartate-
aspartate (YMDD) motif of the reverse transcriptase region, in which methionine was 
replaced by isoleucine (Met552 -} Ile552). This mutation was first described in 
immunosuppressed HBV -infected patients after liver transplantation31 ,32,33 and later in 
immunocompetent HBV-infected patients.34 In the present case the percentages viral 
populations were calculated and we found 0% mutant virus (YIDD) at week 16, 8% at 
week 36 and 100% at week 52, the end of lamivudine therapy. After discontinuation of 
lamivudine, HBV-DNA levels increased tenfold due to resurgence of the wild type virus 
(YMDD). Eight weeks after termination of treatment, 100% of the viral population was 
found to be wild type HBV. It was the emergence of the wild type HBV that provoked the 
hepatitis flare in our patient who had already developed liver cirrhosis. The relationship 
between the development of 'lamivudine-withdrawal hepatitis' and the lamivudine-resistant 
mutant virus is not yet clear. 
In case A and C no mutations were observed in the YMDD motif during hepatitis flares. 
In 5 out of 6 patients with an anicteric hepatitis flare no YMDD mutation was found at the 
time of ALT peak. One patient (figure 4, .) developed a severe hepatitis flare early after 
discontinuation of treatment, this hmnune reactivity was probably triggered by a rapid 
increase in viral replication during therapy, which in fact was a result of a mutation in the 
YMDD motif (Met", --> Val",). Three weeks after discontinuation of therapy the major 
vims population was still the mutant (YVDD). 
Histology during hepatitis jlares 
In case A liver biopsy at the time of the first hepatitis flare showed severe histological 
inflammatory activity (HAl score 10). Immunohistochemistry showed only cytoplasmic 
expression of HBcAg. In case C a spontaneous hepatitis flare occurred in a patient with 
mild liver disease without cirrhosis. During the hepatitis flare, liver histology showed 
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563 
detection limit, digene assay 
o 10 20 30 40 50 
weeks after withdrawal of lamivudine therapy 
HBV-DNA levels in six palients with a hepatitis flare aj/er withdrawal of 
lamivudine therapy. Circles indicate the lime of the ALT-peak and the 
number the peak ALT level (IU/I). HBV-DNA was quantified by the Digene 
liquid hybridization assay (Murex. UK). 
severe inflammatory activity together with unchanged nuclear HBcAg expression. In 
contrast to the liver biopsy 6 months prior to reactivation, HBcAg expression was also 
found in the cytoplasm, which is associated with increased inflanunatory activity.35,36 
HBsAg showed a regular spread of HBsAg expression in the cytoplasm, which was 
unchanged compared to the biopsy 6 months prior to reactivation. 
Management of Itepatitis flares 
Until recently 'lamivudine withdrawal hepatitis' was supposed to he self-limiting and 
patients were left untreated. Nowadays, the goal of management should he the prevention 
of liver failure and death, and - after our observation - could also include enhancement of 
the rate of HBeAg seroconversion. Therefore reinstitution of lamivudine therapy should he 
considered. Especially if HBV-DNA levels are high at the time of diagnosis of the 
hepatitis flare, spontaneous serocollversion is unlikely and therefore effective antiviral 
therapy is a logical choice. Treatment with lamivudine reduces viral replication rapidly hut 
allows the activated cytotoxic T cell response30 to eliminate hepatocytes that present viral 
antigens. This approach can also be tried in the event of spontaneous hepatitis flares during 
chronic hepatitis B. In this way the innnune activity evoked hy reactivation of hepatitis B 
viral replication may be used in a therapeutic setting. 
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In the event of incipient liver failure Gaundice and clotting factors below 50%), the 
question arises whether also immune reactivity should be tapered. Reports by others20,37 as 
well as our case suggest that a short course of prednisone might be helpful. All patients 
who receive prednisone to control a hepatitis flare should -in our opinion- also receive 
lamivudine (figure 5). 
Hepatitis flares are expected to occur morc regularly now that nucleoside analogues are 
going to be introduced 011 a large scale. In our group of patients suffering a lamivudine 
withdrawal hepatitis, HBcAg seroconversion was not observed in the six cases without 
lamivudine retreatment. We believe that controlled evaluation of the management of 
hepatitis flares should be initiated in order to minimize morbidity and mortality but also to 
have the best chance to achieve permanent seroconversion. 
In conclusion, severe hepatitis flares occur after withdrawal of lamivudine treatment. At 
the time that the serum ALT levels are peaking, the level of HBV-DNA is still high, and 
reinstitution of lamivudine is therefore a logical approach. Since lamivudine therapy 
rapidly reduces the viral load and viral spread, the activated inunune system can more 
easily eliminate infected hepatocytes and induce HBeAg seroconversion. 
severe hepatitis flare 
I 
ALT >3x baseline and >10x ULN 
Bilirubin, prothrombin 
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Figure 5. 
prednisone therapy can be initialed, if liver function 
deteriorates (always in combination with lamivudine 
Flow chart jar the managemelll oj hepatitis jlares jar chI'Dnic hepatitis B 
patients. 
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Summary 
Background/Aims: Lamivudine is a non~toxic, potent inhibitor of hepatitis B virus 
replication. Recently, hepatitis B virus resistance to lamivudine has been described in 
patients using immunosuppressive drugs after liver transplantation. 
Methods: From our cohort of 81 consecutive patients treated with lamivudine, we selected 
all immunocompetent patients who received lamivudine monotherapy for a period over 26 
weeks (1I~14). 
Results: Lamivudine resistance with the characteristic mutation in the YMDD motif was 
observed in four patients (actuarial cumulative incidence: 39%). Two patterns of viral 
resistance were observed: incomplete response (1I~2) and viral breakthrough (1I~2). 
Conclusions: The observed high frequency of lamivudine resistance may have implications 
for the concept of long-term virus-suppressive therapy of chronic hepatitis B by lamivudine 
monotherapy. 
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Introduction 
Lamivudine, a non-toxic potent inhibitor of hepatitis B virus (HBV) replication' is well 
absorbed and oral administration of 100-300 mg daily usually reduces HBV-DNA to levels 
undetectable by liquid hybridization techniques. During a treatment period up to 6 months, 
no viral breakthrough has been reported in immunocompetent patients.2,3,4 Lamivudine is 
an inhibitor of the viral enzyme reverse-transcriptase.5 In human immunodeficiency virus 
type I (HIV -I) infected patients, lamivudine monotherapy induces development of drug 
resistance within a few weeks;6 the loss of inhibitory activity is caused by a mutation in 
the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the reverse transcriptase.' 
Recently, cases of lamivudine resistance in vivo have been described in immunosuppressed 
liver transplantation patients.8,9 Here, we report lamivudine resistance due to mutation in 
the YMDD motif in a population of immunocompetent HBV infected patients, occurring 
as incomplete response or breakthrough with a higher than expected incidence in therapy 
of 6-12 months' duration. 
Material and Methods 
Patients 
We analyzed a cohort of 81 consecutive patients treated with lamivudine for chronic 
hepatitis B. Eleven patients colnfected with HCV, HDV or HIV, and three patients 
receiving immunosuppressive drugs after transplantation were excluded. From the 
remaining 67 immunocompetent patients, we selected all 14 patients who received 
lamivudine monotherapy for a minimum period of 6 months; all received a dose of 100 mg 
daily. At entry patients were HBV-DNA positive by liquid hybridization (Digene, Murex, 
UK) and HBeAg positive (Abbott, USA) and had elevated serum transaminases. All 
patients were tested for HBV -DNA quantitatively at least every 8 weeks during treatment. 
If HBV-DNA was positive in the last sample collected during treatment (n~5), we 
sequenced the YMDD motif region in the DNA-polymerase gene. 
HBV nucleotide sequence analysis 
If HBV-DNA remained detectable or reappeared during therapy, the latest serum sample 
under therapy was analyzed. To determine mutations in the YMDD motif, a selected 
genomic region of the polymerase gene of HBV was amplified (nucleotide 56-806), using 
the primers ACPR and S3 (ACPR, sense: 5'-CCT.GCT.GGT.GGC.TCC.AGT.CCC.GGA.-
ACA.GTA-3'; S3, antisense 5'-TIG.GTA.ACA.GCG.GTA.TAA.AGG-3'). Specifically, the 
region 459-806 was sequenced on a Vistra labstation (Amersham, UK) using dye 
terminator chemistry. Analysis was performed on an Applied 373 automated sequencer 
(Perkin Elmer, USA). The sequences were analyzed and aligned using Geneworks software 
(Intelligenetics, UK). 
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Table 1. Patient characteristics 
Patient Age Cirrhosis Previous YMDD YMDD HBV-DNA 
lamivudine analysis mutation during treatment 
treatment at week 
35 No Yes 52 Met~Val incomplete response 
2 41 Yes No 52 Met~lIe incomplete response 
3 18 No No 52 Met~lIe breakthrough 
4 17 No No 52 Met~lle breakthrough 
5 20 No No 46 None incomplete response 
Results 
In 14 consecutive immunocompetent patients with chronic hepatitis B treated with 100 mg 
of lamivudine daily for a period over 26 weeks, HBV-DNA levels initially decreased 2 log 
during the first 2 months of treatment (figure 1). However, after this initial drop in HBV-
DNA levels, three patients remained positive and two others became repeatedly HBV -DNA 
negative but showed a breakthrough after 48 weeks of treatment. In these five patients we 
sequenced the YMDD motif of the DNA-polymerase gene and identified a mutation in four 
of these patients (table I). Methionine was replaced by isoleucine (lie, n~3) or valine (Val, 
n~I). In one patient (patient 5) no mutation was found but this patient admitted to poor 
compliance. The actuarial cumulative incidence of YMDD mutation during 52 weeks of 
lamivudine treatment was estimated to be 39% (standard error 16%). We observed that 
viral resistance is also related to liver inflammation; in the three patients with incomplete 
HBV -DNA response, serum transaminases remained elevated during treatment. The two 
patients with breakthrough showed initially normalization of serum transaminases, which 
then started to rise when the mutant virus became detectable. 
Discussion 
This study shows the development of lamivudine resistance in immunocompetent patients 
with chronic hepatitis B virus infection during prolonged lamivudine monotherapy. The 
actuarial cumulative incidence of lamivudine resistance in our patient group treated for 
more than 6 months amounted to 39% at I year. All cases had a mutation in the YMDD 
motif of the DNA-polymerase gene. 
In HIV-I infected patients lamivudine resistance developed rapidly after initiating therapy.' 
In HBV infected patients, phase I and II studies usually showed inhibition of HBV 
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Figure lAo HBV-DNA levels during lamivudine treatment in five patients suspected of 
developing lamivudille resistance due to viral mulations. YMDD analysis 
revealed characteristic mutation in patients 1 and 2 (incomplete response) 
and patients 3 and 4 (breakthrough). Falielll 5 admitted to not taking 
medication for several weeks (non~compliance). 
Figure lB. REV-DNA levels during lamivudine h'ealment in nine other patients with 
sustained response /0 lamiYlldine. 
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replication until the end of the treatment.'·)·' However in the study with the longest 
treatment period reported (24 weeks),' only about 75% of patients, treated with 100 mg or 
300 mg daily, were HBV-DNA negative at the end of treatment. No analysis of HBV-
DNA in the non-responders has been published. 
Recently, viral resistance to Iamivudine has been reported in patients using 
immunosuppression after liver transplantation.8•9 Sequencing of the YMDD motif in these 
cases showed replacement of methionine by valine or isoleucine, the same mutation as 
described in mv -I infected patients. The development of resistance in patients after liver 
transplantation was thought to be related to immunosuppression and the associated high 
levels of viral replication. Tlus study reports for HBV resistance to lamivudine in a cohort 
of immunocompetent patients. 
We observed two types of viral responses in which resistance occurred. The first type 
showed an hutial decline in HBV-DNA but subsequently an incomplete response to 
lamivudine treatment (patients 1 and 2) and selection of a mutant virus during continued 
treatment. The second type of viral response (patients 3 and 4) showed prolonged 
undetectable HBV -DNA levels and after II months of treatment emergence of a mutant 
virus. The relatively frequent occurrence of the latter response type is particularly 
disappointing since it diminishes hopes for simple long-term virus suppressive therapy in 
chronic hepatitis B. The results of the ongoing phase III studies will point out more 
accurately the incidence of lamivudine resistance during long-teml monotherapy and 
lamivudine/interferon combination therapy. 
A 24-weeks dose ranging study showed that 100 mg of lamivudine daily should be as 
effective as lugher doses.' Tlus conclusion is based on the observation that HBV-DNA 
levels became undetectable by liquid hybridization teclntique in the 100 and 300 mg dose 
groups. However, quantitation of HBV-DNA levels by PCR technique suggests a more 
profound drop in HBV-DNA levels in the 300 mg group." Lamivudine doses over 100 mg 
per day may induce an effective block in viral replication more rapidly, which would delay 
the development of viral mutations. 
In conclusion, lamivudine -resistance of HBV can also occur in chronic hepatitis B without 
immunosuppression. The mutation identified is located in the highly conserved tyrosine-
metluonine-aspartate-aspartate (YMDD) motif of the DNA-polymerase. As in mV-I, the 
relatively easy development of drug resistance following lalfuvudine mono therapy calls for 
studies with combination therapy for long-term virus suppression. 
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Summary 
Lamivudine has been shown to be a potent and non~toxic inhibitor of hepatitis B virus 
(HBV) replication in chronically infected patients. Upon prolonged treatment drug 
resistance may develop, related to a mutation of methionine (Met) to valine (Val) or 
isoleucine (lie) in the YM",DD motif of the HBV-DNA polymerase gene. 
Analysis of the HBV -DNA polymerase gene from eight chronic HBV patients suspected of 
resistance to lamivudine, showed that in addition to a mutation in the YM552DD motif, a 
second mutation located in the B domain of this gene, a Leu528 to Met528 change, was 
consistently and exclusively found in four patients showing the YV 552DD motif. TIllS 
suggests a functional or structural relationship between these domains. Since the presence 
of both the YI",DD and YV",DD motif sometimes preceded the exclusive presence of the 
YVss2DD motif, we conclude that the YIss2DD motif could occur as a temporal 
intennediate. After cessation of therapy, the wild type sequences re-emerged. 
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Introduction 
New therapeutic approaches, including the use of nucleoside analogues like (-)2',3'-
dideoxy-3' -thiacytidine (lamivudine) and 9-( 4-acetoxy-3-acetoxymethyl-butyl)-2-
alllinopurine (falllciciovir), have recently been explored in chronic hepatitis B.1 Most 
information is presently available about the therapeutic use of lamivudine. It has been 
shown to be relatively non-toxic and to reduce HBV-DNA levels in the senlln profoundly, 
often to levels undetectable by polymerase chain reaction (peR),") During treatment 
periods lasting up to six months no breakthrough has been observed. However, after 
cessation of treatment, serum HBV -DNA levels to return to pretreatment values and even 
enhanced replication of HEV has been reported.4 
Recently, Ling et aL5 described resistance to lamivudine in liver transplant recipients, 
which was confirmed by other groups,'" We reported the high frequency of resistance in 
chronic hepatitis B infected patients who received a prolonged therapy with lamivudine. 8 
This resistance proved to be related to mutations in the YMDD motif of the DNA 
polymerase gene: a mutation of Met to Val or lie at position 552 appeared to be 
involved.9.10 Also in HIY-l, changes in the same motif of the reverse transcriptase gene 
proved to be related in lamivudine resistance. I1 •14 
Here we present the results of a longitudinal analysis of HBV polymerase gene sequences 
from eight chronically infected HBY patients treated with lamivudine, showing that a 
second mutation in this gene may be involved in the development of resistance to this 
compound. 
Materials and Methods 
Patients. 
From a cohort of 60 chronically HBV infected patients, treated with lamivudine for more 
than three months with a daily dose of at least 100 mg of lamivudine orally, eight patients 
were selected on basis of either an incomplete response or a breakthrough (table I). 
Patients with an "incomplete response ll to therapy were defined as individuals showing an 
initial drop in senllll of HBV-DNA levels, measured by liquid hybridization teclmiques 
(Digene, Murex, Breukelen, The Netherlands), which however did not decline to 
undetectable levels. Patients with a IIbreakthrough" were defined as individuals with an 
initial response leading to undetectable HBV -DNA serum levels, which later during 
treatment became detectable again, Two of the patients (# 7 and #8) had undergone liver 
transplantation with subsequent immunosuppressive therapy, and lamivudine therapy was 
started after transplantation. Of the other six patients one (#1) had previously been treated 
with lamivudine for 24 weeks with 300 mg daily, and another (#6) proved to be co-
infected with HIY -I and received co-medication with zidovudine. At entry all patients 
were HBV -DNA positive by liquid hybridization and had elevated semm transaminase 
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levels. 
Sequence analysis. 
A selected genomic region of the polymerase gene as well as the HBsAg gene was 
amplified and sequenced using primers ACPR and S3 (ACPR, nucleotide 56-85, sense: 5'-
CCT.GCT.GGT.GGC.TCC.AGT.CCC.GGA.ACA.GTA-3'; S3, nucleotide 806-786, 
antisense 5'-TTG.GTA.ACA.GCG.GTA.TAA.AGG-3'). The PCR products were sequenced 
on a Vistra Labstation (Amersham, Buckinghamshire, United Kingdom) using dye 
temlinator chemistry and analyzed on an Applied 373 automated sequencer (Perkin Elmer, 
Nieuwerkerk, The Netherlands). Both strands were sequenced and analyzed using 
Geneworks software (Oxford Molecular, Oxford, United Kingdom). To confirm the 
sequencing results, two consecutive serum samples were analyzed. 
For further analysis, the PCR products were directly cloned into pGEM-T (Promega, 
Leiden, The Netherlands) or pCRII vectors (InVitrogen, Leek, The Netherlands). The 
obtained colonies were prescreened by PCR to confirm the size of the insert. DNA was 
isolated and sequenced on the Vistra Labstation using Energy transfer dye primer 
chemistry. 
Results 
Kinetics of serum HBV-DNA levels uponlamivudine treatment. 
The kinetics of serum HBV-DNA levels after starting lamivudine therapy are shown in 
figure 1. From the eight patients analyzed, five (#1 to #5) belonged to a group of 
chronically infected HBV patients, who had a pretreatment viral load ranging from 1363 to 
10610 pg per ml (Digene, Murex). After initiating the treatment, the viral loads decreased 
in three out of the five patients to levels undetectable with the hybrid capture assay 
(detection level 5 pg/ml). However, after 48 to 56 weeks a breakthrough occurred, with 
viral loads remaining below the pretreatment levels (median 11.3%, range 2.1-33.6). 
In one patient (#6), who was co-infected with HIY-I, serum HBV-DNA levels remained 
undetectable by hybrid capture assay for 95 weeks, after which the HBV -DNA level under 
therapy reached pretreatment levels. Finally, the HBV-DNA levels of the two liver 
transplant recipients (#7 and #8) under lamivudine treatment were analyzed. One of them 
(#7) showed an incomplete response. Viral load decreased with 98.1 %, but after 53 weeks, 
the viral load increased despite continued treatment to about seventy times the pretreatment 
level. In the other liver transplant recipient (#8), serum HBV-DNA levels became 
undetectable. Breakthrough occurred after 40 weeks of treatment, but the serum HBY-DNA 
load remained less than 6% of pretreatment levels. 
Sequence analysis of the HBV-DNA polymerase gene. 
To study the appearance of lamivudine resistance, PCR products covering nucleotide 56 to 
806 and encoding the YMDD motif (position 733 to 745), were sequenced. In all the eight 
128 
Lamivudine resistance and viral mutations 
patients, Met at position 552 had been replaced by either a Val (patients #1, #5, #6 and #8) 
or an lie (patients #2, #3, #4 and #7) as has been documented previously in the 
development of HBV resistance to lamivudine (table I). In the former four patients, who 
all exhibited theMetss2 to Vals52 mutation, a second mutation - LeuS28 to Mets28 - was 
observed. Cloning and sequencing of individual PCR products from each pretreatment and 
resistance time pair, confirmed an absolute linkage between the LeuS28 to Mets28 mutation 
on the one hand, and the Metm to ValSS2 mutation on the other hand in these patients. No 
additional changes between the two time points were observed. 
Since in mV-l lamivudine resistance it has been shown that the Metss2 to Vals52 mutation 
is preceded by a Met552 to Iless2 mutation, IJ we wondered whether this sequence of events 
also takes place in the development of HBV resistance to lamivudine. Therefore additional 
cloned PCR products from two patients (# 1 and #7), generated towards the end of 
lamivl.ldine therapy, were cloned and sequenced. Sequence analysis was performed on six 
and eight independently generated clones, respectively. Analyses of sequences obtained 
from liver transplant patient (#7) showed that all these clones exhibited the YI",DD 
mutation only. Analysis of a chronically infected HBV patient with a YV",DD mutation 
(#1), revealed that from the six clones analyzed, four had a YV",DD mutation, while two 
had an YIS52DD mutation. In these YV sS2DD containing clones, again the linkage of Mets28 
with ValS52 was demonstrated. 
Finally, in four patients (#1 to #4), therapy was discontinued. Sequence analyses of 
samples collected after cessation of therapy showed viruses with the HBV polymerase gene 
wildtype sequences, Met5s2 and LeuS28 had replaced the mutated viruses. 
Discussion 
In the present paper we have confirmed earlier findings from our group and others, 
showing that the development of HBV resistance to lamivudine is associated with a 
mutation in the YM",DD motif of the HBV-DNA polymerase gene into either YI",DD or 
YV",DD. In addition we have found that in contrast to the YI",DD motif, the YV",DD 
motif is consistently linked to a LeuS28 to Mets2& mutation. This second mutation is located 
in the B domain of the reverse transcriptase part of the HBV -DNA polymerase gene, while 
the YMDD motif is located in the C domain. Analyzing individual clones from a patient 
with a chronic HBV infection and the YVDD motif, indicated that during therapy both the 
YIDD and the YVDD mutations could be present at the same time. The latter finding is 
reminiscent of the same sequence of mutations occurring in the YMDD motif of the 
reverse transcriptase gene of HIV -1 upon lamivudine treatment, in which the YIDD motif 
is a temporal intermediateY Again a linkage of Vals52 with Leum was observed. 
Although HBV as a member of the Hepadnaviridae family is a DNA virus, it replicates 
through a RNA intermediate with a replication strategy similar to retroviruses. By 
comparing the RNA dependent DNA and RNA polymerases, four conserved motifs or 
elements with the same linear arrangements were indentified, in which altogether four 
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Table 1. Patients characteristics and mutations arising in the HBV-DNA polymerase gene during lamivudine therapy of Ii. chronical hepatitis B infected patients. ;3 
0-s· 
Patient Previous Documented Inununo- Arising Response Reduction of " 
" lamivudine co-infection suppressive mutations to therapy HBV-DNA  ~
treatment therapy (L Tx ) under therapy 3 
" a 
#1 Yes No Met ->Val Incomplete response 72.8% S' ~ 
" Leu ->Met g-o 
#2 No No Met -j. lIe Incomplete response 
e. 
66.4% 
" if 
#3 No No Met .... TIe Breakthrough 97.9% '0 ~. 
#4 No No Met -)0- lie Breakthrough 97.1 % :z. ~ 
:;:; tp 
0 #5 No No Met ->Val Breakthrough 97.7% 
Leu ->Met 
#6 No HIV-I No Met ->Val Breakthrough 62.0% 
Leu .... Met 
#7 No Yes Met -j> lie Incomplete response 0% 
(increase 69 fold) 
#8 No Yes Met ->Val Breakthrough 94.5% 
Leu .... Met 
LTx: liver transplant patient. 
sequences determined on peR products. Sequence differences are related to the pretreatment sequences. 
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strictly and eighteen relatively conserved amino acids are present. IS One of these domains 
(domain C) contains the YMDD motif, and it is suggested that one conserved amino acid 
is placed in, or proximal to, turn structures which are crucial for the catalytic activity of 
the enzyme. In the YMDD motif, most likely the D",D", are crucial, since they are 
largely invariable, except in minus strand RNA vimses. The Tyrm (Y) residue is highly 
conserved, but can be replaced by chemically related amino acids. The Metss2 residue is 
conserved among the DNA viruses group, but has been replaced by lie and Val in some 
retroviruses. The LeuS28 residue is located in a highly conserved region of the B domain, 
but is only present in the DNA viruses and hepatitis A virus. The direct linkage between 
the LeuS28 into Mets28 mutation coupled with the YVDD motif, suggests that these two 
regions are mutually under functional or stmctural constraints. 
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Figure 1. HBV-DNA levels dllring lamivudine therapy in five chronically infected 
patients (#1 to #5), one HBV-HIV co-infected patient (#6) and two liver transplant patients 
(#7 and #8) all developing {amivudine resistance. Viral DNA levels were measured with a 
hybrid captllre assay (Digene, Mllrex), which has a detection level of 5 pg/ml. 
The limited data available on serum HBV-DNA levels in lamivudine treated individuals 
and mutated virus indicate that in immunocompetent HBV chronic carriers, the DNA level 
of the mutated virus, does not rebound to pretreatment levels. A reduction up to 98% may 
be achieved. This indicates that in the patients, the mutated virus has a reduced capacity to 
replicate. However, our data and the data presented by Tipples et al.lO suggest that in liver 
transplant patients, the HBV-DNA levels under lamivudine may become higher than before 
131 
Lamivudine treatment for chronic hepatitis B 
transplantation. This may be related to the immunosuppressive therapy that is routinely 
practiced after transplantation. This by itself may lead to relatively high semm HBV -DNA 
levels. Stopping of lamivudine therapy may lead to reactivation of the HBV infection,' 
which may be related to the observation that a virus with the YMDD motif returns, 
probably due to its higher replication capacity. 
The time needed before an increase of viral load related to the observed mutations can be 
detected appears to be different in HIV-l and HBV infected individuals. In HIV-I, 
resistance to lamivudine is usually observed within a few weeks. 14 In our study and those 
of others on the development of hepatitis B virus resistance to lamivudine,5.6.7.lo increase of 
viral load was observed after up to 80 weeks. The difference between HIV -I and HBV in 
tlus respect might be explained by the fact that HBV uses two open reading frames 
simultaneously, which may restrict the emergence of viable mutations. 
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Introduction 
Lamivudine is an effective virostatic drug for the treatment of chronic hepatitis B virus 
infections. However, after prolonged treatment periods lamivudine resistance has been 
observed in both immunosuppressed and immunocompetent patients. I ,2 One year after the 
emergence of this entity incidence, patterns and molecular biology have been described.3 
We present our data on the clinical impact of lamivudine resistance in chronic hepatitis B 
patients. 
Patients and Methods 
We assessed virology and biochemistry data before, during ·and after the emergence of a 
lamivudine resistant viral mutant in 13 patients from our centre. Ten were 
immunocompetent chronic hepatitis B patients, and three were so called immunodeficient 
(two liver transplant recipients with allograft reinfection and one mV-HBV coinfection). 
Ten patients continued lamivudine therapy after the emergence of a mutant virus, while 
three stopped lamivndine at the time of the detection of a viral mutant; two additional 
patients stopped five months later (per protocol). Four patients that continued lamivndine 
therapy after the diagnosis of resistance had additional therapy with famciclovir (1500 mg 
daily for I month). 
HBV -DNA was assessed by liquid hybridization assay (Digene, Murex, UK) with a 
detection limit of 1.5 x 10' genome equivalents per ml (gen.eq.lml), according to the 
Eurohep standard. Sequence analysis of the genomic region (nucleotide 56-806) of the 
polymerase of HBV (including the YM",DD motif) was performed on a Vistra labstation 
(Amersham, UK) using dye terminator chemistry. Analysis was performed on an automated 
sequencer (perkin Elmer, USA). The sequences were analyzed and aligned using 
Geneworks software (lntelligenetics, UK). 
Results 
During lamivndine therapy in 10 out of 13 patients no HBV -DNA was detectable. Three 
patients remained positive at levels between 4.3 and 18 x 10' gen.eq.lml. ALT levels 
nonnalized during therapy in 10 patients. 
After the development of the lamivudine resistant mutant, all patients had detectable serum 
HBV-DNA, but HBV-DNA levels remained below pretreatment levels in 5 out of 9 
patients that continued lamivudine therapy. However, in all three immunosuppressed 
patients higher HBV -DNA levels were observed after the emergence of a mutant virus. 
After the diagnosis of lamivudine resistance ALT levels became abnormal in 11 out of 13 
patients (8 patients had an ALT relapse), ALT levels remained below pretreatment values 
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in 8 out of 9 patients after 5 months. 
We observed 2 hepatitis flares in 9 patients that continued lamivudine therapy in 5 months 
of follow-up. One patient died of a severe hepatitis flare within four weeks after the 
emergence of a mutant virus, this patient used immunosuppression after liver 
transplantation.4 
In four patients after the diagnosis of resistance additional therapy with famciclovir (1500 
mg daily for I month) in combination with continued lamivudine therapy had no effect on 
HBV-DNA and ALT in three. In one patient with rapid increasing HBV-DNA levels and 
an ALT flare, HBV-DNA became negative during famciclovir and remained negative after 
discontinuation of famciclovir. 
After withdrawal of lamivudine, HBV-DNA levels rebounded to pretreatment values, 
associated with more marked hepatitis activity than during lamivudine therapy. In two 
patients hepatitis flares were observed within 6 months of discontinuation, both became 
icteric but recovered. HBV -DNA reverted back to wild type in all cases. 
Table 1. Virological and biochemical results in 13 patients before, during and after 
the emergence of a lamivudine resistant viral mutant 
Durillg iamivlldille therapy 
Pre- 3 months At 5 months After 
treatment lamivudine resistance thereafter withdrawal 
(11~ 13) (11~13) (11~13) (11~9) (11~5) 
HBV-DNA (xlO' gen.eq.lml, Digene, Murex) 
Virus type wild type wild type lie", (11~7) lie", (11~5) wild type 
Metss2 Metm Val", (11~6) Val", (11~5) Metss2 
Median level 398 0.5 87 142 578 
(range) (6.6-2836) (0.5-18) (9.1-2395) (0.5-834) (233-2602) 
AL T level (lUll) 
Median level 79 40 56 59 131 
(range) (40-306) (24-71) (29-1145) (31-97) (54-211) 
Flare' 11~0 II~O n=l, died lF2 lF2 
• Hepatitis exacerbations exceeding ten times the upper limit of nonnal (300 lUll) 
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Discussion 
The clinical impact of lamivudine resistance in chronic hepatitis B needs to be assessed. 
Especially since rapidly increasing use of this drug in the prevention of HBY reinfection 
after liver transplantation, and in the treatment of various fonus of chronic hepatitis B is 
anticipated. In most of such conditions lamivudine will be used as a virostatic drug, and 
persistence of the clinical benefit can only be expected if the antiviral effect can be 
maintained for years. The incidence of lamivudine resistant HBY is reported to be 14 % of 
patients after one year,S but in our centre 50% of patients developed resistance to 
lamivudine within two years, suggesting a time dependent cumulative problem. 
Continuation of lamivudine therapy was associated with lower HBY-DNA and ALT-levels 
than before the start of therapy in the majority of patients. 
Withdrawal of lamivudine led to reappearance of the wild type virus and an increase in 
HBY -DNA levels and marked ALT elevation; in 2 out of 5 an icteric hepatitis flare was 
observed. 
In this situation antiviral combination therapy with famciclovir although attractive, is of 
unproven benefit. 
Currently, continuation of lamivudine monotherapy appears the best approach for most 
patients, in spite of increase in HBV -DNA and ALT levels. This preliminary conclusion on 
short term consequences needs a firm database to be assembled in 1998. 
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Background 
Chronic hepatitis B can give rise to serious conditions like cirrhosis, hepatocellular 
carcinoma and liver failure. Positivity of HBsAg in serum will be followed by additional 
testing of HBeAg and serum transaminase levels. In case one of these is abnonnal further 
evaluation of liver disease is required. \Vhen active viral replication is demonstrated 
standard treatment with alpha-interferon Ca·IFN) has to be considered, since longitudinal 
studies on the natural history of chronic hepatitis B have shown that ongoing viral 
replication and liver inflammation are features which predict unfavourable evolution of the 
disease'. Alpha-interferon therapy will induce viral latency in approximately 30·40% of 
patients.' High levels of viral replication CHBV·DNA) and mild elevation of semm 
transaminase levels (ALT) have shown to be associated with non-response.3 Therefore, the 
majority of patients still do not qualify for a-IFN therapy either will not respond to 
therapy. Therefore potent antiviral nucleoside analogues are a welcome approach in the 
treatment of chronic hepatitis B. 
The studies described in tlus thesis focussed on several aspects of the nucleoside analogue 
lamivudine in the treatment of chronic hepatitis B virus infection. In this chapter: we would 
like to discuss how we tlunk our clinical research opens new horizons for additional 
treatment strategies in patients with chronic hepatitis B. 
Clinical use of lamivudine 
During the initial 28 days clinical trial, lamivudine was well tolerated and doses above 20 
mg once daily resulted in marked suppression of HBV-DNA. Dynamics of HBV 
replication during therapy gave us the opportunity to calculate viral turnover in vivo. The 
minimum virus production and clearance per day was calculated to be over 1011 virions per 
day. This showed the extreme efficacy of one daily tablet of lamivudine that will result in 
undetectable HBV-DNA levels Cas tested by the conventional liquid hybridization assay) 
within four weeks in the majority of patients." In view of the universal reactivation after 
withdrawal, prolongation of therapy up to 6 months was offered to the patients. This study 
showed that beside undetectable HBV-DNA by conventional assays also normalization of 
serum transaminase levels was observed in the majority of patients.s Liver biopsies during 
treatment gave the first clue that also histological activity improved.' Especially piecemeal 
necrosis which is thought to be a predictor for progression of cirrhosis7 improved 
significantly. In spite of the classical markers of successful antiviral therapy CHBV-DNA 
negativity and AL T normalization) reactivation occurred in almost all patients after 
discontinuation of lamivudine. 5.8 However, lamivudine demonstrated to be a non-toxic, and 
potent virostatic drug, deprived of mitochondrial toxicity.9 
The question remains how to use the drug in an optimal way to prevent progression of 
chronic liver disease in hepatitis B patients? Two different strategies are emerging: 
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1. Long-term suppression with potent antiviral drugs will result in long-term suppression 
of disease activity which will result in a better prognosis. 
2. Short-term virus suppression combined with inuuunostimulation will give the host 
immune response the opportunity to induce definite viral clearance, with the 
development of antibodies and thereby improvement of life expectancy. 
For chronic hepatitis B virus infection both strategies are justifiable and we would like to 
expand on these in more detail. 
Long-term virus suppression 
In the past some virus-suppressive nucleoside analogues induced a decrease in HBV -DNA 
levels during therapy, however, in the majority of patients HBV -DNA did not became 
negative. Early lamivudine studies in vitro and in vivo showed that over 99% reduction of 
viral replication was feasible. Since lamivudine induces probably a complete blockade of 
HBV replication, prolongation of therapy resulted in improvement of liver disease without 
immune mediated viral clearance (table 1).4.S,6,8.1O.11 
Table 1. Improvement of disease activity during lamivudine therapy (25, JOO 01' 300 mg) 
Duration of lamivudine therapy I month 3 months 6 months 12 months 
Loss of HBV -DNA (hybridization) 65%4 73%5 81%5 
Loss of HBV -DNA (peR) 12%10 26%10 
HBeAg negativity 0%4 4%5 8%5 14W' 
ALT normalization 6%4 28%5 47%5 68%11 
Histological improvement 46%6 67%11 
However, in view of the very large number of viral particles produced each day, the 
emergence of mutant viruses with resistance to lamivudine seems to be unavoidable. 
Especially in case of lamivudine monotherapy one single mutation in the lamivudine 
sensitive part of the genome of the virus is enough to escape the antiviral pressure. 
Lamivudine resistance 
Lamivudine resistance was first observed in patients using immunosuppressive therapy 
after liver transplantation,12.I3,14 but soon thereafter also in immunocompetent patients. 15 
Until now we observed lamivudine resistance in 13 patients and calculated a risk of 32% 
after 12 months of lamivudine therapy (figure I). Recently Lai et al. reported that 
lamivudine resistance was detected in 14% of patients after 52 weeks of therapy in an 
Asian population. 16 This difference in incidence of lamivudine resistance between our 
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European centre and the Asian population needs further exploration. Currently lamivudine 
resistance has not been observed during the initial 6 months of treatment and thereafter 
lamivudine resistant mutants will occur in 3-5% of patients every month. 
The clinical implication of lamivudine resistance is poorly known. After the development 
of the lamivudine resistant mutant HBV -DNA levels remained below pretreatment values 
in 5 out of 9 patients that continued lamivudine therapy. However, in all three 
immunosuppressed patients higher HBV -DNA levels were observed after the emergence of 
a mutant virus. After the diagnosis of lamivudine resistance serum transaminase levels 
became abnormal in 11 out of 13 patients, ALT levels remained below pretreatment values 
in 8 out of 9 patients after 5 months. In our group of 13 patients, 5 experienced an AL T 
flare over ten times the upper limit of normal (300 lUll), three during continued therapy 
and two after withdrawal of lamivudine. Therefore relapse of disease activity is usual after 
the emergence of a lamivudine resistant viral mutant. At the moment it is uncertain if 
lower HBV-DNA levels are associated with delayed disease progression, however, 
continuation of lamivudine therapy appears the best approach. If rapid progression of 
disease activity is observed, the addition of other antiviral drugs may be required. 
100 % of 
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Figure 1. 
number of patients at risk 
Percentage of patients becoming HBV-DNA negative (hybridization assay) 
and the percentage of patients developing the famivudille resistant mutant. 
Future studies should be performed to know how lamivudine resistance can be delayed or 
even prevented. In our opinion higher dosages of lamivudine should also be considered. 
The standard dose of 100 mg daily was found to be optimal based on HBV-DNA levels 
measured by liquid hybridization teclmique. However, viral replication is still ongoing 
below the limit of detection of this assay, which allows the development of viral 
mutations. Therefore sensitive methods as peR are required to show more properly the 
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level of virus suppression during lamivudine therapy. By peR with a detection limit of !OJ 
gen.eq.!ml, we observed a trend towards superior suppression of viral replication by the 
300 mg group in comparison to the 100 mg dose group. During early phase II studies, 600 
mg of lamivudine was not associated with more side-effects in comparison to lower doses. 
Therefore 600 mg lamivudine can he considered during the initial 4 weeks of therapy, 
followed hy 100 mg maintenance period. 
Also combination with other nucleoside analogues can be helpful to prevent 
development of lamivudine resistant mutants. Recently Locarnini et aI. observed 
lamivudine and famciclovir act 
the 
that 
synergistically during in vitro 
experiments. 17 In conclusion, 
comparable with the observation 
during nucleoside analogues studies 
in HIV infected patients, maximal 
antiviral induction therapy might he 
the best way to minimize the 
emergence of mutants during 
therapy. 
Table 2. Golden rilles of antiviral therapy 
+ 
+ 
+ 
+ 
+ 
Discontinuation of therapy 
Prolong survival 
Low side effects 
Maximal antiviral induction therapy 
Sensitive assays for monitoring 
Delay or prevent viral evolution 
The question at what time antiviral therapy can be discontinued based on what parameters 
still remains unanswered. When viral replication is completely blocked by antiviral 
therapy, infection of new hepatocytes will not occur and the chronic infection might 
extinguish. Therapy can theoretically he discontinued at the time the whole liver is 
regenerated in the presence of antiviral drugs. This approach will take several years since 
whole liver regeneration has been calculated to occur in a period of 4-10 years. To 
determine the time of discontinuation of therapy beside serological tests liver biopsy with 
immunohistochemical staining of HBsAg and HBcAg will be necessary. At the moment 
data on the effect of lamivudine on the the most resistant viral DNA species (cccDNA) are 
lacking. Tins DNA will remain ahle to resume the viral replication cycle. 
Immune mediated viral clearance 
Patients chronically infected with the hepatitis B virus still have the opportunity to 
eliminate the virus. Therefore we should not treat them life-long with antiviral drugs in 
case they have a real chance to control the virus by their own immune-system. Previous 
studies with combination therapy of a-IFN and nucleoside analogues were 
disappointing. '8.'9,2o Since the antiviral effect of lamivudine was found to be superior, 
combined approaches with a-IFN were evaluated. In this thesis we described the first study 
on lamivudine and a-IFN combination therapy in previous interferon non-responders.21 
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Combination therapy was well tolerated, phannacokinetic interaction of both drugs was not 
observed and HBV-DNA levels decreased dramatically during therapy. However only lout 
of 20 patients had a sustained HBeAg seroconversion. In our opinion this combined 
approach needs to be studied in more detail because 4 patients (previously not responding 
to interferon) became HBeAg negative at the end of treatment. This is unusual in 
lamivudine monotherapy, therefore prolongation of the treatment period may induce 
sustained response as is shown in several patients when interferon monotherapy was 
prolonged beyond 16 weeks." Another attractive approach is to start lamivudine therapy a 
few weeks before initiating interferon. Following this scheme HBV-DNA levels are low at 
the time of the first dose of interferon, which is found to be a good predictor of response 
to interferon treatment.) In our opinion combination therapy with a strong antiviral drug 
and an inlllllne stimulator is likely to offer the patient the best chance of disease 
remission. However, at the moment we still have to learn how to combine these 
approaches. 
Other immune modulators 
Recently some other immune modulating agents showed promising in vitro results, for 
example Tucaresol and lL-12 are both candidates to stimulate the inlllllne system which in 
combination with the antiviral effect of lamivudille may induce seroconversion.23,24 
Especially since IL-12 seems to playa crucial role during seroconversion at least during 
interferon therapy.2S 
After liver transplantation when the infected liver is replaced by a donor liver, reinfection 
can be prevented by polyclonal hepatitis B immunoglobulin (HBlg). Since lamivudine is 
able to decrease viral replication below the limit of detection of the peR assay, passive 
vaccination with monoclonal or polyclonal antibodies should be evaluated also in patients 
chronically infected with HBV. 
Hepatitis jlares 
Acute exacerbations in chronic hepatitis B have been described after withdrawal of 
corticosteroids26,27 and cancer chemotherapy.28.2!1 The mechanism of this syndrome is in all 
likelihood increased HBV replication and antigen expression on hepatocytes.30 After 
withdrawal of therapy rebound immune reactivity and immune-mediated cytolysis of HBV-
infected hepatocytes occurS.3l Spontaneous hepatitis exacerbations have been described 
both in HBeAg negative and positive patients.32 The majority of these hepatitis flares were 
presumed to represent increased host immunity against HBV -infected hepatocytes. Some of 
these flares will precede HBeAg seroconversion and others will not?3 Monthly monitoring 
of patients with chronic hepatitis B revealed the serological patterns preceding the hepatitis 
exacerbations."·35.35 Hepatocyte damage was found to be preceded by a rise in HBV-DNA 
levels, the same pattern as observed during acute hepatitis B.37 During the spontaneous 
hepatitis flares associated with chronic hepatitis B, low levels of HBY-DNA (and HBeAg) 
at the time of the ALT peak are associated with a subsequent HBeAg seroconversion.34.35,36 
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A rapid increasing viral replication also occurs after discontinuation of potent antiviral 
therapy and can be followed by hepatocyte damage. We observed acute hepatitis 
exacerbations in 20% of cases after withdrawal of lamivudine.38 All patients demonstrated 
high levels of viral replication at the time of the AL T peak. Therefore, subsequent HBeAg 
seroconversion was unlikely and we started lamivudine retreatment in the icteric cases 
which resulted in normalization of serum transaminase levels; HBV -DNA levels became 
undetectable by peR, and HBeAg seroconversion followed in these cases within two 
months. Virus suppression by lamivudine in combination with the activated cytotoxic T 
cell response39 might thus be synergistic in effective clearance of virus infected cells. In 
this way the immune activity evoked by reactivation of hepatitis B viral replication may be 
used in a therapeutic setting. 
Based on these observations reinstitution of lamivudine therapy should be considered in all 
cases with acute exacerbation of hepatitis B virus infection, either to prevent further liver 
damage or to enhance the rate of HBeAg seroconversion. Especially if HBV-DNA levels 
are high at the time of diagnosis of the hepatitis flare, spontaneous seroconversion is 
unlikely and therefore effective antiviral therapy is a logical choice. Furthermore in 
patients with incipient liver failure as a re~ult of an acute hepatitis exacerbation, itmnune 
reactivity can be tapered by a short course of prednisone. However, all patients who 
receive prednisone to control a hepatitis flare should -in our opinion- also receive 
lamivudine 
Table 3. Clinical indications for lamivudine therapy 
• Contra-indication for alpha-interferon 
• 
• 
• 
• 
• 
Non-response to alpha-interferon 
Pre-treatment before liver transplantation 
Reinfection after liver transplantation 
Fulminant hepatic failure 
Severe acute exacerbation 
Summary clinical impact of lanlivudine 
Decompensated liver cirrhosis 
• High level of viral replication 
Low level of immune reactivity 
Lamivudine is a strong inhibitor of hepatitis B virus replication without significant toxicity. 
This gives us the opportunity to offer chronic hepatitis B patients one single daily tablet to 
induce significant disease remission. However viral clearance is feasible in chronic 
hepatitis B and the first choice antiviral approach still is interferon-alpha, in the near future 
probably combined with lamivudine. Since the majority of patients will not quality for or 
will not respond to interferon therapy, a major role for lamivudine will be put aside in the 
treatment of chronic hepatitis B. 
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Summary 
The new potent nucleoside analogues have generated important changes in the therapeutic 
approach in the treatment of chronic hepatitis B. The studies presented in this thesis focused 
on lamivudine which was found to be one of the most effective inhibitors of HBV 
replication both ill vitro and in vivo. At least an advance for the majority of patients in need 
for antiviral therapy. that will not qualify for, or will not respond to standard interferon-
alpha therapy (chapter I). Viral dynamics during the initial 28 days of therapy showed a 
dramatic drop of HBV -DNA levels in patients treated with a single daily tablet of 
lamivudine. These complete blockade of viral replication allowed us to calculate the 
minimum virus production and clearance which was found to be over lOll virions per day. 
Based on these results prolonged treatment up to six months was offered to the patients. In 
chapter 3 we discussed the biochemical, virological and histological remission of disease 
activity. During 6 months of lamivudine therapy ALT levels normalized in 47% of patients. 
This was accompanied by improvement of inflammatory activity in liver biopsy specimens 
taken during treatment. Virological response was obvious and we observed continued viral 
suppression below the detection limit of the liquid hybridization assay. By the sensitive 
peR assay HBV-DNA became undetectable in 26% of patients, with evidence for continued 
suppression with longer duration and higher dose of lamivudine. 
Since HBeAg seroconversioll is not observed during lamivudine monotherapy, the 
combination with interferon-alpha appears logic. In chapter 4 we presented the first 
combination study on lamivudine and interferon-alpha. This combined approach was well 
tolerated and we could not detect any phannacological interaction of both drugs. However, 
in this group of patients who had previously failed interferon therapy, efficacy was not 
superior to mono therapy . Therefore other treatment schedules should be investigated. 
In chapter 5 we evaluated morphology and function of mitochondria in patients during 
lamivudine treatment, since severe clinical problems due to mitochondrial injury were 
observed in studies with a related nucleoside analogue (fialuridine). We discussed the 
mechanism of toxicity and observed that lamivudine did not induce mitochondrial toxicity. 
After withdrawal of lamivudine therapy HBV replication will reappear in almost all cases, 
which can be accompanied by a an acute exacerbation of hepatitis activity. TillS so called 
'lamivudine withdrawal hepatitis flare' will occur in about 20% of patients and may result 
in incipient liver failure in 5% of patients. However, the activated immune system during 
the exacerbation, in combination with reinstitution of lamivudine have been shown to 
eliminate infected hepatocytes and induce definite HBeAg seroconversion (chapter 6). 
In case lamivudine therapy is continued beyond 6 months, the emergence of a viral mutant 
with resistance to lamivudine have been described (chapter 7). The mutation found is 
located in the highly conserved YMDD motif of the HBV polymerase gene, the same 
mutation as described in HIV-l infected patients during lamivudine therapy. One single 
mutation is responsible for a 45-fold decrease in lamivudine susceptibility and will result in 
increased HBV-DNA and ALT levels. However. in most immunocompetent patients HBV-
DNA and ALT levels during continued iamivudine therapy were below pretreatment values. 
Therefore. continuation of lamivudine appears the best approach for most patients. 
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Samenvatting 
De nieuwe effectieve nucleoside analogen hebben belangrijke veranderingen veroorzaakt in 
de therapeutische mogelijkheden yoor cen patient met chronische hepatitis B. De studies in 
deze dissertatie richtten zich op de meest effectieve femmer van HBV replica tie, 
lamivudine. Dit is een aanwinst aangezien de meerderheid van de patienten geen haat heeft 
bij de standaard therapie met interferon-alpha (haafdstuk I). De dynamiek van de 
virusdeling gedurende de eerste 28 dagen van de behandeling met Mn enkele tablet' 
lamivudine, Heten cen dramatische daling zien van de hoeveelheid virus in het bleed. Door 
deze complete remming van virusactiviteit kon herekend worden dat iedere dag meer dan 
10 11 virusdeeItjes worden geproduceerd bij een chronisch gei'nfecteerde patient. 
Op basis van deze effectiviteit is de behandelingsperiade verlengd tot 6 maanden (haafdstuk 
3). Dit resulteerde in zowel biochemische, virologische als histologische verbeteril1g van 
ziekteactiviteit. Serum transamil1asen normaliseerden in 47% van de patienten, dit ging" 
gepaard met een verbetering van histalogische antstekingsactiviteit tijdens therapie. Bij 90% 
van de patienten was niet langer HBV-DNA aantoonbaar met behulp van hybridisatie 
technieken. Zelfs met behulp van de zeer gevaelige peR techniek werd bij 26% van de 
patienten geen HBV -DNA aangetoond, met aanwijzingen voor een betere virus 
anderdmkking bij hagere dasering en langere duur van de behandeling. 
HBeAg seroconversie wordt zelden waargenomen tijdens lamivudine monotherapie, daarom 
is de combinatie met standaard therapie logisch. In hoofdstuk 4 wordt de eerste combinatie 
studie beschreven met lamivudine en interferon-alpha. Deze comhinatie werd goed 
verdragen en er werden geen farmacologische interacties waargenomen. Echter in de 
behandelde groep patienten die eerder niet ap interferon-alpha hadden gereageerd was het 
succes matig. Daarom moeten ook andere behandelingsschema1s onderzocht gaan worden. 
Aangezien er emstige klinische problemen als gevoJg van mitochondriale schade werden 
waargenamen bij gebmik van een gerelateerd nucleoside (fialuridine), werd in hoafd§tuk 5 
de morfologie en functie van de mitochondrien in patienten tijdens lamivudine behandeHng 
onderzocht. Het mechanisme werd geevalueerd en wij konden geen mitochondriale schade 
als gevolg van lamivudine gebruik aantonen. 
Na het stappen van de lamivudine behandeling zal in de meerderheid van de patienten d~ 
virusdeling reactiveren, dit kan gepaard gaan met een acute exacerbatie van de hepatitis 
activiteit. Deze zogenaamde 1lamivudine onttrekkings hepatitis1 zal bij 20% van de patiel1ten 
voorkomen, in 5% zelfs met dreigend leverfalen. Echter, het op dat moment geactiveerde 
immuunsysteem kan, in combillatie met een opnieuw ingestelde lamivudine behandeling de 
gei"luecteerde hepatocyten opruimen en leiden tot een defillitieve HBeAg seroconversie 
(haafdstuk 6). 
Lamivudille mOllotherapie voor een periode langer dan 6 maandell kan resulterell in de 
antwikkeling van een HBY mutant die resistent is tegen lamivudine (haafdstuk 7). De 
gevonden mutatie is gelokaliseerd in de Yi'vlDD regio van het HBV polymerase gen, 
averigens dezelfde nlUtatie zaals beschreven is bij HIY -I ge[nfecteerde patienten tijdens 
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lamivudine gebruik. Een enkele mutatie is verantwoordelijk voor een factor 45 verminderde 
gevoeligheid van het virus voor lamivudine en zal resulteren in een stijging in HBV-DNA 
en serum transaminasen. Echter, in de meeste ruet immuun-gecompromitteerde patienten 
zullen de HEV-DNA en ALT waarden bij continuering van de behandeling lager zijn dan 
voor aanvang van de therapie. Daarom lijkt voortzetten van de lamivudine op dit moment 
de beste optie voor de patient. 
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D.nkwoord 
Vee! menscn hebben op hun manier bijgedragen aan dit proefschrift, langs deze weg wil ik 
aUen daarvoor hartelijk danken. 
Allereerst dank ik mijn promotor, Prof. Solka Schalm, voor zijn onuitputtelijke bron nieuwe 
ideeen en het enthousiasme waannee hij mij de afgelopen jaren heeft wetcn te stimuleren. 
Daamaast wil ik in het bijzonder mijn co-promotor Rob de Man bedanken voor zijn 
beschikbaarheid, oak voor problemen op de polikliniek en voor de praktische adviezen om 
vooruitgang te bevorderen. 
Bert Niesters ben ik zeer erkentelijk voor de snelheid en perfectie waannee virus uitslagen 
tot stand kwamen. Indien nodig was jij met je robot 24 nur per dag vimssen .an het 
karakteriseren op zoek naar mutaties. Verder zijn op de afdeling Virologic onmisbaar 
geweest Prof. Ab Osterhaus, Ruud Heijtink, Fons Uytdehaag en Ann Vossen evenals het 
laboratorium personeel en het secretariaat van de diagnostiek. 
Pieter Zondervan dank ik voor de vele vroege en late uurues dat er weer een biopue 
gescoord moest worden, zonder Monica had dit nooit resultaat gehad. Verder dank ik Prof. 
Mooi en Loek Rademakers voor hun medewerking. 
Op het gebied van mitochondriale toxiciteit heb ik dankbaar gebmik kmmen maken van de 
kennis en ervaring van Prof. Jasper Scholte en zijn laboratorium. 
Het personeel van het lab Interne II dank ik voor hun adembenemende inspanningen. 
Op het gebied van statistiek werd ik op kundige wijze bijgestaan door Wim Hop en Bettina 
Hansen. 
Marian, de eerste hepatitis verpleegkundige in Nederland, verdient een pluim voor haar 
werklust, orgallisatietaient en gezelligheid. 
Ollmisbaar voor de organisatie en afwerking van dit proefschrift waren het secretariaat en 
het trialbureau van de Hepatologie. Met name MarceUe en Sylvia waren altijd bereid weer 
iets 'tussendoor' te doen. 
Het personeel van de Clinical Research Unit onder leiding van Aart-Jan van de Lely en 
Hans van Nunspeet wiI ik bedanken voor het geduld dat ze voor mij en mijn patienten 
hebben opgebracht. Daarnaast waardeer ik Cootje voor haar bewezen diensten. 
Op de poli Interne II hebben de dames mij altijd door die lange spreekuren heengeholpen. 
De junior staf hepatologie' wil ik hartelijk danken voor de sfeer onderling en de nuttige en 
gezellige uurtjes in bilmen- en buitenland. 
Onnoemelijk veel heb ik te danken aan mijn ouders die mij altijd hebben weten te steunen 
en te stimuleren. Altijd hebben ze met veel belangstelling mijn studie-resultaten gevolgd. 
Daarbij denk ik aan mijn anvergetelijke vader die aUeen de start van dit onderzoek nog 
mocht beleven. 
Wilma, deze keer wil ik je (in tegenstelling tot afgelopen jaren) niet vergeten. Jouw steun 
en lief de zijn en blijven van anschatbare waarde voor mij, ook als ik geen tijd voor jou had. 
Pieter, jouw bJijdschap en enthousiasme, ook als ik weer te Iaat thuiskwam, zijn onmisbaar. 
Boven allies komt Hem de eer toe, die mij dit aUes gegeven heeft. 
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Curriculum Vitae 
De auteur van dit proefschrift werd op 2 september 1969 geboren te Kampen. Na het 
V.W.O. aan het Van Lodenstein College in Amersfoort gevolgd te hebben werd in 1987 
begonnen met de studie Geneeskunde aan de Erasmus Universiteit Rotterdam. In 1991 was 
hij 3 maanden werkzaam in het Nkandla hospitaal, Kwazulu, Rep. Zuid-Afrika (E. 
Thalmeyer MD.) In 1992 werd gedurende 6 maanden een post-doctoraal onderzoek verricht, 
op de afdeling Immunologie, naar het effect van eytokine behandeling in een 
huidtransplantatie model bij muizen (Prof. dr R. Benner). Op 18 maart 1994 werd (Cum 
Laude) het artsexamen afgelegd. Van april 1994 tot december 1997 was hij werkzaam op 
de afdeling Hepato-gastroenterologie van het Aeademiseh Ziekenhuis Rotterdam-Dijkzigt 
(prof. dr S. W. Sehalm). Tijdens deze periode werd onder begeleiding van Dr R.A. de Man 
onderzoek verricht naar antivirale therapie bij patienten met chronische hepatitis B, hetgeen 
de basis vormde voor dit proefsehrift. Sinds januari 1998 voigt hij de opleiding to internist 
in het Ikazia Ziekenhuis te Rotterdam (opleider Dr RJ.Th. Ouwendijk). 
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Abbreviations 
ACV 
ALT 
ARA-A 
AST 
AUC 
AZT 
cccDNA 
CMV 
CPK 
ddl 
ddC 
DNA 
EBV 
ER 
FIAU 
gen.eq. 
HAl 
HAV 
HBeAg 
HBeAg. 
HBsAg 
HBV 
HCV 
HOV 
HIV 
HLA 
a~IFN 
IU 
IIe 
KICA 
Leu 
LTx 
Met 
mt~DNA 
MU 
NA 
N-DNA 
PCR 
PEl 
RNA 
RT 
SddC 
SD 
SEM 
ULN 
Val 
acyclovir 
alanine aminotransferase 
adenine arabinoside 
aspartate aminotransferase 
area under the curve 
zidovudine 
covalently closed circular DNA 
cytomegalovirus 
creatine phosphokinase 
didanosine 
zalcitabine 
deoxyribonucleic acid 
Epstein-Barr virus 
endoplasmic reticulum 
fialuridine 
genome equivalents 
histology activity index 
hepatitis A virus 
hepatitis B core antigen 
hepatitis B envelop antigen 
hepatitis B surface antigen 
hepatitis B virus 
hepatitis C virus 
hepatitis delta virus 
human immunodeficiency virus 
human leucocyte antigen 
interferon-alpha 
international units 
isoleucine 
a~keto-isocaproic acid 
leucine 
liver transplantation 
methionine 
mitochondrial-DNA 
mega-units 
nucleoside analogue 
nuclear-DNA 
polymerase chain reaction 
Paul Ehrlich Institute 
ribonucleic acid 
reverse transcriptase 
lamivudine 
standard deviation 
standard error of the mean 
upper limit of noruml 
valine 
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